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SUMMARY
The aims of this thesis were firstly to investigate gene expression profiles in human
colonic and terminal ileal biopsies using microarray technology in a well phenotyped
cohort of patients with Crohn's disease, ulcerative colitis and a control cohort. The
role in disease pathogenesis of differentially expressed genes was investigated along
with the expression of candidate genes identified by genome wide association study
and cell lineage analysis. Parallel studies attempted to replicate the Nature Genetics
publications of Peltekova and Stoll and colleagues who investigated the role the IBD5
locus and the DLG5 gene respectively in patients with inflammatory bowel disease.
In the healthy adult colon cluster analysis showed differences in gene expression
between the right and left colon. (%2=25.1, p<0.0001). Developmental genes
HOXA13, (p=2.3xl(T16), HOXB13 (p <lxl0"45), GLI1 (p=4.0xl0"24), and GLI3
(p=2.1x10" ) primarily drove this separation.
Upregulated genes in the Crohn's disease biopsies compared to the controls included
SAA1 (Fold change (FC) +7.5, p= 1.47xl0"41) and REGL (FC +7.3, p =2.3xl0"16).
Cellular detoxification genes including-SLC14A2 (FC -2.49, p= 0.00002) were
downregulated. In the Crohn's disease terminal ileal biopsies diubiquitin (FC+11.3,
pdxlO"45), MMP3 (FC +7.4, p= 1.3x10'") and IRTA1 (FC -11.4, p= 4.7xl0"12) were
differentially expressed compared to controls. In the colon SAA1 (FC +6.3, p=
5.3xl0"8) was upregulated and TSLP (FC -2.3, p= 2.7xl0"6) was downregulated
comparing non-inflamed Crohn's disease and control biopsies.
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Of the Crohn's disease susceptibility genes identified by genome wide association
scan IL-23A, JAK2 and STAT3 were upregulated in Crohn's disease confirming
dysregulation of Thl7 signalling. Modest differential expression was also observed in
a number of the autophagy genes, notably ATG16L1. When clustering analysis was
undertaken, terminal ileal Crohn's disease and terminal ileal control biopsies
separated from colonic Crohn's disease and colonic control biopsies. Further
clustering analysis of the terminal ileal biopsies showed separation between the
terminal ileal Crohn's disease and control biopsies.
When the ulcerative colitis biopsies and control biopsies were compared,
differentially upregulated genes in ulcerative colitis included SAA1 (p<10~45) the
alpha defensins, DEFA5&6 (p=0.00003 and p=6.95xl0~7 respectively), MMP3
(p=5.6xlO~10) and MMP7 (p=2.3xl0~7). Increased DEFA5&6 expression was further
characterized to Paneth cell metaplasia by immunohistochemistry and in-situ
hybridization.
Variants in all the examined IBD5 SNPs were associated with Crohn's disease
(p<0.003). The IBD5 locus was also associated more severe Crohn's disease
behaviour. In the absence of the IBD5 risk haplotype, no association of OCTN1/2
variants with Crohn's disease was detected. The analysis of the DLG5 variant 113A
showed there were no associations with inflammatory bowel disease, Crohn's disease
or ulcerative colitis.
Overall these data emphasise the key role of a number of inflammatory molecules and
pathways in pathogenesis ofCrohn's disease and ulcerative colitis, and their potential
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for translation to therapeutic targets. The results also add considerably to the recent
genome wide association studies in providing complimentary human colonic and ileal
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ABBREVIATIONS
Apaf-1: Apoptotic peptidase activating factor 1,




DLG5: Drosophila Discs large homolog
DNA: Deoxyribonucleic acid
FDR: False discovery rate
GFI: Glioma-associated oncogene homolog
GWAS: Genome wide association study
HOX: Homebox genes
IBD: Inflammatory bowel disease
IBD5: Inflammatory bowel disease 5 locus
IL: Interleukin
FFR Feucine rich region
FOD: Logarithm (base 10) of odds
JAK2: Janus kinase 2
MAQC: Microarray quality control project




NOD2/CARD15: Nucleotide binding oligomerization domain containing 2
OCTN: Organic cation transporter
15
PAR: Population attributable risk
PDZ: Post synaptic density protein, Drosophila disc large tumor suppressor, and
zonula occludens-1 protein
PCR: Polymerase chain reaction
RNA: Ribonucleic acid
SAA1: Serum amyloid A1
SCCAI: Simple clinical colitis activity index
STAT3: Signal transducer and activator of transcription 3
TI: Terminal ileum
TLRs: Toll like receptors
TSLP: Thymic stromal lymphopoietin
UC: Ulcerative colitis
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1.1 History of Crohn's disease and Ulcerative colitis
Although not labelled Crohn's disease, descriptions of regional intestinal
inflammation have been documented for at least 200 years. Perhaps the most detailed
early description ofCrohn's disease was written in 1913 by Thomas Kennedy Dalziel,
an Edinburgh trained surgeon who was working in Glasgow. He observed two
patients who had died as a result of gross small bowel disease and 7 patients with
diseased small bowel segments that were able to be removed surgically, resulting in a
clinical recovery.(l)
In the USA in the 1920s and 1930s increasing numbers of young patients were being
referred with symptoms of fevers, abdominal cramps, weight loss and diarrhoea. In
1923 at the Mt Sinai Hospital in New York three surgeons Berg, Oppenheimer and
Ginzberg, collated a case series of 12 patients who presented with these symptoms
and at surgery had small bowel inflammation that did not fit with any known disease.
These cases were combined with two further cases under the care ofDr Burril Crohn
and Crohn, Ginzburg and Oppenheimer published their findings in the Journal of the
American Medical Association in 1932.(2) They described a disease if the terminal
ileum- 'terminal ileitis' as a clinical entity, however it was quickly realised that the
disease could present in the jejunum and colon resulting in the name 'regional
enteritis' being adopted. Over the years this has fallen from favour and the name
'Crohn's disease' has been adopted. The involvement of peri- anal disease was also
recognised as a phenotype of Crohn's disease in 1938.(3)
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The initial management of Crohn's disease was largely surgical or conservative with
medical therapy relying on nutritional support, correction of anaemia, antibiotics and
in the 1950s the administration ofACTH or corticosteroids.(4) Even with the modern
armourmentarium of medical therapy the debate continues about the optimal
management ofCrohn's disease. At the forefront of this debate is the question of
whether to persue a step up approach escalating treatment in response to symptoms or
to try to alter the natural history of the disease by embarking on early aggressive
medical therapy from diagnosis.(5)
Infectious and non- infectious bloody diarrhoea have existed and been documented
for hundreds of years as a clinical syndrome. Ulcerative colitis was first described as a
distinct clinical entity by Samuel Wilkes a physician at Guy's Hospital in London in
1859. In his initial letter to the editor of the Medical Times and Gazette he described
the post-mortem appearances of a colon of a patient with ulcerative colitis. The
disease was further characterised in a cohort of 300 patients from the London
Teaching Hospitals in 1909 and it was observed that the disease ran a relapsing
remitting course and that the first attacks were often the most severe.(6)
Prior to the 1950s the mainstay in the management of ulcerative colitis was surgery,
however the introduction of corticosteroids in the early 1950s had a dramatic effect in
lowering the mortality from exacerbations of ulcerative colitis from 37% to less than
1%.(7) Sulphasalazine was the first drug to be used in the aminosalicylate class that
mediate their anti-inflammatory action via 5-aminosalicylic acid (5-ASA) in the
colon. This family of drugs have continued to form the mainstay of maintenance
therapy in ulcerative colitis.(8) The thiopurine analogues azathioprine and 6-
25
mercaptopurine were introduced in the early 1970s further reducing the need for
surgical intervention in ulcerative colitis, however it is now becoming apparent that in
selected cases of difficult to treat ulcerative colitis elective surgery reduces
mortality.(9)
1.2 Epidemiology of Crohn's disease and Ulcerative colitis
In the last century, despite factoring in the increasing awareness, case definition and
improving diagnostic techniques there has been an ever increasing incidence of
inflammatory bowel disease in the United Kingdom.(10) Seven prospective and
retrospective studies over a period of greater than 20 years in the adult Crohn's
disease population have shown an increase in the incidence of Crohn's disease in
Northern Europe and North America in the 1960s and 1970s, but since the 1980s the
incidence has largely plateaued.(l 1) Incidence rates in the UK have been estimated to
be between 5.9 and 11.1 cases per 100 000 of the population^ 12) The most recent
data from Scotland was published in 1992 and in North East Scotland and the
Northern Islands the incidence of Crohn's disease was observed to be 11.7 cases per
100 000 population^ 13)
In the Scottish paediatric population (under 16), the incidence of Crohn's disease has
increased by approximately 3 times between the 1970s and the 1980s paralleling the
increase in the adult populations following a lag period.(14) Further data from our
unit have shown a North to South gradient with higher incidences in the North- 3.2
per 100 000 versus the South 2.1 per 100 000.(15) The incidence of paediatric
Crohn's disease in Stockholm doubled during the 1990s.(16) However, data from
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England showed no increase in incidence during the 1990s (17) and differences in
these data may be due to an earlier diagnosis of Crohn's disease or changes in
diagnostic criteria.
There have been fewer studies on the incidence of ulcerative colitis probably due to
the spectrum of disease and the difficulty in distinguishing a single episode of
ulcerative colitis from other aetiologies. That said there has been a modest increase in
the incidence of ulcerative colitis in the adult population (11) and data from faecal
occult blood testing for colon cancer in Nottingham in previously undiagnosed
subjects put the prevalence of ulcerative colitis at 700 per 100 000 of the
population^ 18) The incidence of ulcerative colitis in the Scottish paediatric
population has also been steadily increasing.(19) Overall these data suggest that the
increasing incidence of inflammatory bowel disease is strongly indicative of a change
in the environment that we live in and this allied to genetic susceptibility has led to
the observed increases.
1.3 Clinical Presentation of Inflammatory Bowel Disease
Crohn's disease can affect any part of the GI tract from the mouth to the anus.
Symptoms at presentation include diarrhoea, abdominal pain, weight loss and in the
case of peri- anal Crohn's disease pain or discharge around the anus. Patients can also
have extraintestinal manifestations including seronegative arthritis, uveitis and
dermatological conditions such as erythema nodosum and pyoderma gangrenosum.
In patients who present in adulthood with Crohn's disease the distribution of disease
is largely in the terminal ileum, colon or a combination of the two.
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In the paediatric population growth retardation is a common presenting complaint and
in this population Crohn's disease is characterised by extensive intestinal involvement
and rapid disease progression to more complex disease involving strictures and
fistulae formation.(20) The inflammation involved in Crohn's disease is often
transmural and discontinuous leading to complications such as strictures and fistulae
formation whereas in ulcerative colitis the disease typically involves only the mucosal
and sub-mucosal layers of the bowel.(21)
Ulcerative colitis affects the colon in a confluent manner from the rectum proximally
and classically presents with diarrhoea mixed with blood and mucus. In adults around
1/3 of patients will have distal disease, 1/3 will have involvement of the left side of
their colon and 1/3 will have extensive disease involving the majority of the colon. In
the paediatric population ulcerative colitis involves the majority of the colon in 82%
of the patients.(20)
1.4 Evidence for the genetic basis of inflammatory bowel disease
The most convincing evidence in support of a genetic contribution towards the
development of inflammatory bowel disease is provided from twin concordance
studies in the UK, Sweden and Denmark.(22-24) When data from these studies was
combined the concordance rates in monozygotic twins with Crohn's disease was
19/53 (36%), compared to concordance rates of 4/99 (4%) in dizygotic twins with
Crohn's disease.(25) In twins with ulcerative colitis concordance rates of 12/75 (16%)
and 4/99 (4%) were observed in monozygotic and dizygotic twins respectively,(25) a
weaker genetic effect than that which was observed in patients with Crohn's disease.
28
Moreover, when data from the Swedish(26) and Danish (22) cohorts were examined
with regards to location and date of diagnosis in the Crohn's disease concordant pairs,
64% were concordant with regards to disease location and 57% had been diagnosed
within two years of each other.(25)
Further studies examining multiply affected families would also suggest a strong
genetic contribution towards the development of inflammatory bowel disease with
sibling relative risks of 25-42 for Crohn's disease (27-30) and 8-15 for ulcerative
colitis.(28;31) The twin of a patient with inflammatory bowel disease has the highest
relative risk of developing inflammatory bowel disease, followed by a patient's
sibling and overall the relative risk to a first degree relative (sibling, offspring or
parent) of developing inflammatory bowel disease is 5-35 if the proband has Crohn's
disease and 10-15 if the proband has ulcerative colitis.(25)
Whilst initial data supported the hypothesis that the segregation pattern observed in
ulcerative colitis indicated that a major dominant gene had a role in the susceptibility
to ulcerative colitis and that a major recessive gene had a role in susceptibility to
Crohn's disease,(32) more recent data would suggest that the genetic contribution
towards the development of these diseases is inherited in a non- mendelian polygenic
fashion.(33)
1.5 Disease Pathogenesis
In the broadest terms the main hypothesis for the pathogenesis of inflammatory bowel
disease is that in genetically susceptible individuals there is a persistent excessive
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immune response to commensal gastrointestinal flora.(33;34) Within this hypothesis
investigators continue to define the role of the gut microflora and the role of potential
pathogenic bacteria along with the importance of gut barrier integrity in inflammatory
bowel disease. At the barrier organ interface of the gastrointestinal tract where a
single layer of epithelial cells, goblet cells, Paneth cells and dendritic cells separate
the host from the intestinal milieu, tolerance is required to commensal bacteria along
with the ability to neutralize pathogenic bacteria.
In order to maintain mucosal integrity in the gut continued sampling of the luminal
contents is undertaken. This allows for the antigen detection which focuses the
immune response and this process is dominated by the antigen presenting myeloid
derived dendritic cells in the lamina propria.(35) Disruption of the epithelial barrier or
the presence of pathogenic bacteria results in the activation of resident dendritic cells
via a CX3CR1- dependent mechanism, the production of IL-23, intestinal
inflammation and the migration of innate immune cells such as neutrophils,
macrophages and dendritic cells.(36)
From an evolutionary perspective, the innate immune response is more ancient than
the adaptive immune response and it is present in nearly all taxa.(37) As a further
measure of the importance of the innate immune response in plants, genes involved in
plant disease resistance occupy >1% of the genome ofprimitive species, such as
Rockcress.{38)
Toll like receptors (TLRs) are transmembrane proteins which play a pivotal role in
mediating the innate immune response to viral, bacterial and fungal pathogens.(39)
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TLRs were initially identified in Drosophila and they have been widely conserved
across animal species.(40) In mammals TLRs are integral membrane glycoproteins
which recognise conserved products unique to microbial metabolism and signal via a
number of downstream signalling molecules (MyD88, Il-lR-associated kinases, TGF-
P, and TNF- receptor associated factor 6).(41) To date 11 members of the TLR
family have been identified in mammals.(40) Initially it was thought that these
receptors were only expressed on macrophages and dendritic cells but it is now
recognized that they are present on a wide variety of cell types.(35)
The exciting finding of an association between variants in the NOD2/ CARD 15 gene
and Crohn's disease has also focused investigation on the NOD2 (nucleotide- binding
oligomerization domain) - LLR (leucine rich region) protein family.(42;43) These
proteins are key regulators of innate immunity and apoptosis in mammals and
plants.(44) NOD-LLR proteins play a central role in recognizing pathogens at the cell
surface and in the cytosol, and a family of greater that twenty human proteins that
possess a NOD domain have been identified.(45) The NOD-LLR proteins are
comprised of three distinct functional domains, the amino terminal effector domain
which is involved in signalling, the centrally located NOD domain and the LLR
ligand-sensing domain.(46) The effector domains are distinct linking these proteins to
multiple signalling pathways. Three of the human NOD-LLR proteins have effector
domains which are caspase-recruitment domains (CARD): NOD1/CARD4,
NOD2/CARD15 and Apaf-1.(44)
NOD2/ CARD 15 functions as an intracellular sensor ofmuramyl dipeptide, a highly
conserved peptidoglycan motif common to many intraluminal bacteria.(47;48)
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Watanabe and colleagues have suggested thatNOD2/CARD15 -/- mice lose negative
control of TLR2 mediated activation ofNFkB, potentially offering an explanation for
the Thl phenotype characteristic of Crohn's disease.(49) However, more recently
published studies do not provide support for NOD2/CARD15 interaction with the
TLR2 pathway and collectively these data emphasise the complexity of
NOD2/CARD15 activation.(50;51)
The discovery ofATG16L1 as a Crohn's disease specific susceptibility gene has
strongly implicated the autophagy pathway in the pathogenesis of Crohn's disease.
Autophagy is a highly conserved cellular process where the cell digests part of its own
cytoplasm and it functions as a normal physiological response to remove toxic
material or intracellular bacteria from the cell. The pathway has also been implicated
in the pathogenesis of neurodegenerative diseases such as Alzheimers's and
Parkinson's disease.(52)
Recent data have linked the innate immune response and the autophagy pathway via
Toll-like-receptor (TLR) engagement.(53) TLR induced phagosomes within
macrophages triggered ATG5 and ATG7 mediated acidification and enhanced killing
of the ingested organisms. These interactions between the innate immune system and
the autophagy pathway have provoked investigators to speculate about specific
interaction between NOD2/ CARD 15 and autophagy and this is an area of active
investigation.
Following on from the activation of the innate immune response the adaptive immune
response sustains the persistent inflammation and tissue damage observed in patients
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with inflammatory bowel disease.(21) Previously it was thought that ulcerative colitis
patients exhibited a Th2 T cell cytokine profile and Crohn's disease patients displayed
a Thl T cell cytokine profile, but it is now obvious that there is considerable overlap
between the T cell responses in ulcerative colitis and Crohn's disease and that the
Thl7 T cell pathway is central to the inflammatory response observed in Crohn's
disease.(35)
Th 17 T cells are derived from naive CD4 T cells and this differentiation is driven by
the sequential action of transforming growth factor (3, IL-6 and IL-23.(54) Production
of IL-23 appears to be limited to dendritic cells and macrophages and this amplifies
the IL-23/ Th 17 pathway at several levels.(55;56) Genetic and functional studies
have now emphasised the importance of this pathway in the pathogenesis of
inflammatory bowel disease (57;58) and therapeutic targets have been identified.
Clinical trials of a monoclonal antibody against the p40 subunit of IL-23 have
produced promising early clinical data.(59)
Elegant murine studies have demonstrated that in germ free environments genetically
susceptible or inbred mice do not develop colitis, however following the introduction
of specific bacteria or different combinations ofbacteria, differing patterns of
inflammation occur in the gut.(60) Increased virulence of commensal bacterial species
such as E Coli can result in invasion of the epithelial layer thus stimulating a
pathological response from the host which results in chronic inflammation and tissue
injury. In humans it has been observed that invasive mucosal adherent bacteria are
more common in Crohn's disease than in controls, but whether this is the primary
insult or a secondary phenomenon remains unanswered.(61)
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Impaired epithelial barrier function may also contribute to the pathogenesis of
inflammatory bowel disease and enhanced mucosal permeability has been observed in
a number of colitis susceptible mice models.(62) The tight junctions between the
epithelial cells are dynamic and permeability is increased by pro- inflammatory
mediators including TNF and IL-17.(35) In mucosal biopsies taken from patients with
IBD it was observed that the junctional proteins E- cadherin and p catenin were
downregulated .(62)
Specific interest has also focused on the role of the Claudin gene family in
maintaining mucosal integrity.(62) Claudin 2 downregulates and redistributes tight
junction components and Claudins 5 and 6 increase apoptosis of epithelial cells in
Crohn's disease.(63) The importance of barrier exclusion thus reducing and
neutralising translocated luminal bacteria has been observed in a number ofmouse
models and specific interest has focused on the multidrug resistance-1 gene (Mdr-1).
Mdr-1 encodes p-glycoprotein which functions to clear microbial xenotoxins and
Mdr-1 deletion in mice induces colitis.(64) Moreover, genetic variants in the Mdr-1
gene have been associated with ulcerative colitis.(65)
Integral to epithelial integrity and pathogen killing is the secretion of anti- microbial
peptides by epithelial cells and Paneth cells. Levels of the human alpha defensins 5
and 6 have been observed to be reduced in patients with ileal Crohn's disease
regardless of the degree ofmucosal inflammation.(66) Furthermore in Crohn's
disease patients who carry the NOD2/ CARD 15 frame shift mutation Leu 1007 there
is a further decrease in ileal defensin alpha 5 suggesting that NOD2/CARD15
function may affect alpha defensin secretion.(67)
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More recently Simms and colleagues also showed that expression ofDEFA5&6 was
down regulated in terminal ileal CD biopsies.(68) However, this downregulation was
inflammation specific probably reflecting a loss of the epithelial layer and a reduction
of epithelial and Paneth cells as a consequence of persistent inflammation.
Taken together these data strongly support the hypothesis that inflammatory bowel
disease results from a genetic predisposition and a consequent excessive immune
response to normal gut flora and the challenge is to decipher the complex interplay
between the host immune system and the gut microflora.
35
1.6 MOLECULAR STRATEGIES FOR THE IDENTIFICATION OF
SUSCEPTIBILITY GENES
1.6.1 Positional Cloning Genotyping
Genome-wide linkage analysis using highly polymorphic microsatellite markers
identified during the course of the Human Genome Project (69) has led to success in
identifying genetic determinants in both single gene disorders and in complex genetic
diseases. Successful genome scans have typically involved several hundred
microsatellite markers and large numbers ofmultiply affected inflammatory bowel
disease families (typically sibling pairs). The classical positional cloning approach
uses this technique to examine whether the degree of sharing of variant alleles
between affected individuals exceeds that which would be expected by chance
alone.(70) These confirmed regions of linkage need to be further narrowed by fine
mapping of these areas, as each spans a large genomic region.
The most widely accepted guidelines for assessing the results are those defined in
1995 by Lander and Kruglyak, who proposed criteria for reporting areas of linkage,
(71) with areas of 'suggestive linkage' having LOD scores of 2.2 and above and p
values of less than 7 x 10"4, areas of'significant linkage' having LOD scores above
3.6 and p values of less than 2 x 10 5, and areas of 'highly significant linkage' having
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LOD scores of 5.4 and above and p values of less than 3x10". Areas of 'confirmed
linkage' were defined as areas of significant linkage that have been replicated in an
independent cohort, with a nominal p value of less than 0.01. Prior to genome wide
association studies loci with confirmed linkage were identified on chromosomes
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1(72), 3 (IBD9)(73;74), 5 (IBD5)(75-77), 6 (IBD3; HLA)(76;78), 12 (IBD2)(79), 14
(IBD4)(75;80), 16 (IBD1)(79;81) and 19 (IBD6)(76).
1.6.2 Positional Candidate Gene Approach
The positional candidate gene approach to identifying association involves the use_of
data concerning gene function and expression allied to chromosomal location. -In
inflammatory bowel disease genes involved in the regulation of the immune system,
mucosal integrity and cell-cell interactions are all clearly plausible candidate genes.
By comparing the allelic frequencies of variants in these genes between patients with
IBD and matched controls (case control analysis), or by investigating intra-familial
association/ linkage, genes that contain critical disease causing mutations may be
identified.
1.6.3 Discovery of the NOD2/ CARD15 Gene
The discovery of the NOD2/ CARD 15 gene as the susceptibility gene in IBD1 serves
as proof ofprinciple of both the positional cloning and positional candidate
techniques. The IBD1 locus located on chromosome 16 was first identified by two,
two stage genome scans of inflammatory bowel patients in 1996.(79;81) This led to
the discovery published in consecutive Nature publications in 2001 using a positional
cloning and a positional candidate technique, that variants of the NOD2/ CARD 15
gene located within IBD1 were associated with susceptibility to Crohn's
disease.(42;43) Since the identification of the three single nucleotide polymorphisms
(SNPs) that have been associated with susceptibility to Crohn's disease- Gly908Arg
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and Arg702Trp and the frameshift mutation Leul007fsinsC, extensive studies
examining the frequencies of these variants in cohorts of patients with inflammatory
bowel disease have been undertaken.
Reported carriage of the three major risk alleles ofNOD2/CARD15 in Crohn's
disease vary between 0 and 50.0%, with highest rates seen in central European
populations, (42;82) while mutations are absent in Japanese and Chinese
series.(83;84) In the Northern European Crohn's disease population- Sweden,
Finland, Denmark and Scotland lower NOD2/CARD15 frequencies have been
reported suggesting genetic heterogeneity within Europe.(85;86) The calculated
population attributable risk, the difference in rates of a condition between an exposed
and unexposed population, of these variants has been lower, 11.4% in Stockholm
county (86) and 11% in Scotland (85) compared to those in central Europe (27%-
33%).(42;87)
A meta-analysis of 42 studies in patients with Crohn's disease revealed that
heterozygote carriage of one of the 3 major risk alleles ofNOD2/CARD15 conferred
a 2.39 fold increased risk of developing Crohn's disease and homozygous/ compound
heterozygous carriage conferred a 17 fold increased risk of developing Crohn's
disease. (88)
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1.7 THE IBD5 LOCUS
In 1999 a genome wide scan was carried out in 222 individuals from 46 families (20
Jewish and 26 non-Jewish), together with a total of 65 sibling pairs diagnosed with
Crohn's disease.(75) One of the suggested areas of linkage in the Jewish families was
at chromosome 5q33-q35 (Maximum LOD score = 2.2, p = 0.0003). In a further
genome wide scan carried out by Rioux and colleagues an area of linkage was
observed at chromosome 5q31-33 and when the authors carried out high density
mapping of this area a significant association was observed with Crohn's disease
(LOD score 3.9).(76) The area of observed association spanned a large 18cM area of
chromosome 5q31 and this area of association was labelled IBD5.
To better delineate this region, Rioux and colleagues genotyped 256 Canadian father-
mother, child trios where the child had Crohn's disease and at least one of the parents
was unaffected using 56 microsatellite polymorphisms with an average spacing of
0.35cM. (77) Tight linkage disequilibrium was observed across the area examined and
two adjacent markers demonstrated significant overtransmission IRFlpl (p =
0.00016) and D5S1984 (p = 0.00039). A 435 kb risk haplotype block was identified
spanning a cytokine cluster that contained a number of attractive candidate genes,
however, no candidate risk alleles were identified in these genes. In order to look for
novel SNPs in the risk locus DNA was sequenced in eight individuals across the
region. 651 SNPs were identified and genotyped in the Crohn's disease population
and 11 of these SNPs identified a 250kb risk haplotype.(77)
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This 250kb region was of particular interest as it contained a number of
immunoregulatory genes including interferon regulatory factor 1, IL-3, IL-4, IL-5 and
IL-13. High resolution haplotypic analysis of the 5q31 region using 103 common
SNPs (minor allele frequency >5%) revealed 11 discrete haplotype blocks that
measured tens of kilobases in length that had limited genetic diversity and were
punctuated by apparent sites of recombination.(89)
The association between the IBD5 locus and Crohn's disease was confirmed in a
German cohort of trios by transmission disequilibrium testing (TDT) (p = 0.007) and
interestingly an association was also observed with ulcerative colitis (p = 0.002).(90)
Further data confirming the association between IBD5 and Crohn's disease has also
been shown in a European case control study, (91) a British family based association
study, (92) and a British case control study.(93)
Interestingly, data from Japan have shown that IBD5 variants are rare in the Japanese
population (<1% for Crohn's disease, ulcerative colitis and healthy controls),(94)
suggesting IBD5 is not a major component of inflammatory bowel disease
susceptibility in Japan. However, given the ethnic diversity and large number of
patients involved in studies showing a positive association between Crohn's disease
and IBD5, the IBD5 locus remains one of the most robust susceptibility loci
associated with immune mediated complex disease genetics.
In 2004 Peltekova et al suggested that the organic cation transporters SLC22A4
(OCTN1) and SLC22A5 (OCTN2) harboured the critical mutations that were
associated with disease susceptibility in the 250 kb IBD5 locus.(95) They constructed
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a two allele TC haplotype (SLC22A4 exon 9 1672C—>T and SLC22A5 promoter -
207G—>C) and went on to demonstrate in a cohort of Canadian Crohn's disease
patients, that in patients who lacked the extended IBD5 risk haplotype- homozygous
with regards to the IBD5 marker SNP IGR2078, the TC haplotype was more
prevalent in Crohn's disease patients than in controls. Population attributable risk
(PAR %) for the TC haplotype were estimated at 19% for heterozygotes and 27% for
homozygotes and no individual allelic data were given.
Case control data from cohorts of inflammatory bowel disease patients from Scotland
and Germany replicated the association between the IBD5 loci, OCTN1/2 and
Crohn's disease, however, an independent effect of the OCTN1/2 variants was not
observed.(96;97) An overall association between the IBD5 locus and susceptibility to
Crohn's disease and ulcerative colitis was also noted in more recent data from
England and in a cohort of patients from Scotland who were diagnosed with IBD
under the age of 16 years.(98;99) However, again no independent association between
the variants in the OCTN1/2 genes and Crohn's disease was observed.
Using applied regression-based haplotypic analysis in 1200 European case control
pairs Fisher and colleagues observed a highly significant association between the
IBD5 locus and Crohn's disease.(lOO) The addition of the OCTN1/2 variants to a null
model that included the background risk haplotype did not significantly improve the
model fit and the authors concluded that the molecular basis for Crohn's disease
susceptibility at the IBD5 locus remains to be defined. Taken together these data
suggest that it may be premature to confirm that the OCTN1 (SLC22A4 exon 9
1672C—>T) and OCTN2 (SLC22A5 promoter -207G—>C) polymorphisms are the
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critical mutations that confer disease susceptibility within the IBD5 locus and that
they may simply be markers for the risk haplotype.
1.7.1 Function of OCTN1/2
OCTN1 is a 551 amino acid protein that is strongly expressed in kidney, trachea, bone
marrow and to a lesser extent the small bowel and it has been characterised as a
carnitine transporter.(lOl) An intronic SNP (rs2268277) in the RUNX1 (Runt-related
transcription factor 1) binding site ofOCTN1 has been associated with susceptibility
to rheumatoid arthritis in the Japanese population^ 102) OCTN2 is a 557 amino acid
protein that is 75.8% homogenous to OCTN1, and functional studies have shown it to
be a high affinity sodium carnitine transporter, expressed in kidney, smooth muscle
and heart tissue.(103) Peltekova and colleagues suggested that the OCTN1 variant
(1672C—>T) has altered function in fibroblasts in vitro, with variant forms having less
affinity for carnitine and a greater affinity for tetraethyl ammonium and some
xenobiotics, and that the OCTN2 variant (-207G—»C) disrupted a heat-shock
transcription factor binding site in fibroblasts in vitro.(95) No data demonstrating the
altered function or expression of OCTN1/2 gene products in Crohn's disease have yet
been provided.
1.7.2 Other Candidate Genes within the IBD5 locus
Other attractive candidate genes that are located within the IBD5 locus in close
proximity to OCTN1/2 include interferon regulatory factor 1 (IRF1), PDLIM4 and
CSF2. IRF1 is a transcriptional factor that is involved in the regulation of a number of
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genes related to the innate and adaptive immune response.(104) It has been observed
that IRF1 is up regulated in intestinal mucosal mononuclear cells in Crohn's disease
patients.(105)
PDLIM4 also known as RIL is a member of the ALP (actinin-associated LIM protein)
subfamily of proteins who share an N-terminal PDZ domain and a C-terminal LIM
domain.(106) PDZ domains are protein-protein interaction modules that are crucial
for the assembly of structural and signaling complexes and interestingly it has been
suggested that polymorphisms in another PDZ containing protein DLG5 which will
be discussed in more detail later in the introduction are associated with the
development ofCrohn's disease.(107;108)
CSF2 encodes for granulocyte macrophage-colony stimulating factor (GMCSF) a
myeloid growth factor that plays a crucial role in the potentiation and phagocytic
ability of circulating neutrophils and macrophages.(109) Clinical data have
demonstrated that recombinant GMCSF improved disease severity and quality of life
in patients with moderate to severe Crohn's disease,(110) and more recently it was
shown that GMCSF was more effective than placebo for inducing corticosteroid free
remission in patients with corticosteroid dependant Crohn's disease.(111)
1.7.3 Genotype Phenotype Associations with IBD5: Age of Diagnosis
Data from the original genome wide scan carried out by Rioux and colleagues showed
that the strongest association between the IBD5 locus and Crohn's disease was
observed in families where the sibling was diagnosed with Crohn's disease under the
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age of 16.(76) Mirza and colleagues also observed a significantly earlier onset of
Crohn's disease in patients who were homozygote for the IBD5 risk haplotype (p =
0.0019),(91) however, when all the studies are considered no consistent association
between IBD5 variants and an earlier age of diagnosis has been observed.
(96;97;99;112;113)
1.7.4 Disease Location
Phenotypic data looking for associations between disease location and IBD5 variants
has been inconsistent. Associations between individual IBD5 alleles or the IBD5
haplotype and gastric antral,(98) ileal, (112) colonic,(97) and perianal (93) Crohn's
disease have all been reported and this variation may reflect different phenotypic
classification categories or the fact that IBD5 variants may be associated with
multiple disease locations. Further standardisation of Crohn's disease location may
help to resolve this questional 14)
1.7.5 Disease Behaviour
Probably the most robust phenotypic associations have been observed between IBD5
variants and disease behaviour. In the Scottish Crohn's disease population variant
alleles have been associated with markers of disease severity, namely disease
progression from Vienna classification (115) inflammatory disease behaviour at
diagnosis to stricturing and penetrating disease behaviour at follow up the adult
population.(96) In Scottish Crohn's disease patients diagnosed at aged 16 or under an
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association between low weight, low height, low body mass index at diagnosis and
IBD5 variants was observed.(98)
In an Italian Crohn's disease cohort, a significant association between the OCTN1/2
TC haplotype and the presence of perianal fistulae and stricturing-fistulizing disease
behaviour was observed (116) and in a further cohort of Crohn's disease patients from
Belgium an association between IBD5 variants and penetrating Crohn's disease was
observed.(l 13) These consistent data would suggest that IBD5 variants are associated
with a more severe Crohn's disease phenotype.
1.7.6 Other Phenotypic Associations
When response to infliximab was examined in a Cohort of Spanish patients with
Crohn's disease, the frequency of the IBD5 homozygous mutant genotype was
significantly increased in Crohn's disease patients lacking response to infliximab (RR
= 3.88).(117) Consistent with data suggesting an association between IBD5 variants
and a more severe disease behaviour, Palmieri and colleagues also observed an
association between IBD5 variants and patients on immunosuppressive
medications.(118)
1.7.7 Epistasis between the IBD5 locus and NOD2/ CARD15
A number of publications have investigated potential gene-gene interactions between
the IBD5 locus and NOD2/ CARD 15 in patients with Crohn's disease, with the
majority finding no association.(90;93;96;98;99) However, in two data sets an
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interaction between the IBD5 locus and NOD2/ CARD 15 was observed in patients
with ulcerative colitis and this interaction appeared to be specific to the
Leul007fsinsC variant ofNOD2/ CARD 15.(90; 119)
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1.8 DROSOPHILA DISCS LARGE HOMOLOG 5 (DLG5)
A locus on chromosome 10 was first implicated in genome wide scanning of 282
affected sibling pairs in a European cohort (United Kingdom, Germany and the
Netherlands) in 1999 as conferring susceptibility to inflammatory bowel disease
(LOD score 2.30). (78) By fine mapping this region in a German cohort on four
occasions progressively narrowing the area of association and better delineating it
with more microsatellite markers, Stoll and colleagues identified one marker-
rs 1344966 that was significantly associated with inflammatory bowel disease (p =
0.0006) and Crohn's disease (p = 0.002).(107) This marker was adjacent to the gene
DLG5 and following the sequencing of exons 2-32 of the gene, 33 SNPs were
identified within this gene. These SNPs were then genotyped in 457 trios with
inflammatory bowel disease and 18 of these variant SNPs were significantly
overtransmitted compared to the wild type SNPs in the patients with inflammatory
bowel disease.
Tight linkage disequilibrium (LD) was observed across the DLG5 gene that fell
significantly at the boundaries of the gene and Stoll and colleagues identified two
extended DLG5 haplotypes that influenced disease susceptibility in the German
population^ 107) The first haplotype (named haplotype D) was especially notable for
the presence of a G—>A substitution at nucleotide 113 that resulted in an amino
change at position 30 from Arginine to Glutamine (R30Q). On analysis of carrier
frequency, Stoll found the 113A variant to be associated with Crohn's disease (25%
Crohn's disease v 17% healthy controls, P=0.001) in a case control study and trends
between 113A transmission and inflammatory bowel disease (P=0.09) and Crohn's
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disease (p = 0.065) were observed on transmission disequilibrium testing. The second
haplotype, (haplotype A) was tagged by eight marker SNPs and was observed to be
significantly under-transmitted in the inflammatory bowel disease group (P=0.006)
suggesting the haplotype may be protective.(107)
There have now been a number of studies in genetically diverse populations
attempting to replicate these associations (Table 1.1). Daly and colleagues
investigated the 113AJ R30Q haplotype and haplotype A in cohorts of patients with
Crohn's disease from Canada, Italy and the United Kingdom.(120) The association
between the 113A/ R30Q variant and Crohn's disease was replicated in one of the
case control studies involving patients from Italy and Canada and in a family based
study involving families from Canada and the UK, however, no association was
observed in the other case control study ofUK patients. Haplotype A was not found
to confer protection and the authors postulated DLG5 constituted a true IBD risk
factor of modest effect. Further analysis of these data would argue that there was
significant heterogeneity between the control groups from these ethnically diverse
populations and that pooling data may mask true changes among different
populations.(121)
A number of other studies have failed to replicate the initial association between the
113A /R30Q variant ofDLG5 and Crohn's disease. Torok and colleagues found no
association between DLG5 variants and inflammatory bowel disease, Crohn's disease
or ulcerative colitis in a case control study in Germany and this data was replicated in
Scotland where again no associations were observed.(97;122) No association was also
observed in two cohorts of inflammatory bowel disease patients from Belgium- 373
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patients in transmission disequilibrium testing analysis and 608 patients and 305
controls in a case control analysis,(113) and more recent data from cohorts of
inflammatory bowel disease patients from Canada,(123) Norway,(124) Germany and
Hungary,(125) Hungary alone (126) and Britain (127; 128) also showed no association
between DLG5 variants and IBD5.
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Interestingly no 113A /R30Q variants were found in the Japanese Crohn's disease population
(130) and this finding was replicated in a cohort of inflammatory bowel disease patients from
Greece.(131) These studies confirm data examining variants in NOD2 /CARD 15,(86)
SLC22A4 /SLC22A5,(132) and CCL20 (133) where in ethnically diverse inflammatory
disease populations, marked differences in the frequency of variants in these genes exist and
further illustrate the difficulty in pooling ethnically diverse populations.
No studies have replicated the protective effect of haplotype A demonstrated by Stoll and
colleagues,(107) and interestingly in analysis of cohorts of patients with inflammatory bowel
disease and Crohn's disease from Canada and Scotland there was a trend towards haplotype A
being overrepresented in patients compared to controls.(122;123)
1.8.1 Phenotypic Associations with DLG5- Gender Stratification
Perhaps the most interesting genetic data to emerge about DLG5 since it was proposed as a
susceptibility gene by Stoll and colleagues has come from analysis of variant carriage in male
and female patients with inflammatory bowel disease. In a cohort of patients diagnosed with
inflammatory bowel disease at the age of 16 or under from Scotland, Russell and colleagues
observed an overtransmission of the 113A /R30Q allele in male patients with Crohn's disease
compared to females- 29.3% vs. 16.9%, p=0.04 OR 2.04.(134)
These data were supported by further analysis of the original German cohort of patients used
by Stoll and colleagues,(107) combined with the Italian and Canadian patients used by Daly
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and colleagues.(120;135) A significant association was observed between the 113A /R30Q
allele and males with Crohn's disease- p < 0.001, OR = 2.49, but not females with Crohn's
disease- p = 0.979, OR = 1.01.(135) The association between the 113A /R30Q variant and
Crohn's disease in male patients appeared to be primarily driven by the difference between the
allelic frequencies of the 113A /R30Q DLG5 variant in controls-males 5.2%, females 11.3%,
rather than Crohns disease patients-males 10.1%, females 10.9% and this was supported by
data from a newborn non-inflammatory bowel disease screening study- newborn males 7.1%;
newborn females 11%, p = 0.036.
A further meta- analysis of 12 case-control cohorts containing 4707 Crohn's disease patients
and 4937 controls showed no male-female allelic frequency differences in the control
populations and a trend towards the 113A/R30Q variant being less common in the female
Crohn's disease patients.(136) When 5 further case- control cohorts were added to the existing
data the 113A/R30Q variant was associated with a small reduction in risk in female Crohn's
disease patients- OR = 0.86 (CI 0.76- 0.97).
1.8.2 Influence of DLG5 113A/R30Q Stratified by Social Affluence and Disease Location
Multifactorial analysis by Russell and colleagues suggested that in the Scottish paediatric
Crohn's disease population, higher social class (increased affluence) was independently
associated with carriage of variants of 113A /R30Q - p = 0.001, OR=6.92.(134) A borderline
association between the 113A /R30Q DLG5 allele and inflammatory bowel disease overall
which became more significant in patients with increasing affluence in the paediatric Scottish
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population, together with the lack of association in the Scottish adult inflammatory bowel
disease population may suggest a specific DLG5 113A /R30Q- environment
interaction.(122; 134)
Further associations have been observed between DLG5 113A /R30Q variants and ileal
disease location, smoking behaviour (128) and steroid resistance,(129) however, these data
have not been consistent and in the majority of studies examining disease phenotype no
associations have been observed.(97;122;123;125)
1.8.3 DLG5 Epistasis with NOD2 /CARD15
Data investigating potential gene-gene interaction between DLG5 and NOD2 /CARD 15 have
been varied and this lack of consistency probably relates to the size of studies required to
prove an epistatic effect, and the difficulty in deciphering genetic, biological and statistical
epistasis.(137) In the initial study by Stoll and colleagues, Crohn's disease patients who
carried one or more of the common NOD2/ CARD 15 variants also had a significant increase
in transmission of the DLG5 113A /R30Q allele compared to Crohn's disease patients who
were wild type for all 3 NOD2 /CARD15 variants.(107) This finding was replicated by
Vermiere and colleagues who observed a higher frequency ofDLG5 113A /R30Q in patients
with one or more variant in NOD2/ CARD 15- 12.2% compared those with no NOD2
/CARD 15 variants- 8.7%, p = 0.033.(113)
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However, in 3 large well designed case control studies from Britain including 2800 patients
with inflammatory bowel disease, no evidence of epistasis between DLG5 and NOD2
/CARD15 was observed (122; 127; 128) and these findings were replicated by 2 central
European studies involving over 1400 patients with inflammatory bowel disease.(97;129)
Newman and colleagues also found no evidence of epistasis between DLG5 and NOD2
/CARD15 in a Canadian cohort of patients with Crohn's disease.(123)
1.8.4 Function of DLG5
DLG5 is a member of the MAGUK (membrane associated gyanylate kinase) gene family
which encode cell scaffolding proteins and are also involved in intracellular signal
transduction^ 13 8) MAGUKs interact with other proteins to create an assembly of large multi-
protein complexes that bind transmembrane proteins at the cytoplasmic side to other signal
transduction proteins, therefore creating a platform for specific signal interactions^ 139; 140)
Thus, DLG5 is important in maintaining epithelial integrity and variants in the gene may
encode proteins that alter epithelial integrity and affect disease pathogenesis.
The DLG5 gene spans 79KB and contains 32 exons which encode a 180kb protein containing
1900 amino acids.(141) DLG5 is expressed most strongly in placental tissue and less so in
heart, skeletal muscle, liver, small bowel and colon.(141) Stoll and colleagues carried out in
silico analysis that suggested that the 113A /R30Q variant probably impairs DLG5 scaffolding
function.(107)
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Recent data have shown expression ofDLG5 in human colonic tissue and close homology of
DLG5 to CARD 10, CARD11 and CARD 14.(142) It was observed that DLG5 contains a N-
terminal caspase recruitment domain (CARD) domain, and the authors suggested it may
function in the regulation ofNFkB activation or caspase activation as part of host defence
mechanism.
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1.9 GENOME WIDE ASSOCATION STUDIES
By using data generated from the Human Genome and International HapMap projects
investigators are now able to use genome wide chips containing 300 000 to 500 000 single
nucleotide polymorphisms (SNPs) to interrogate large case control data sets.(69) At present
European ancestry population genome wide scans have been estimated to cover 80% of the
Human genome variation where the calculated linkage between the SNPs-linkage
disequilibrium r2 is greater than 0.8.(143) With these dense genotyping chips becoming
increasingly available and cheaper to purchase well powered studies to investigate complex
inherited diseases are now possible.
In Crohn's disease the first genome wide association study was carried out in the Japanese
Crohn's disease population and in a 2 stage process initially involving 94 Crohn's disease
patients and 80 000 SNPs and secondly 484 Crohn's disease patients, a variant in the tumour
necrosis superfamily gene TNFSF15 was significantly associated with Crohn's disease.(144)
This finding was replicated in 2 European populations significantly strengthening this
association.(57)
In a US wide study of 567 non-Jewish, European ancestory Crohn's disease patients with a
bias towards ileal Crohn's disease, genome wide scanning was carried out using a chip that
contained 308 332 SNPs.(145) Following a Bonferroni correction for multiple comparisons 3
SNPs remained significant- 2 SNPs representing the NOD/CARD 15 gene and a further
nonsynonymous SNP (Arg—>Gln) in the IL-23R gene on chromosome lp31. In addition 9
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other SNPs in this region were found to be in linkage with the index SNP and were associated
with Crohn's disease. This finding was replicated in a panel of patients of Jewish ancestory
using a case control method and in a mixed Jewish and non- Jewish family trio cohort using
family based association testing.(145)
The association between IL-23R and Crohn's disease has now been replicated in a UK wide
case- control panel ofCrohn's disease patients using 8 SNPs to represent the IL-23 gene.(146)
Further to this a lesser association was observed between the IL-23R variants and ulcerative
colitis. Three subsequent genome wide association studies in Flemish, UK and Quebec
Crohn's disease cohorts have also replicated the association between variants in the IL-23R
gene and Crohn's disease.(57; 147; 148) Taken together these data emphasise the importance of
the proinflammatory IL- 23 pathway in the pathogenesis of inflammatory bowel disease and
the potential for therapeutic intervention.
The largest and most impressive genome wide scan to date was carried out in the UK using
DNA from 14000 patients and 3000 controls encompassing 7 major diseases- bipolar disease,
coronary artery disease, Crohn's disease, rheumatoid arthritis, type 1 and type 2 diabetes.(57)
Of the 24 SNPs that were found to have an association with their respective disease with p
value of less than 5x10~7, 9 were observed in Crohn's disease. The strongest association in
Crohn's disease mapped to the gene ATG16L1, a gene that is part of the autophagosome
pathway implicated in processing of intracellular bacteria. The previous associations with
NOD2/ CARD 15, IL- 23R, the IBD5 locus and the gene desert on chromosome 5p 13.1 were
replicated and novel associations were observed with SNPs representing the genes IRGM, a
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gene also involved in autophagy, MST1, the protein ofMST1 influences phagocytic activity
ofperitoneal macrophages, NKX2-3, part of the NKX family of transcription factors and
PTPN2, a negative regulator of inflammatory response.
A 'second tier' of areas of linkage was also reported based on statistical significance and
biological plausibility. Among the loci reported were the HLA region on chromosome 6, the
candidate gene TNFAIP3 whose protein product inhibits NFkB dependent TNFa production
and TNFSF15 where a previous association had been observed in the Japanese
population.(144) A number of the most significant areas of association have now been
replicated in an independent panel of 1,182 Crohn's disease individuals of European descent
using 37 SNPs in tight linkage disequilibrium with SNPs form the index study.(149)
ATG16L1 was initially identified in a study of 20,000 nonsynonymous SNPs in 735 patients
with Crohn's disease and controls.(78) The SNP (rs2241880) which results in an amino acid
change A197T in exon 8 was observed to be significantly less common in the Crohn's disease
patients compared to controls, thus conferring protection against Crohn's disease. When
multiple regression analysis was carried out using further SNPs in the ATG16L1 locus,
virtually all of the disease risk of the gene was explained by this SNP. The association
between the protective allele A197T ofATG16L1 and Crohn's disease was also replicated in
the USA wide, non- Jewish, European ileal Crohn's disease cohort mentioned above in a
further report of their genome wide association study.(150)
In a genome wide scan of the Flemish Crohn's disease population an area of chromosome
5pl3 was observed to contain multiple SNPs that were strongly associated with Crohn's
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disease.(147) The 1.25- Mb region of chromosome 5 that was identified is a gene desert,
although the authors presented some expression data that correlated with variant alleles of the
candidate gene prostaglandin receptor EP4 which flanks the area of association. This
association was also replicated in the UK wide genome wide scan.(57)
Further combined analysis of the US, UK and Flemish genome wide studies have identified 32
loci that reach statistical significance (p<10"7).(151) Eleven of the loci had been previously
identified and 21 of the loci were novel.
In the first genome wide scan to be reported in patients with ulcerative colitis, a UK wide
study of nonsynonymous SNPs identified a novel susceptibility locus ECM1 that was
associated with ulcerative colitis.( 152) Interestingly, some of the previous associations with
Crohn's disease were replicated- IL-23R, the FIFA locus, NKX2.3 and MST1. The autophagy
genes ATG16F1 and IRGM were not associated with ulcerative colitis eloquently illustrating
the genetic relationship between the two inflammatory bowel diseases. Further genome wide
association studies carried out in patients of European ancestry have identified ulcerative
colitis risk loci on chromosomes lp36 and 12ql5 that were replicated in independent
populations,(153) and a SNP flanking IF-10, a strong candidate gene in ulcerative colitis
pathogenesis^ 154)
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1.10 MICROARRAY GENE EXPRESSION STUDIES
Genome wide microarray expression studies allow a comprehensive picture of gene
expression at the tissue and cellular level, thus helping understand the underlying
physiological processes. Over the last 10 years microarray publications have had a major
impact on gene expression research and have led to a significant number of novel findings.
1.10.1 History of Microarray Technology
Microarray technology was developed from spotted nylon array technology used to identify
genomic inserts in bacterial colonies by hybridization with preidentified cDNAs.(155) In the
seminal microarray experiment using a two- colour fluorescent pattern of differential gene
expression, expression patterns were compared between the root and the leaf ofArabidopsis.
(156) Twenty seven of the 45 genes examined were found to have significantly different
expression levels when the root and leafwere compared and in 26 of these genes the
difference in expression was more than 5 fold. Interestingly mRNA from the light regulated
chlorophyll a/b binding gene was found to be around 500 times more abundant in the leaf
compared to the root. The authors concluded that cDNA microarrays could provide a useful
link between human gene sequences and clinical medicine, thus helping in the investigation
and understanding of physiological and pathological conditions.
Since 1995 there has been a rapid increase in the number of papers published using microarray
technology from 7 in 1995-96 to 139 in 1999 and to 3000 in 2003, (157) with the majority of
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these papers using microarrays to measure expression rather than sequencing, re-sequencing
or genotyping.(155) The optimism set out by Mark Schena one of the authors of the seminal
Arabidopsis microarray experiment suggesting that "all human illness can be studied by
microarray technology, with the ultimate goal of this work being to develop effective
treatments and cures for every human disease by 2050" has yet to be been fully realised,
however, a number of exciting and novel observations have been generated.
1.10.2 Basic Microarray Function
Microarray is defined as a tool that allows the simultaneous study of expression of large
numbers of genes and initially arrays that contained feature spots of 200pm or smaller were
defined as microarrays.(158) To undertake a microarray experiment first RNA is extracted
from a biological sample and converted into cDNA or cRNA.(159) The sample is then
fluorescently labelled and hybridized on the microarray chip containing known DNA
sequences from genes of interest (Figure 1.1). At this point it is worth noting that microarray
nomenclature differs from conventional molecular biology nomenclature and the term 'probe'
refers to the known sequence which is tethered to the chip, where as the 'target' is the
unknown sequence that is in solution and binds to the known 'probe'. Previous conventional
techniques have the nomenclature the other way around-'probe' is in solution and 'target' is
the known and fixed sequence. The nomenclature was initially reversed by Phimister (160)
and this has been carried on by Afjymetrix, (Santa Clara, California) one of the established
microarray manufacturers^ 161)
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Figure 1.1: Schematic of gene expression analysis using oligonucleotide microarray
technology.
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Figure 1.1: Oligonucleotide arrays use short sequence 'probes' that span conserved exons
across transcripts of targeted full length genes. Thus, the fluorescent signal from each of the
probe pairs from a specific gene are measured and averaged, substantially reducing the risk of
cross hybridization and background noise. Figure copied and modified from.(162)
Following the hybridization the microarray chips are washed so that all that remains are the
fluorescent 'targets' tethered to the microarray 'probes'. Laser technology is then used to
measure the location and intensity of the fluorescent signal from each spot on the microarray
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chip and the degree of intensity of fluorescence measured is calibrated to calculate the levels
ofmRNA expression for each sequence.
1.10.3 Development of Microarray Technology
Genomic research and in particular microarray studies have turned molecular biology from a
data poor into a data rich science and to process and manage these large volumes of data new
technologies and techniques have been developed. (163) With each step in the miniaturization
ofmicroarray technology increasing numbers of sequence probes can be placed on each array
chip. In the first study in patients with inflammatory bowel disease in 1997 Heller and
colleagues examined the expression of 96 genes whereas the Agilent arrays used to generate
the data presented in this thesis have 41058 sequences on each chip.(l64;165) It is expected
that the number ofprobes on each chip will continue to grow in an exponential manner until
the physical limitations imposed by the diffraction of light limit further expansion at around
lpm per feature size.(155)
Attention has also focused on reducing the amount ofRNA required for each array chip as
RNA from diseased tissue is often only available in small quantities and is difficult to obtain.
In microarray studies in patients with inflammatory bowel disease this trend towards the
ability to analyse smaller amounts ofRNA has been illustrated with initial studies having to
use full thickness blocks from surgical resections for analysis,(166;167) where as more recent
studies have been able to use endoscopic pinch biopsies.(168) Some initial studies also pooled
RNA from a number of diseased samples enabling there to be sufficient quantities ofRNA to
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be analyzed, however, in many cases this approach resulted in significant volumes of
background noise.(157;169)
One of the technologies put forward for enhancing the detection of low levels ofRNA from
small samples has been the use of longer oligonucleotide probes.(170) Affymetrix one of the
established microarray manufacturers constructs oligonucleotide arrays containing 25
nucleotides where as Agilent probes contain 60 nucleotides.(161;171) Data from Hughes and
colleagues examining expression profiles using microarrays fabricated by ink-jet
oligonucleotide synthesizer would strongly suggest that 60 nucleotide probes have a better
sensitivity and specificity compared to probes with smaller numbers of nucleotides to detect
transcripts in complex biological samples.(172) Having larger probes allows the Agilent
platform to function with only 50ng ofRNA for amplified cRNA labelling microarray and this
made it the most appropriate platform to use in the present study.(171)
Unpublished work carried out by Genisphere (Hatfield, Pennsylvania) has shown that using
fluorescently tagged DNA based dendrimers during sample amplification to 'capture'
complimentary sequences, microarrays can be carried out on as little as O.lng of total RNA
which equates to around 10 cells.(170) This technology should better enable researchers to
examine cells harvested by laser capture micro- dissection as these analysis have previously
been hampered by limited quantity and quality of RNA.(173)
Another area where microarray technology has advanced is in the interrogation of formalin
fixed or paraffin embedded tissues, many ofwhich are a number of years old and the RNA has
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degraded. By using conventional 60 nucleotide arrays on RNA extracted from these tissues
one would expect a 30%- 40% probe success rate compared to a success rate ofmore than
80% with fresh frozen tissue (Z Modrusan, Genentech, personal communication). However,
by using large numbers of tag sequences to quantify amplified primer extension products,
samples 20 years old have been analysed.(170)
1.10.4 Experiment design and interpretation
Experimental design and planning are crucial to interpreting the large volumes ofmicroarray
data that are generated. This process starts with the collection and phenotyping of the
biological material.(174) In the case of inflammatory bowel disease it is paramount to obtain
as much phenotypic information about the patients in order to investigate the effect of
variables such as disease location and smoking status on gene expression. The scoring of
biopsies for the degree of inflammation also helps differentiate the acute inflammatory signal
from quiescent disease where subtle changes may yield susceptibility genes.
Microarray technology has been and still is expensive, so a number of studies have been
hampered by insufficient replication of results and in some cases the pooling of biological
samples, thus generating false positive data.(155) The failure to undertake replication studies
has slowly been addressed as the importance of validating results has been realised,
technology become cheaper and more funding is made available.
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Increasing insight has also been gained into individual probe error distribution and the
corrections that are required to model these potential multiplicative errors.(175;176) Different
manufacturers have adopted a variety of approaches to ensuring experimental quality and one
way is to 'spike- in' known amounts of a positive control at a level roughly corresponding to
one copy per cell in order for these sequences to easily detectable and biologically valid.(155)
By correcting for these known values comparisons can be made across different data sets.
Other platforms have adopted a multiple scan approach, further extending the sensitivity of
detection.(171)
1.10.5 Validation ofMicroarray Results
Comparing different gene expression studies using different microarray formats to validate
results has been fraught with difficulty, however, a number of collaborative efforts have now
compared different formats and set minimum standards for data presentation^174; 177) When
the technology was in its infancy microarray chip manufacturers were reluctant to divulge the
exact sequences of their probes so investigators were unable to identify which part of the gene
or indeed which splice variant of the gene the probe was targeting.(157) Since 2001 increasing
numbers ofmicrochip manufacturers have made their probe sequences readily available on
databases such as ensemble (http://www.ensembl.org/index.html).
Recent data presented by the Microarray quality control project (MAQC) and the External
RNA Controls Consortium (ERCC) have compared gene expression data derived from
common samples among different microarray platforms.(178; 179) In this study 4 pools of
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samples were created- sample A contained 100% Universal human reference RNA (UHRR),
sample B contained 100% Human brain reference RNA (HBRR), sample C was composed of
75% UHRR and 25% HBRR and sample D was composed of 25% UHRR and 75%
HBRR.(179) Six platforms were tested- Applied biosystems, Affymetrix, Agilent technologies,
GE healthcare, Illumina and Eppendorf
All the sequence information for the probes was provided by the manufacturers and these were
found to represent between 15,429 and 16,990 genes. To simplify comparison one probe was
chosen to represent each gene and genes were selected if they were represented on each
platform resulting in 12,091 probes matching 12,091 common reference sequences from
12,091 genes. Overall the median coefficient of variation ranged from 10% to just over 20%
which was not dramatically higher than the replicate values calculated on the same platform.
The results displayed a high level of intra-platform consistency across different test sites as
well as a high level of intra- platform concordance with comparing differentially expressed
genes. Three of the platforms- the Affymetrix, Illumina and the Agilent platforms also
displayed a correlation of greater than 0.9 with TaqMan assays of 450 of the examined genes
adding further validity to the results.
In a parallel publication, one, two and three colour microarray platforms were investigated and
found to have high correlation coefficients suggesting that the colour number need not be a
factor in determining microarray design.(180) In a further study by Canales and colleagues a
high correlation was again observed between microarray data from three platforms and 997
TaqMan assays, 205 real time PCR assays and 244 QuantiGene assays.(181) Taken together
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these data validate the use of carefully designed and executed trials using microarray
technology to quantatively characterise gene expression.
1.10.6 Statistical analysis of microarray data
Microarray technology has driven forward an experimental method that is based on a
hypothesis free, unbiased sample screening approach and to manage these novel data sets new
data interpretation techniques have been required.(182) A number of initial microarray studies
only published fold changes without p values and confidence intervals, however, as the field
has matured more rigorous statistical techniques are being used.(183)
As thousands of genes are looked at simultaneously correction for multiple comparisons is
important as if 20000 genes are investigated for expression changes with a p threshold of 0.01,
200 genes would by differentially expressed by chance alone. A Bonferroni correction corrects
the p value for the number of comparisons in each experiment, however, many would argue
that the Bonferroni correction is too conservative a correction and true biological differences
will be missed.(163) Less conservative corrections for multiple comparisons have been
proposed and these probably strike a more realistic balance between eliminating false
positives and observing true biological differences.(184)
To correct for multiple hypothesis testing, Storey and colleagues have proposed a method for
calculating a q-value for each tested feature on the microarray chip.(185) The q-value
estimates significance in terms of the false discovery rate rather than the false positive rate.
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From the q-values a false discovery rate for each individual analysis can be calculated and a
false discovery rate of less than 5% is considered satisfactory.
1.10.7 Gene Ontology
Gene ontology is the categorization of all of the genes in a field of knowledge into functional
pathways showing the relationships between each gene. By analyzing genes that are
differentially regulated in microarray experiments and plotting their biological pathways and
function, networks of interacting genes/ proteins can be identified and potentially targeted. To
be able to plot and define these pathways, details about individual protein function and
interaction need to be understood and annotated and this has involved a considerable amount
manual labour.(186) Automated systems involving entering genes discussed in publications
from PubMed to ontology data sets are being developed and an example of a gene ontology
map is shown in Figure 1.2.
With increasingly large numbers of sequences that represent genes being recognised by
ontology software packages, a more meaningful interpretation of the data can be gathered and
this type of analysis provides a conceptual framework for semantic representation of textual
information.(187)
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Figure 1.2: A Gene ontology map involving a subset of differentially regulated genes in
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Figure 1.2: Upregulated genes are shown in a spectrum of pink where there is a small level of
upregulation to red where there is a high degree of upregulation. Downregulated genes are
shown in a spectrum of light green where there is a small level of downregulation to dark
green where there is a high degree of downregulation. No change in expression was noted in
genes shown in white. The area of the cell in which the protein products function is also
illustrated. Solid lines between genes illustrate confirmed interactions in the direction of the
arrow and hatched lines between the genes show probable interactions in the direction of the




As the cost ofmicroarray technology declines and results generated become more robust
microarrays will increasingly become available as a routine diagnostic test in clinical
medicine. Also with the miniaturization of the technology, smaller samples including those
captured by laser micro- dissection will be analysed with greater sensitivity. Microarrays are
increasingly being used for genotyping with simple discrimination arrays used to identify
SNPs in the DNA.(188) Genome wide epigenetic analysis and splice variant analysis are two
further fields where microarray based techniques are being developed.
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1.11 CLINICAL DATA GENERATED BY MICROARRAY STUDIES
Probably the most provocative and clinically relevant data generated by microarray has been
in the field of cancer research. An example of the potential ofmicroarray was demonstrated by
Alizadeh and colleagues who carried out microarray analysis on 96 samples ranging from
normal lymph node tissue to a variety of different non-Hodgkin's lymphoma.(189) By
comparing expression analysis in a 'Lymphochip' panel of 3,186 genes between patients with
diffuse large B- cell lymphoma (DLBCL) prior to treatment the investigators were able to
group these patients into two discrete groups- germinal centre DLBCL and activated DLBCL.
A subset of these markers were followed up and validated by PCR. When the clinical
progress of these two groups of patients were examined the germinal cell DLBCL had a higher
five year survival than the activated DLBCL (75% n=25 versus 16% n=37 respectively, p
<0.01) prompting the authors to suggest that the DLBCL category harboured two different
diseases and that expression profiling in combination with clinical indicators would help
manage therapeutic intervention in these patients.
Gene expression profiles have also been successfully used to predict prognosis in 295 patients
with breast cancer,(190) however, a meta- analysis of 84 studies found that DNA microarrays
had a variable prognostic performance in measuring prognosis in a number of different
cancers.(191) In this meta-analysis, larger studies with appropriate clinical design and larger
probe sets yielded better prognostic information than smaller studies.
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Because of the relative ease of biopsy of the gastrointestinal tract there have been a number of
microarray studies in gastrointestinal cancer and coeliac disease. Differential expression of
duodenal biopsies in patients with coeliac disease who were untreated, patients on a gluten-
free diet and healthy controls have led to the discovery of a number of candidate genes that are
under further investigational92; 193)
1.11.1 Microarray Studies in Patients with Inflammatory Bowel Disease
In 1997 microarrays were used to compare synovial tissue obtained from patients with
advanced rheumatoid arthritis undergoing arthroplasty or remedial synovectomy with
inflamed bowel of patients undergoing surgery for Crohn's disease.(194) Ninety six candidate
genes were selected and their expression was compared in the rheumatoid arthritis and the
Crohn's disease tissue. As expected many inflammatory genes were commonly expressed
between the two diseased tissues and the authors then went on to investigate several genes that
were expressed preferentially in the rheumatoid arthritis tissue as opposed to the Crohn's
disease tissue. In the three Crohn's disease samples that were microarrayed IL-1 converting
enzyme, tissue inhibitor ofmetalloproteinase 1 (TIMP-1) and Migration inhibitory factor
(MIF) had notably increased expression.
In 2000 Dieckgraefe and colleagues published a study using microarray technology to
compare eight patients who had ulcerative colitis and were having colectomies for disease
refractory to medical management and a control group.(166) The severity of the ulcerative
colitis was assessed by taking a paired biopsy and having a pathologist assess it for disease
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severity. Because these samples reflected the more severe end of the disease activity spectrum
one specimen was taken from uninvolved mucosa of one patient with ulcerative colitis having
a colectomy. The control group was made up of 3 non inflamed samples, resections for
adenocarcinoma, diverticular abscess and diverticulitis. Four patients formed the inflamed
control group, one patient with an inflamed colon as a result of a rectal prolapse and three
patients with Crohn's disease-1 fistulating, 1 ileal and 1 Crohn's colitis.
These samples were then microarrayed and 6500 genes were analysed. The results confirmed
increases in a number of genes previously implicated in the pathogenesis of ulcerative colitis
(IL1, IL1 RA and IL8) and suggested that multiple members of the chemokine subfamily may
play a role in disease pathogenesis.
In 2001 Lawrance and colleagues assessed gene expression in surgically resected colonic
specimens from six patients with Crohn's disease, six patients with ulcerative colitis and six
control samples.(167) The inflammatory bowel disease samples had their diagnosis confirmed
endoscopically and a pathologist selected biopsies from areas ofmoderately severe
inflammation in a blinded and random fashion. The control samples were taken from 4 colon
cancers, one diverticular disease and one caecal polyp and tissue was taken at least 10cm away
from the area ofpathology. The RNA was extracted from the full thickness colonic tissues.
The respective groups of samples were pooled and microarrayed.
7070 genes were examined and a three fold change was judged to be a significant threshold
for differential gene expression. 170 genes were differentially expressed in ulcerative colitis
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and Crohn's disease with almost an equal number up regulated and down regulated. 20% of
the differentially regulated genes were common to both forms of inflammatory bowel disease.
The locations of these genes were mapped and several were found to lie within IBD2 locus
which is located on chromosome 12. Comparing ulcerative colitis and Crohn's disease, in the
ulcerative colitis samples there was over expression ofHLA 1 transcripts and in Crohn's
disease samples were associated with an over expression of antimicrobial defensins.
Endoscopic investigation of inflammatory bowel disease with the ability to take pinch
mucosal biopsies has allowed investigators to microarray tissue from a larger range of
patients, encompassing those with less severe disease compared to patients who have required
resectional surgery. Langman and colleagues used microarrays to analyse biopsy specimens
from macroscopically non affected areas of the colon and terminal ileum.(168) Biopsies were
taken from nine patients with Crohn's disease, 18 patients with ulcerative colitis and 14
control patients who were having colonoscopic surveillance as a result of having a family
history of colon cancer. Tissue samples from the inflammatory bowel disease patients were
taken from at least 10cm away from pathological areas of inflammation. 22,283 genes were
analyzed and the samples were pooled from four patients in each group. Terminal ileal and
transverse colon samples were pooled to represent gene expression across the whole bowel.
Interestingly genes which were involved in cellular detoxification and biotransformation
(pregnane X receptor and MDR1) were significantly downregulated in the colon of patients
with ulcerative colitis, however, there was no change in the expression of these genes in the
biopsies from patients with Crohn's disease.
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In a study of 24 patients with ulcerative colitis Okahara and colleagues investigated the
difference in gene expression between endoscopic biopsies taken from inflamed and non
inflamed areas using a 1300 gene cDNA microarray.(195) Using a stringent three fold
difference in expression the authors found five genes- (Migration inhibitory factor- related
protein 14 (MRP 14), growth-related oncogene gamma (GROy) and serum amyloid A1
(SAA1) were upregulated where as TIMP1 and elfin were down regulated in the inflamed
biopsies when compared to the non-inflamed biopsies. These results were confirmed using
real time PCR.
Costello and colleagues examined the expression of 33792 sequences in endoscopic sigmoid
colon biopsies obtained from 11 healthy controls, 10 patients with Crohn's disease and 10
patients with ulcerative colitis.( 196) A number of sequences representing novel proteins were
differentially regulated and in silico analysis suggested that these proteins had putative
functions related to disease pathogenesis-transcription factors, signaling molecules and cell
adhesion.
Chemokines are known to determine inflammatory leukocyte recruitment and retention and
Puleston and colleagues investigated expression of 41 chemokines and 21 chemokine
receptors in 101 endoscopic biopsies from patients with Crohn's disease, ulcerative colitis and
histologically normal controls.(197) Chemokines CXCLs 1-3 and 8 and CCL20 were
upregulated in active colonic Crohn's disease and ulcerative colitis when compared to
uninflamed inflammatory bowel disease biopsies and controls. Real time PCR showed
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increased expression of the receptors of the chemokines that were upregulated in the inflamed
biopsies (CXCR1, CXCR2 and CCR6).
Microarray analysis has also been used to analyse peripheral blood mononuclear cells in
patients with inflammatory bowel disease. To attempt to identify different expression
signatures from patients with Crohn's disease and patients with ulcerative colitis Burczynski
and colleagues studied peripheral blood mononuclear cells from 59 patients with Crohn's
disease and 26 patients with ulcerative colitis.( 198) Twelve genes were identified that
distinguished Crohn's disease patients from ulcerative colitis patients with a high degree of
accuracy and the authors went on to speculate that looking at expression of these genes would
be a useful way to determine the diagnosis in patients with indeterminate colitis.
In a further microarray experiment looking at peripheral blood mononuclear cells
in Crohn's disease patients who were homozygote or compound heterozygote for the three
common NOD2/CARD15 variants- Arg702Trp, Gly908Arg and Leul007fsinsC, and
comparing these samples to Crohn's disease patients who were wild type for these
NOD2/CARD15 variants, a globally blunted transcriptional response was observed in the case
of the NOD2/CARD15 variants following the addition ofmuramyl dipeptide.(199)
These data generated from surgical resections, endoscopic biopsies and peripheral blood
mononuclear cells from patients with inflammatory bowel disease illustrate how useful
microarrays have been in the investigation and understanding of inflammatory bowel disease.
They also show how as microarray technology has developed with increasingly large numbers
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of sequences being analysed with greater sensitivity and specificity in increasingly small
biological samples.
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1.12 OTHER MOLECULAR IDENTIFICATION STRATIGIES
1.12.1 Proteomics
Proteomic analysis is another new investigative tool that has not been used to any large extent
in the field of inflammatory bowel disease. Proteomics refers to the study of the total protein
content of cells.(200) This is achieved by combining the techniques of protein electrophoresis
and mass spectrometry. Expression profiles of proteomes may be generated from samples of
serum or secreted fluid, and these may be able to differentiate disease progression, response to
therapy and identify novel therapeutic targets.
Preliminary data has been generated in our unit comparing serum of patients with severe
ulcerative colitis who responded to corticosteroid therapy and matched patients who were
resistant to and failed corticosteroid therapy.(201) Proteomic profiles of corticosteroid
resistant and responsive groups were significantly different with 12 proteins up-regulated and
7 proteins down-regulated in the corticosteroid resistant group. These results suggest that
protein profiling may be useful in predicting patient response to corticosteroid therapy and
identification of these proteins is currently underway.
1.12.2 Yeast Two-Hybrid Screening
The yeast two-hybrid assay is an elegant means of investigating protein-protein interactions,
which have become increasingly important in our understanding of biological systems and
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pathways. The yeast two-hybrid system can also be used to characterize interactions already
known to occur, thus helping delineate the protein domains responsible for the interaction and
the environmental conditions involved.(202)
The yeast two-hybrid assay is performed in the budding yeast, S cerevisiae using two fusion
proteins: the target protein of interest, known as 'bait' is fused to a DNA binding domain
attached to its N-terminus. The second protein, the 'prey' is fused to an activation domain. If
the bait protein interacts with the prey, these bring the binding domain and the activation
domain of transcriptional activator together, which in turn switches on the expression of the
reporter genes. The reporter genes are constructed to allow growth of the yeast in a selective
medium when the interaction occurs. When investigating 'protein- protein' interactions, a
single bait protein is used to search for interaction with a library of proteins fused to the
activation domain. The choice of library is determined by the tissue of interest, e.g. intestinal
cell library for inflammatory bowel disease.(203)
Schizophrenia is a disease of polygenic genetic susceptibility where the yeast two hybrid
system has been successfully used to identify candidate genes. The disrupted-in-
schizophrenia 1 (DISCI) gene which was identified in 2000 (204) and confirmed in other
cohorts,(205 ;206) was used as bait. DISCI encodes a novel protein of unknown function and
full-length human DISCI protein was used to screen human adult and foetal brain libraries for
interacting proteins, using the yeast two-hybrid system.(207) Twenty-one proteins from a
variety of locations were identified implicating DISCI in several aspects of central nervous
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system signalling and confirming data from other yeast two-hybrid scans using DISCI as
bait.(208;209) From these data the authors were able to identify a number of potential DISCI
interactions and they were able to speculate that DISCI one may be at the centre of an
extensive protein interaction network.
In inflammatory bowel disease, Barnich and colleagues used NOD2/CARD15 gene as 'bait' to
screen a bone marrow library and they identified GRIM 19, a protein with homology to the
NADPH dehydrogenase which interacted with endogenous NOD2.(210) GRIM 19 is required
for NFkB activation following NOD2 mediated recognition of bacterial muramyl dipeptide
and the authors hypothesised that GRIM 19 is a key component of the CARD15/NOD2





From the discovery of the NOD2/CARD15 gene to the era of genome wide association
studies, genetic studies in inflammatory bowel disease have advanced at a rapid rate. The plan
for this thesis was created in 2004 to follow up the Nature Genetics publications of Stoll and
Peltekova and colleagues,(95;107) along side investigating genome wide expression in
endoscopic colonic and terminal ileal biopsies of patients with inflammatory bowel disease
using microarray technology. As such the genetic data presented in this thesis must be seen in
the context of this fast moving field. The primary aims were:
1) To investigate gene expression profiles in human colonic and terminal ileal biopsies using
microarray technology in a well phenotyped cohort of patients with Crohn's disease,
ulcerative colitis and a control group. The role in disease pathogenesis of differentially
expressed genes was investigated along with expression of candidate genes identified by
genome wide association study and cell lineage analysis.
2) To investigate the contribution of polymorphisms in the IBD5 locus in determining
susceptibility and disease phenotype in Crohn's disease and ulcerative colitis in the Scottish
population.
3) To investigate the contribution of variants rsl248696 (113A) and rs2289311 in the
candidate gene DLG5 in determining genetic susceptibility to Crohn's disease and ulcerative
colitis in the Scottish population.
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4) To examine the colonic and terminal ileal expression of genes in the IBD5 locus and







ABI Techne Touchgene PCR Gradient machine
Agilent feature extraction software (version 7.5) (Agilent Technologies).
Agilent G2505B model slide scanner (Agilent Technologies).
Agilent whole human genome oligo microarray chips G4112A.
Endoscopic biopsy forceps (Olympus Endoscopy, Tokyo, Japan)
Endoscope and endoscopy stack (Olympus Endoscopy).
Endoscopic scope guide (Olympus Endoscopy).
Graph Pad Prism software (San Diego, CA)
Hybridization rotator oven for Agilent Microaray Chambers (Agilent Technologies).
Ingenuity Software (Mountain View, CA)
Microsoft Office XP/ 2007 software (Microsoft, Seattle).
Minitab software (Coventry, UK).
NanoDrop ND-1000 Spectrophotometer (NanoDrop Technologies, Wilmington,
Delaware)
Rosetta Resolver software (Rosetta Inpharmatics, Seattle).
Stratagene model MX4000 (La Jolla, Ca, USA).
TaqMan® ABI Fast Real Time PCR 7600 HT (Applied Biosystems)
TissueRuptor (Quiagen, Valencia, CA)
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3.1.2 Reagents
Micro total RNA isolation from animal tissues kit 74004 (Quiagen)







Carrier RNA, poly A
Low RNA input fluorescent linear amplification kit 5184-3523 (Agilent Technologies)
T7 promoter primer
5X first strand buffer
0.1MDDT












RNeasy Mini Kit 74104 (Qiagen)





Agilent stabilization and drying solution protocol 5185- 5976 (Agilent technologies).
Gene Expression Wash buffer 1
Gene Expression Wash buffer 2
DNase/ RNase free water
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100% Ethanol
MessageAmp™ II aRNA Amplification Kit AM1751 (Ambion technologies, Austin, TX).
T7 Oligo (dT) primer
ArrayScript
RNase inhibitor
10X First strand buffer
dNTP Mix













The microarray study was set up so that the patients were recruited at the Western General
Hospital in Edinburgh and then the snap frozen biopsies were sent for microarray analysis to
Genenetch Inc, in South San Francisco. For one year, all the patients who were attending for
colonoscopy at the Western General Hospital in Edinburgh were written to if they had existing
inflammatory bowel disease or symptoms consistent with a new diagnosis of inflammatory
bowel disease. During this year 67 patients with ulcerative colitis, 53 patients with Crohn's
disease and 31 control patients who were undergoing colonoscopy for other indications were
recruited. This gave us a data set that was at least three times larger than any previously
published microarray series in inflammatory bowel disease.
3.2.2 Recruitment of Patients for Endoscopic Biopsy Collection
The demographics of the ulcerative colitis and Crohn's disease patients are described in detail
in the subsequent chapters. All inflammatory bowel disease patients attended the clinic at the
Western General Hospital, Edinburgh and the diagnosis of inflammatory bowel disease
adhered to the criteria of Lennard-Jones.(211)
Phenotypic data were collected by interview and case-note review and comprised of
demographics, date of diagnosis, Vienna classification of disease location, disease behaviour
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and progression,(115) extra-intestinal manifestations, surgical operations, current medication,
smoking history, family history and ethnicity. Data were recorded on a proforma. At the time
of colonoscopy patients symptoms were evaluated using the simple clinical colitis activity
index (SCCAI) (212) for patients with ulcerative colitis and the Harvey Bradshaw Index for
patients with Crohn's dsease.(213) Patients with inflammatory bowel disease were defined as
'new diagnosis' if the colonoscopy took place at the time of their index presentation and they
had less than 24 hours of oral/IV therapy.
Eleven of the controls were male, 20 were female and they had a median age of 43 at the time
of endoscopy. Six of the controls had normal colonoscopies for colon cancer screening, 9
controls had symptoms consistent with irritable bowel syndrome and had a normal
colonoscopic investigation and 7 patients had a colonoscopy for an other indication and
histologically normal biopsies were obtained. Eight control patients had abnormal inflamed
colonic biopsies (1 pseudomembranous colitis, 1 diverticulitis, 1 amoebiasis, 2 microscopic
colitis, 1 eosoinophilic infiltrate, 2 scattered lymphoid aggregates and a history of
gastroenteritis).
3.2.3 Microarray Ethical Approval
Written informed consent was obtained from all patients. Lothian Local Research Ethics
Committee approved the study protocol: REC 04/S1103/22.
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3.2.4 Biopsy Collection
Anatomical location was confirmed by operator experience, distance of endoscope insertion
and endoscope configuration using a Scope Guide ™. Paired biopsies were taken from each
anatomical location. One biopsy was sent for histological examination and the other was snap
frozen in liquid nitrogen for RNA extraction. Each biopsy was graded histologically into those
with no evidence on inflammation, biopsies with evidence of chronic inflammation and a
chronic inflammatory cell infiltrate and those with acute inflammation and an acute
inflammatory cell infiltrate. Two hundred and forty five paired inflammatory bowel disease
biopsies and 76 paired control biopsies were collected. The number of paired biopsies from
each anatomical location are shown in Table 3.1.
Table 3.1: The location and number of biopsies in ulcerative colitis, Crohn's disease
patients and controls
Ulcerative Colitis Crohn's Controls
(n =67) disease (n=53) (n =31)
Total number of paired biopsies 139 106 76
Terminal Ileum 4 16 6
Ascending colon 33 20 17
Descending colon 35 30 23
Sigmoid colon biopsies. 57 33 27
Removed from analysis 10 7 3
3.2.5 RNA Isolation
RNA was isolated from the biopsies by Jennine Cornelius and Colin Noble at Genentech. The
biopsies weighed between 0.2mg and 16.5mg with a mean weight of 5.5mg. The biopsies
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were disrupted using a TissueRuptor in 350pl of Buffer RLT for 30 seconds. The supernatant
was then centrifuged for 3 minutes and 70% ethanol was added. The sample was placed in an
RNeasy MinElute spin column and centrifuged for 15 seconds and the flow through was
discarded. 350pl ofRW1 buffer was added. lOpl ofDNase was then added to 70pl of buffer
RDD and this was added to the samples and left for for 15 minutes. The samples were again
centrifuged for 15 seconds and the follow through was discarded. The samples were washed
with 350pl of buffer RW1 and the follow through was discarded. 500pl of buffer RPE was
then added and the samples and they were centrifuged for 15 seconds and the follow through
discarded. 80% ethanol was added and the samples were centrifuged for 2 minutes and the
follow through was discarded. The MinElute column was then removed and centrifuged for a
further 5 minutes. 14pl ofRNase free water was added and centrifugation was carried out for
1 minute to elute the RNA. To evaluate purity and integrity lpl of total RNA was assessed
from each sample with the Agilent technologies 2100 bioanalyzer using the Pico LabChip
reagent set.
3.2.6 Low Input Fluorescent Linear Amplification
The amplifaication was carried out by Karen Toy and Colin Noble at Genentech. A schematic
of the Agilent low input fluorescent linear amplification protocol is shown in Figure 3.1. One
lpg ofRNA was added to a centrifuge tube along with 5pl of T7 promoter primer and the
total volume was brought up to 11.5pl with nuclease free water. The primer was denatured by
incubating at 65°C for 10 minutes. The samples were then placed on ice. 8.5pl of the cDNA"
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master mix were then added to each sample and the samples were incubated in a circulating
water bath at 40°C for 2 hours (Table 3.2).
Table 3.2: cDNA Master Mix
Reagent Stock Amount (pi)
5X-lst Strand cDNA buffer 4.0
0.1 MDTT 2.0
10 mM dNTP mix 1.0
MMLV RT 1.0
RNaseOUT 0.5
total volume (pi) 8.5
The samples were then heated to 65°C for 15 minutes to inactivate the MMLV RT and the
samples were then placed on ice for 5 minutes and then briefly centrifuged.
To each sample tube 2.4pl of cyanine 3-CTP (lOmM) or cyanine 5-CTP (lOmM) was added
minimizing light exposure and the samples were warmed to 40°C for 1 minute and then
vortexed briefly. At room temperature 57.6pl of transcription master mix was added and the
samples were left in a covered water bath for at 40°C for 2 hours (Table 3.3).
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Figure 3.1: Agilent low input RNA amplification process



















Figure 3.1: A schematic representation of the low input RNA amplification process for cRNA
oligo microarray analysis. Copied and modified from www.chem.agilent.com/scripts/
generic.asp?lpage =9234&indcol= N&prodcol=Y
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Table 3.3: Transcription Master Mix
Reagent Stock Amount (pi)
H20 15.3






T7 RNA Polymerase 0.8
Cy5 or Cy3 2.4
total volume (pi) 60.0
3.2.7 Purification ofAmplified cRNA
The purification was carried out by Karen Toy at Genentech. 20pi of nuclease free water was
added to each sample to make a total volume of lOOpl. To each sample 350pl of buffer RLT
was then added and the samples were mixed thoroughly. 250pl of 100% ethanol was added,
the sample was mixed thoroughly and 700pl was placed in a RNeasymini column. The
samples were centrifiiged for 30 seconds at 9447 times gravity (x g) and the follow through
was discarded. 500pl of buffer RPE was then added and the samples were centrifuged for 30
seconds at 9477 x g and the follow through was discarded. 500pl of buffer RPE was again
added and the samples were centrifuged for 60 seconds at 9477 x g and the follow through
was discarded. The RNeasy column was then transferred to a new 1.5ml collection tube and
30pl of nuclease free water was added and the samples were left for 60 seconds.
Centrifugation was then carried out at 9477 x g for 30 seconds and the follow through was
kept. 30pl of nuclease free water was again added and the samples were left for 60 seconds.
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Centrifugation was then carried out at 9477 x g for 30 seconds and the follow through was
kept making a total final volume of around 60pl which was stored at -80°C. lpl and of
amplified cRNA was quantified using the NanoDrop ND-1000 Spectrophotometer.
3.2.8 Agilent Oligonucleotide Microarray Hybridization
The hybridization was carried out by Karen Toy and Colin Noble at Genentech. 750ng of
Stratgene universal human reference labelled with Cy-3 and 750 ng of the test sample labelled
with Cy-5 were fragmented for 30 minutes at 60°C in the dark using the target preparation mix
in Table 3.4. 250pl of hybridization buffer was then added to terminate the fragmentation
reaction.
Table 3.4 Target Hybridization Mix
Components lx44K
cyanine 3-labeled cRNA 750 ng
cyanine 5-labeled cRNA 750 ng
lOx Control Targets 50 pi
Nuclease-free H20 up to 240 pi
25X Fragmentation buffer 10 pi
total volume 250 pi
The samples were then centrifuged at 9477 x g and placed on ice before 490pl was loaded
onto the Agilent whole human genome oligo microarray slide G4112A. The samples were
hybridized for 18 hours at 60°C with constant rotation.
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3.2.9 Stabilization, Drying and Scanning Protocol
The stabilization, drying and scanning protocol was carried out by Karen Toy and Colin Noble
at Genentech. Following hybridization the slides were quickly placed in wash 1 (Agilent
stabilization and drying protocol) and covered for 10 minutes at room temperature. They were
then moved into wash 2 on ice for 5 minutes and finally into wash 3 at room temperature for 5
seconds. The slides were loaded into the agilent scanner.
Microarray slides were scanned using the Agilent G2505B model. Expression signals were
calculated using the Agilent feature extraction software (version 7.5). The scan settings are
shown in table 3.5.
Table 3.5 Agilent Scan Settings
Array
Scan Settings lx44K
Scan region (Scan Area) 61x21.6 mm
Scan resolution (pm) 10




3.3.1 Real Time PCR
Real time PCR was undertaken by Jennine Cornelius at Genentech. It was carried out on 8
genes in a cohort of the ulcerative colitis and control biopsies- SAA1, IL8, DEFA5, DEFA6,
MMP3, MMP7, S100A8 and TLR4 and 5 genes in the terminal ileal Crohn's disease biopsies-
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SAA1, IL8, DEFA5, DEFA6 and MMP3. Prior to RTPCR analysis 1 RNA amplification cycle
was carried out using the MessageAmp™ II aRNA Amplification Kit. 5pg of total RNA was
added to 6pl ofRNA free water with lpg of T7 Oligo (dT) primer. This was incubated for 10
minutes at 70°C and then centrifuged. The reverse transcription master mix was then prepared
(Table 3.5) and the samples were incubated for 2 hours at 42°C, briefly centrifuged and then
placed on ice.
Table 3.5: Reverse Transcription Master Mix for Single Amplification Cycle
Reagent Stock Amount pi




Reverse transcription PCR was then performed on 50ng ofRNA using Stratagene model
MX4000. TaqMan primers and probes were manufactured in house at Genentech. (Table 3.6)
PCR conditions comprised of 48°C for 30 minutes, 95°C hold for 10 minutes, followed by 40
cycles of 30 second 95°C melt and 1 minute 60°C anneal/extend. (Table 3.6) Absolute
quantification of product was calculated by normalizing to RPL19. Results were analysed
using Minitab software (Coventry, England).
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3.3.2 In Situ Hybridization for Defensin Alpha 5
Navneet Pal and Fiona Zhong (Core Labs, Genentech Inc) designed PCR primers to amplify a
318 bp fragment of human defensin alpha 5 spanning from nt 55-372 ofNM 021010 (upper¬
s' catccttgctgccattct and lower- 5' ggaccttgaactgaatcttgc). Primers included extensions
encoding 27-nucleotide T7 or T3 RNA polymerase initiation sites to allow in vitro
transcription of sense or antisense probes, respectively, from the amplified products. Surgical
biopsies were fixed in 10% neutral buffered formalin and paraffin-embedded. Sections 5 pm
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thick were deparaffinized, deproteinated in 10 ug/ml Proteinase K (Amresco) for 45 minutes
at 37 °C, and further processed for in situ hybridization as previously described.(214) P-
UTP labelled sense and antisense probes were hybridized to the sections at 55°C overnight.
Unhybridized probe was removed by incubation in 20pg/ml RNAse for 30 min at 37°C,
followed by a high stringency wash at 55°C in 0.1 X SSC for 2 hours and dehydration through
graded ethanols. The slides were dipped in NTB nuclear track emulsion (Eastman Kodak),
exposed in sealed plastic slide boxes containing dessicant for 4 weeks at 4°C , developed and
counterstained with hematoxylin and eosin.
3.3.3 Immunohistochemistry for Rabbit Anti-Human Lysozyme and Rabbit Anti-
Human Defensin Alpha 6
Sreedevi Chalasani (Core Labs, Genentech Inc) formalin fixed paraffin embedded tissue
sections and deparaffinized them prior to quenching of endogenous peroxidase activity (KPL,
Gathersburg, MD) and blocking of avidin and biotin (Vector, Burlingame, CA). Sections were
blocked for 30 minutes with 10% normal goat serum in PBS with 3% BSA. Tissue sections
were then incubated with primary antibodies for 60 minutes, biotinylated secondary antibodies
for 30 min, and incubated in ABC reagent (Vector) for 30 minutes followed by a 5 minute
incubation in Metal Enhanced DAB (Pierce, Rockford, IL). The sections were then
counterstained with Mayer's hematoxylin. Primary antibodies used were rabbit anti-human
lysozyme at 5.0 pg/ml (Dako, Carpinteria, CA) and rabbit anti-human defensin 6 alpha at 5.0
pg/ml (Alpha Diagnostics, SanAntonio, TX). Secondary antibody used was biotinylated goat
anti-rabbit IgG at 7.5 pg/ml (Vector) Defensin 6 alpha staining required pre-treatment with
100
Target Retrieval High pH (Dako, Carpenteria,CA) at 99C for 20 minutes, lysozyme staining
did not require pretreatment. All other steps were performed at room temperature.
3.3.4 Statistical Analysis
The microarray expression values were normalized using the Stratagem Universal Human
Reference. For quality control purposes the distribution of log intensities for each sample were
plotted and outlying samples (greater than 2 standard deviations from the mean) were
excluded from the subsequent analyses- 10 ulcerative colitis samples, 7 Crohn's disease
samples and 3 control samples.
The data were analyzed using the Rosetta Resolver software. Statistical significance of the
microarray data was determined by Student's unpaired t test, p < 0.01 and a fold change of
greater or less than 1.5 were considered statistically significant. To correct for multiple
hypothesis testing a q-value was calculated for each tested feature to estimate significance in
terms of the false discovery rate (FDR) rather than the false positive rate. For every
differential expression analysis the q-value was calculated and a FDR was calculated using the
method proposed by Storey and colleagues.(185) A FDR of less than 5% was calculated for
each of the presented analysis.
Hierarchical clustering analysis was undertaken using the Pearson correlation method. Genes
that had a greater or less than 1.5 fold change in expression were included in the cluster
analysis of the control, Crohn's disease and ulcerative colitis biopsies. Statistical significance
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of clustering into specific disease groups was calculated by Chi squared analysis. Gene
ontology was analyzed using Ingenuity software (Ingenuity Systems, Mountain View, CA).




3.4.1 Recruitment of Patients and Healthy Controls
The definitions of ulcerative colitis and Crohn's disease were based on the classifications as
described by Lennard-Jones.(211) Patients were recruited from the gastroenterology units of
The Western General Hospital, Edinburgh, Royal Infirmary, Edinburgh and St. John's
Hospital, Livingston (all in Lothian region serving a catchment population of approximately
500 000 patients) between 1997-2005. Fourteen patients with ulcerative colitis and 7 patients
with Crohn's disease were recruited to both the micoarray study as well as in the genetic
studies. Patients were recmited by Ian Arnott, Jack Satsangi, Colin Noble, Janice Fennell and
Linda Smith. Control patients were actively recruited from healthy volunteers and also
obtained from anonymous Scottish-Caucasian blood donors from the Lothian region. The
demographic details and numbers used are described in detail in the subsequent chapters. All
patients and controls were coded anonymously prior to entry to database as described below.
In each of these patients, 10 mis ofwhole blood were obtained for DNA extraction.
3.4.2 Phenotypic data acquisition and Storage
Phenotypic data were collected by Ian Arnott, Colin Noble, Hazel Drummond, Janice Fennell
and Gwo-Tzer Ho. Phenotypic classification were based on the Vienna classification (115)
and data were collected by patient questionnaire, interview and case-note review and
comprised of demographics, date of onset and diagnosis, disease location, disease behaviour,
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progression, extra-intestinal manifestations, surgical operations, smoking history, joint
symptoms, family history and ethnicity. All original phenotypic data was stored in a Microsoft
Access Database™, which was independently maintained by a database manager (Hazel
Drummond). The main statistical analyses were performed using the Minitab vlO
3.4.3 Ethics Approval
Written consent was obtained from each patient and the Medicine and Oncology
Subcommittee of the Lothian Local Research Ethics Committee approved the study protocol:
LREC 2000/4/192.
3.4.4 DNA extraction and storage
Genomic DNA was extracted by Norman Anderson in Edinburgh from peripheral venous
blood by a modified salting-out technique and resuspended in lxTE (lOmM Tris (pH 8.0),
ImM EDTA (pH 8.0) at a final concentration of 100 ng/ml. The optical density of the
resultant DNA was measured using a Gene Quant Pro instrument to estimate the actual DNA
concentration. Using a standard protocol, 10 mis of whole blood were added into a 50ml
conical tube together with 40 mis of red cell lysis buffer, and mixed and resuspended for 5
minutes. This was then centrifuged at 804 x g for 10 minutes. Following this, the supernatant
was removed, the pellet resuspended with 10 mis ofRCLB and re-centrifuged at 804 x g for a
further 5 minutes. The pellet was then further resuspended in 3 mis of nuclear lysis buffer and
sodium dodecyl sulphate. One ml of 6M sodium chloride and 3mls of chloroform were
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subsequently added leading to emulsification ofDNA (after vigorous mixing). This was then
centrifuged at 804 x g for 20 minutes. The contents of the tube separated into 3 layers with the
DNA in the middle layer. This layer was then removed and added into ethanol to allow
precipitation ofDNA. This DNA pellet was then removed and washed in lOmls of 70%
ethanol and then dried in room air for 5 minutes. The precipitated DNA was transferred into
0.5 mis ofTE buffer and stored at 4°C until it dissolved. Genomic DNA was diluted to
100ng/pl for PCR analysis.
3.4.5 PCR reaction: TaqMan® technology
The genotyping in this thesis was performed using TaqMan® by Angela Fawkes and Stuart
Bayliss at the Wellcome Genetics Core, Edinburgh. This PCR-based assay uses laser scanning
technology which excites fluorescent dyes present in the specially designed TaqMan® probes.
The system includes a built-in thermal cycler, a laser to induce fluorescence, CCD (charge-
coupled device) detector, real-time sequence detection software, and TaqMan® reagents for
the fluorogenic 5' nuclease assay. The cycle-by-cycle detection of the increase in the amount
of PCR product is quantified in real time as the special probes, "reporter dye", fluoresces when
the "quencher" is removed from the fragment during the PCR extension cycle. The prepared
genomic DNA was laid out in 96-well plates prior to genotyping by the Wellcome Genetics
Core, Western General Hospital, Edinburgh. (Table 3.7) In each plate, negative control wells
are used to check the quality of reaction. Thermal cycling conditions were two initial holds
(50° C for 2 min and 95° C for 10 min) followed by a 40-cycle two-step program (95° C for
15 sec and 60° C for 1 min).
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Table 3.7: TaqMan reaction volumes
Reaction Component Assay by Design 40X mix
Abgene Absolute QPCR ROX mix 2.5pl
Genotyping Assay Mix 0.125pl
dH20 2.375pl
3.4.6 Allelic discrimination in TaqMan
Allelic discrimination was scored independently by 2 blinded-laboratory scientists (Angela
Fawkes and Stuart Bayliss, Wellcome Genetics Core, Edinburgh). As quality control, a
random selection ofDNAs was re-genotyped and compared with original data. An example of
the allelic discrimination plot was as shown in Figure 3.2.
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Figure 3.2: TaqMan® allelic discrimination plot.
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Figure 3.2: An example of the readout from the TaqMan® allelic discrimination PCR-based
assay showing the results of the alleles.
3.4.7 Genetic Data Analysis
Each SNP was analyzed for association with inflammatory bowel disease overall, Crohn's
disease, ulcerative colitis and disease phenotype. Each of the variants studied was shown to be
in Hardy-Weinberg equilibrium in the control population. Genotype-phenotype associations
were analyzed by chi squared test, using Minitab statistical software package. Linkage
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disequilibrium was assessed using cocaphase software (Rosland Franklin centre for genomics
research, www.hgmp.mrc.ac.uk) and results were presented as pairwise D' values, a measure
between 0 and 1 where 0 is equal to no correlation and 1 shows complete correlation.
Haplotype analysis was investigated using Haploview (http://www.broad.mit.edu/mpg/
haploview/). Evidence for epistasis was investigated by comparing allelic frequencies of the
individual variants by chi squared analysis.
To identify significant independent variables associated with genotype, multiple logistic
regression analysis was carried out using Minitab statistical software package. The population
attributable risk percentage (PAR%) was defined as the excess rate of disease in individuals
with a mutation compared with those without. This was estimated by the method of
Schlesselman (215) which estimates PAR% as equal to attributable risk as a function of the
prevalence in the exposed population, divided by incidence of IBD in the population. To
calculate this, the prevalence of IBD was estimated at 100/100,000 and the frequency of all
alleles in the control population was assumed to reflect that of the general population.
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CHAPTER 4
CHARACTERIZATION OF INTESTINAL GENE EXPRESSION PROFILES
IN CROHN'S DISEASE BY GENOME-WIDE MICROARRAY ANALYSIS
SUMMARY
Introduction and Aims: Genome-wide microarray expression analysis creates a
comprehensive picture of gene expression at the cellular level. The aim of this study
was to investigate differential intestinal gene expression in patients with Crohn's
disease (CD) and controls with sub-analysis of confirmed CD susceptibility genes,
associated pathways and cell lineages.
Methods: 53 CD and 31 control subjects-23 normal and 8 inflamed non-inflammatory
bowel disease patients were studied. Paired endoscopic biopsies were taken from 5
specific anatomical locations for RNA extraction and histology. 41058 expression
sequence tags were analyzed using the Agilent platform.
Results: When all the CD biopsies were compared to the controls, 259 sequences
were upregulated and 87 sequences were downregulated. Upregulated genes in CD
included SAA1 (FC +7.5, p =1.47xl0"41) and REGL (FC +7.3, p =2.3xl0"16).
Downregulated genes included genes involved in cellular detoxification-SLC14A2
(FC -2.49, p =0.00002), CA2 (FC -2.4, p =8.4xlO"10) and CA1 (FC -2.3, p =7.5xl0"6).
In the CD terminal ileal biopsies diubiquitin (FC+11.3, p<lxl0"45), MMP3 (FC+7.4,
p=1.3xl0"), IRTA1 (FC-11.4, p=4.7xl0"12) and CCL23 (FC-7.1, p= 1.6x10"10) were
differentially expressed compared to controls. In the colon SAA1 (FC+6.3, p=5.3xl0"
8) was upregulated and TSLP (FC-2.3, p=2.7xl0"6) was downregulated comparing
non-inflamed CD and control biopsies, and the colonic inflammatory CD signature
was characterised by downregulated organic solute carriers-SLC38A4, SLC26A2 and
OST alpha. Analysis of the IL-23 pathway revealed IL-23A, JAK2 and STAT3 were
upregulated in the CD group compared to controls and in the inflamed compared to
non-inflamed CD biopsies. Modest changes in expression were also observed in a
number of the autophagy genes.
Conclusion: Expression of a number of key inflammatory molecules and pathways
were significantly dysregulated in CD emphasising their role in disease pathogenesis
and potential for translation to therapeutic targets.
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4.1 INTRODUCTION
Current evidence suggests that the inflammatory bowel diseases, Crohn's disease and
ulcerative colitis are complex non-Mendelian polygenic disorders with important
gene-environmental interactions.(34)
In the past 2 years, a number of genome-wide association studies (GWAS) in
populations ofEuropean descent and a subsequent meta-analysis have identified 32
confirmed Crohn's disease susceptibility genes/loci.(151) These include innate
immune genes that are specific to Crohn's disease; NOD2 (originally described in
2001)(42;43) and the autophagy genes ATG16L1 and IRGM,(57) clearly indicating
that defects in the intracellular processing ofbacteria constitute a central feature in the
pathogenesis of Crohn's disease. The discovery that germline variants of IL23R were
protective in Crohn's disease coincided with murine experiments detailing the
contribution of IL23 (rather than IL12 with which it shares the p40 subunit) to Thl7
driven chronic intestinal inflammation.(145;216) The meta-analysis and subsequent
studies in ulcerative colitis have demonstrated that 3 other IL23 pathway genes
(IL12B, JAK2 and STAT3) are all inflammatory bowel disease susceptibility
genes.(151)
At present there are no large scale intestinal genome-wide expression studies in
Crohn's disease. There is now an immediate need to explore in detail the function and
expression of the novel genetic associations.
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A number ofmicroarray studies have now been carried out in immune cell subsets to
try to understand differences in gene expression during activation and inflammation.
Genome wide expression from a compendium of six immune cell types has allowed
investigators to identify a collection of immune response in silico genes that have
specific expression in immune cells.(217) These genes have allowed investigators to
differentiate signaling pathways in immune cell subsets and to charcterize the
inflammatory response of genes known to play a role in immune response and genes
of unknown function.
The aim of the present study was to use microarray expression analysis to describe the
transcriptional profiles in the colon and the terminal ileum in patients with Crohn's
disease and controls. In additional to this hypothesis-free scanning, expression of
germ line variants identified by GWAS and cell specific lineage analysis were also
investigated.
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4.2 MATERIALS AND METHODS
53 patients with Crohn's disease and 31 control patients who did not have
inflammatory bowel disease and who were undergoing colonoscopy were recruited
(Table 4.1). Patient recruitment and data collection are detailed in the methods section
(Chapter 3.2.1). Combined analysis of all the inflammatory bowel disease biopsies
was also undertaken, adding in biopsies from patients with ulcerative colitis (Table
5.1).
4.2.1 Biopsy Collection
Paired biopsies were taken from each anatomical location. One biopsy was sent for
histological examination and the other was snap frozen in liquid nitrogen for RNA
extraction (Chapter 3.1.2-3). The number of paired biopsies from each anatomical
location are shown in Table 4.2.
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Table 4.1: The demographics of the Crohn's disease and control patients.
Crohn's disease Controls
Number of patients 53 31
Male/ Female 26/27 11/20
Median age at diagnosis (years) 28.6 43 at time of endoscopy
Median duration of follow up (years) 8.1
Disease Group
New Diagnosis (1) 7 (13%)
Quiescent disease (2) 30 (57%)
Active disease (3) 16(30%)
Vienna Classification of disease location
at diagnosis
Ileal disease (LI) 7 (13%)
Colonic disease (L2) 33 (62%)
Ileo-colonic disease (L3) 11 (21%)
Vienna Classification of disease location
at endoscopy
Ileal disease (LI) 6(11%)
Colonic disease (L2) 28 (53%)
Ileo-colonic disease (L3) 19(36%)
Vienna Classification of disease
behavoiur at diagnosis
Inflammatory (B1) 40 (75%)
Stricturing (B2) 3 (6%)
Penetrating (B3) 7(13%)
Vienna Classification of disease
behavoiur at endoscopy
Inflammatory (Bl) 32 (60%)
Stricturing (B2) 8(16%)
Penetrating (B3) 12 (23%)
Surgery* 20 (38%)
Current Smoker 11 (21%)
Family history of IBD 12 (23%)
Extra-articular symptoms 13 (25%)
5 ASA Therapy 21 (40%)
Corticosteroid therapy 4 (8%)
Immunosuppressant therapy (AZA, 6MP,
MTX, MMF)
13 (25%)
* Includes patients who were operated on for luminal complications of Crohn's
disease. Full phenotypic data were available on 94% of patients at the time of
diagnosis and 100% of patients at the time of endoscopy.
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Table 4.2: The location, number and inflammation status of biopsies from
Crohn's disease patients and controls
Crohn's disease Controls
Total number of paired biopsies 106 76
Removed from analysis 7 3
Inflamed Non-inflamed Inflamed Non-inflamed
Terminal Ileum 10 6 1 5
Ascending colon 12 8 3 14
Descending colon 14 16 6 17
Sigmoid colon biopsies. 16 17 8 19
4.2.2 Microarray Analysis
Detailed methods are provided the methods section (Chapter 3.2.4-8). Total RNA was
extracted from each biopsy and one 1 pg of total RNA was amplified using the low
RNA input fluorescent linear amplification protocol.
The samples were hybridized for 18 hours at 60°C with constant rotation. Microarray
slides were scanned using the Agilent G2505B model. Expression signals were
calculated using the Agilent feature extraction software.
4.2.3 Real Time PCR
Real time PCR analysis was undertaken in 4 genes-IL-8, SAA1, DEFA5 & 6 using
RNA from 15 Crohn's disease and 6 control terminal ileal biopsies. SAA1 and IL-8
were selected as they are robust markers of inflammation and showed significant
changes in the microarray data set. DEFA5 and A6 were selected as we had a
particular interest in their expression in the terminal ileum. Detailed methods are
described in the methods (Chapter 3.3.1). TaqMan primers and probes were
manufactured in house (Genentech, Inc) and are shown in Table 4.3.
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Statistical significance of the microarray data was determined by Student's unpaired t
test, p < 0.01 and a fold change of greater or less than 1.5 were considered statistically
significant. To correct for multiple hypothesis testing a q-value was calculated for
each tested feature to estimate significance in terms of the false discovery rate (FDR)
rather than the false positive rate. For every differential expression analysis the q-
value was calculated and a FDR was calculated using the method proposed by Storey
and colleagues.(185) A FDR of less than 5% was calculated for each of the presented
analysis. Gene ontology was analyzed using Ingenuity software.
The Mann-Whitney U test was used to analyze the real time PCR data, p < 0.05 was
considered significant. Gene ontology was analyzed using Ingenuity software.
Hierarchical clustering analysis using a collection of immune response in silico genes
from a compendium of six immune cell types was undertaken.(217) Hierarchical
clustering analysis was also undertaken using a set of 14 epithelial cell cytokines-
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CXCL1, CXCL2 CXCL5, CXCL9, CXCL10, CXCL11, CCL2, CCL4, CCL7,
CCL20, IL-8, IL-12A, IL-23A and MDK.(218-220)
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4.3 RESULTS
4.3.1 Gene Expression in Crohn's Disease and Controls
When 99 Crohn's disease biopsies were compared to 73 control biopsies, 259
sequences were upregulated and 87 sequences were downregulated. The 20 most
upregulated and downregulated sequences are shown in (Table 4.4) and the complete
table is Supplementary Table 1 on the Appendix 1 CD. Notably upregulated genes in
the Crohn's disease biopsies included the acute phase proteins serum amyloid Al,
SAA1, (FC +7.5, p =1.47xl0"41), the regenerating C-type lectin family member
REGL, (FC +7.3, p =2.3x10"16), the acute phase proteins S100A9, (FC +4.4, p
=2.4xl0~22) and S100A8, (FC +4.0, p = 3.5xlO"18). IL-8 a robust marker of mucosal
inflammation was the sixth most upregulated gene (FC +3.6, p =5.6xl0"19) and a
protein that interacts with TNFAIP3 (A20) TNIP3 was also increased (FC +3.8,
4.2x10"6). Among the most downregulated genes were genes involved in cellular
detoxification- SLC14A2, (FC -2.49, p =0.00002), carbonic anhydrase 2, (FC -2.4, p
=8.4xlO"10) and carbonic anhydrase 1, (FC -2.3, p =7.5xl0"6).
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Table 4.4: Expression changes in the 40 most dysregulated sequences comparing
all the Crohn's disease biopsies to control biopsies.
Gene Name Sequence Code Fold
Change
P-value
SAA1 A 24 P335092 7.47764 1.47E-41
REGL A 23 P108546 7.26194 2.25E-16
S100A9 A 23 P23048 4.37037 2.37E-22
S100A8 A 23 P434809 4.00494 3.48E-18
TNIP3 A 23 P386478 3.83902 4.17E-06
IL8 A 32 P87013 3.60471 5.60E-15
IF A 24 P92472 3.52236 6.18E-13
KCND3 A 32 P140268 3.38296 2.37E-18
CLECSF12 A 24 P235988 3.28581 6.65E-10
chromosome 10 open reading frame 81 A 23 P23980 3.19877 6.76E-13
regenerating islet-derived 3 gamma A 32 P65628 3.15414 6.74E-07
TFEC A 32 PI84394 3.10908 5.09E-12
IGSF6 A 23 PI06629 2.99982 1.28E-12
A 32 P90385 A 32 P90385 2.99826 5.10E-14
GW112 A 23 P2789 2.84338 5.99E-19
MGC27165 A 24 P315941 2.63927 2.00E-06
MMP3 A 23 P161698 2.62676 3.91E-10
KLK12 A 23 P500010 2.60484 2.40E-11
TZFP A 23 PI31024 2.57661 1.09E-08
REG4 A 24 P58673 2.56805 1.39E-12
CLECSF9 A 24 P78531 2.56703 2.91E-06
AATK A 23 P10559 -1.71307 1.55E-13
ECT2 A 24 P366033 -1.72142 2.52E-06
SLC26A2 A 23 P250951 -1.72588 0.00003
XRRA1 A 23 P370162 -1.73618 6.37E-07
RPS28 A 24 P40010 -1.77456 3.88E-17
ISL1 A 23 P81529 -1.79059 5.87E-07
MGC29643 A 23 P419696 -1.79074 4.43E-09
AQP8 A 23 P26522 -1.79996 0.00004
FLJ25770 A 24 P401185 -1.85266 0.00031
IL1R2 A 23 P79398 -1.86364 5.39E-11
ANKRD17 A 24 P220771 -1.87438 1.63E-06
A 32 P191066 A 32 P191066 -1.89029 1.62E-06
FLJ12572 A 24 P65121 -1.90062 0.00052
LOC339881 A 24 P846810 -1.94299 1.28E-10
NKD1 A 24 P304881 -2.10407 1.48E-17
CA1 A 23 P168916 -2.26411 7.46E-06
PRAC A 23 P15619 -2.42192 4.16E-11
CA2 A 23 P8913 -2.44317 8.36E-10
LOC389023 A 32 P86578 -2.48381 2.18E-28
SLC14A2 A 24 PI36471 -2.49075 0.00002
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4.3.2 Gene Expression in the Terminal Ileum
When all of the CD terminal ileal (TI) biopsies were compared to control TI biopsies
1035 sequences had a fold change of greater than 1.5 and 1014 sequences had a fold
change of less than 1.5 (p<0.01). The 20 most upregulated and downregulated
sequences are shown in (Table 4.5) and the complete table is Supplementary Table 2.
Upregulated genes in the Crohn's disease biopsies included diubiquitin (UBD) which
is involved in protein degradation in eukaryotic cells, (FC +1 1.3, p <1x10"45), MMP3,
(FC +7.4, p =1.3xl0"n), IL-8, (FC +4.9, p =2.3xl0"8), trefoil factor 1 (TFF1) which
acts in the GI tract to maintain the mucosal surface barrier, (FC +4.3, p =1.3xl0"7) and
the cytokeratin keratin 5p, (FC +4.2, p =0.005) (Table 4.6). Downregulated genes
included immune associated genes IRTA1- a novel surface B-cell receptor, (FC -11.1,
p =4.7xl0~12), CCL23, (FC -7.1, p =1.6xlO"10), CXCR4, (FC -6.0, p =8.2xl0"18), and
o
genes involved in cholesterol metabolism APOC3, (FC -8.2, p =7.0x10" ) and
APOA1, (FC -6.9, p =0.0031).
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Table 4.5: Expression changes in the 40 most dysregulated sequences comparing
Crohn's disease and control terminal ileal biopsies.
Gene Name Sequence Code Fold Change P-value
UBD A 23 P81898 11.30144 <10E-45
TIMD4 A 32 P69616 10.1666 1.21E-08
FLJ25393 A 24 P305993 9.5289 0.00061
FLJ27099 A 32 P200144 9.09174 2.98E-32
SOX14 A 32 P183652 8.89445 2.28E-14
BX108833 A 24 P460405 8.28796 4.11E-08
HK2 A 32 P175739 7.76749 5.97E-19
MMP3 A 23 P161698 7.42185 1.29E-11
RP11-653A5.1 A 32 P84237 7.41899 2.75E-07
TEX 12 A 23 P150362 7.1498 7.01E-09
III A 32 P157391 7.06942 2.35E-10
SI OOP A 23 P58266 6.37114 3.88E-28
Clorf34 A 23 PI60214 6.28438 4.85E-18
Sprn A 24 P930415 5.92864 0.00002
FOLH1 A 23 P47616 5.8971 1.55E-20
LOC92552 A 23 P361744 5.3328 6.97E-06
EYA2 A 23 P500421 5.32674 0.00091
CEACAM3 A 23 P130515 5.29423 1.44E-06
C14orf81 A 24 P323298 5.29169 8.53E-08
MGC27165 A 23 P259763 5.26036 0.00012
HEBP1 A 23 PI 17082 -4.43185 3.24E-09
ARHGAP24 A 32 P72067 -4.48983 7.05E-10
LOC375180 A 32 P49764 -4.52586 3.49E-12
SUSD2 A 23 P314101 -4.683 6.76E-06
AGXT2 A 24 P63468 -4.84685 0.00011
CYFIP2 A 24 P465879 -4.89606 0.0001
FNBP1 A 24 P899020 -4.92271 7.33E-19
SLC28A2 A 23 P48816 -5.02797 1.05E-15
OTTHUMPO11522 A 23 P45821 -5.03803 2.68E-08
PAX8 A 23 P324916 -5.80485 0.00263
CXCR4 A 23 PI02000 -6.01856 8.18E-18
CGGA17790 A 32 P203728 -6.46865 0.00016
APOA1 A 23 P203191 -6.8623 0.00305
C6orf32 A 24 P941359 -7.02034 1.09E-13
NPPC A 24 PI74353 -7.14015 0.00395
CCL23 A 24 P133905 -7.14857 1.62E-10
APOC3 A 23 P203183 -8.17858 7.02E-08
IRTA1 A 23 PI 15200 -9.62094 6.82E-06
MGC27169 A 23 P407695 -9.89477 4.82E-08
IRTA1 A 23 PI 15201 -11.4284 4.72E-12
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4.3.3 Colonic Gene Expression Analysis
To minimize the effect of differential gene expression related to the anatomical
location of the biopsy, sigmoid colon biopsies were used for analysis. To also remove
the acute inflammatory expression signature non- inflamed Crohn's disease biopsies
(n=17) were compared to non- inflamed control biopsies (n=18) (Supplementary
Table 3, Appendix 1 CD). SAA1 remained the most upregulated gene, (FC +6.3, p
o
=5.3x10") and in total 279 sequences were upregulated. 349 sequences were
downregulated and the most downregulated genes included MMP1, (FC -3.6, p
=2.4xl0~15), CXCL13, (FC -2.7, p =0.005) and TSLP-thymic stromal lymphoprotein;
(FC -2.3, p =2.7x10"6) (Table 4.7).
When the acute inflammatory signal was examined in the sigmoid colon and 16
inflamed Crohn's disease biopsies were compared to 17 non-inflamed Crohn's disease
biopsies, 279 sequences were upregulated and 148 sequences were down regulated
(Supplementary Table 4). Upregulated genes in the inflamed biopsies included
OLFM4- an anti-apoptotic molecule that inhibits the capsase cascade and also binds
to GRIM 19, (FC +6.2, p =2.9x10"14) and TNIP3. Downregulated genes included
organic solute carriers SLC38A4, (FC -2.7, p= 0.005), SLC26A2, (FC -2.5, p
=0.00001) and OST alpha, (FC -2.5, p =0.008).
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4.3.4 Analysis of Gene Expression Changes in Inflammatory Bowel Disease
Biopsies and Controls
To look for overall changes in gene expression, all 99 Crohn's disease biopsies and
control biopsies were analyzed alongside 129 ulcerative colitis biopsies, giving a total
of 228 inflammatory bowel disease biopsies which were then compared to the 73
control biopsies. 154 sequences had a fold change of greater than 1.5 and 37
sequences had a fold change of less than 1.5 (0.01>p>10 45) (Supplementary Table 5).
The most upregulated gene was serum amyloid A1 SAA1, (FC +7.15, p = < lxlO"45)
followed by TNFAIP3, (FC +6.0, p = 6.7xl0"17), which is involved in the TNF
signaling pathway and then the S100 proteins S100A8, (FC +3.9, p = 1.4xl0"34) and
Oft
S100A9, (FC +3.7, p = 1.7x10" ). A smaller number of genes were downregualted
including SLC14A2, (FC -1.9, p = 0.0024) and the fold changes observed were
smaller.
4.3.5 Expression of Genes implicated by GWAS Meta-analysis
Expression of susceptibility genes identified by GWAS meta- analysis by Barrett and
colleagues (151) were investigated along with further detailed analysis of the IL-23
and autophagy pathways (Table 4.8). Upregulated genes with modest increases in
expression in the Crohn's disease biopsies compared to the controls included NOD2/
CAD15, (FC +1.23, p =0.000243), PTGER4- prostaglandin E receptor 4, (FC +1.1, p
=0.00010) and NKX2.3, a 3 exon homeobox gene, (FC +1.37, p =0.001). There was
no expression probe on the Agilent microarray chip that represented IGRM and no
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differences were observed between disease groups when expression ofTNFSF15,
PTPN22, ICOSLG, ITLN1, ZNF365, LRRK2 and PTPN2 were examined.
When inflamed and non-inflamed Crohn's disease sigmoid colon biopsies were
compared MST1-Macrophage stimulatory protein; FC -1.58, p =0.0037 was
downregulated in the inflamed biopsies.
Table 4.8: Expression of genes identified by Barrett and colleagues (151) as being
associated with Crohn's disease




Inflamed CD sigmoid (16) v
non-inflamed CD sigmoid (17)
ID Symbol Agilent ID Fold Change p value Fold Change p value
717 JAK2 A 23 P123608 +1.90 9.43E-07 + 1.58 0.000031
5054 ATG16L1 A 32 PI 13508 -1.16 1.96E-05 +1.06 0.549
593 IL-23A/ pi 9 A 23 P425197 +2.32 0.000099 +2.11 0.000031
734 PTGER4 A 23 P435394 +1.11 0.000104 -1.04 0.55
1127 NOD2 A 23 P420863 +1.23 0.000243 + 1.24 0.1092
774 STAT3 A 24 PI 16805 +2.23 0.000353 + 1.66 0.0002
59296 NKX2-3 A 23 P52425 +1.37 0.000994 -1.17 0.456
1901 CDKAL1 A 23 P44781 -1.1 0.00964 -1.14 0.0919
1103 ORMDL3 A 23 P38190 +1.13 0.0140 +1.07 0.656
5946 CllorfiO A 23 P380839 +1.1 0.0156 -1.22 0.0077
)66 TNFSF15 A 23 P94754 + 1.08 0.0447 + 1.09 0.5281
5191 PTPN22 A 23 P201181 +1.07 0.107 + 1.03 0.6849
135 CCR6 A 24 P234921 +1.21 0.144 + 1.84 0.0566
5308 ICOSLG A 23 P317667 +1.1 0.161 -1.10 0.857
5600 ITLN1 A 23 P95790 -1.1 0.162 -1.02 0.905
1891 ZNF365 A 23 P86610 +1.17 0.244 -1.22 0.423
10892 LRRK2 A 23 P128447 +1.25 0.413 + 1.37 0.135
771 PTPN2 A 23 P309701 -1.04 0.483 +1.07 0.545
185 MST1 A 24 P148796 -1.04 0.709 -1.58 0.0036
19233 IL-23R A 23 P7560 -1.02 0.823 +1.05 0.4271
For each experiment the fold change and p values have been calculated. The number
of biopsies analyzed in each experiment are shown in brackets.
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4.3.6 The IL-23 Pathway
When Crohn's disease samples were compared to controls IL-23A/pl9, (FC +2.32, p
=0.000099), JAK2, (FC +1.90, p =9.4xl0"7), STAT3, (FC +2.23, p =0.0004) and
INFy, (FC +2.31, p =0.0019) were significantly upregulated in the Crohn's disease
biopsies (Figure 4.1). When inflamed Crohn's disease biopsies were compared to non-
inflamed Crohn's disease biopsies IL-23A/pl9, (FC +2.11, p =0.000031), JAK2, (FC
+ 1.90, p =0.00003), STAT3, (FC +1.66, p =0.0002) and INFy, (FC +2.33, p <0.0001)
had increased expression in the inflamed biopsies. No significant changes were
observed in IL-23R expression.
127


















Figure 4.1 The IL-23 pathway (Alex Abbas, Genentech, personal communication) is
illustrated along with gene expression of constituent molecules in Crohn's disease and
control biopsies separated by inflammation status. Gene expression is shown as box-
whisker plots. The boxes are 25th to the 75th centile. The IL-23 pathway is
upregulated in Crohn's disease biopsies compared to controls and in inflamed Crohn's
disease biopsies compared to non-inflamed Crohn's disease biopsies.
4.3.7 Autophagy Pathway
ATG16LI and 19 other genes and key regulators of the autophagy pathway were
analyzed (Figure 4.2). ATG16LI was modestly downregulated in the CD biopsies
regardless of inflammation status compared to controls; FC -1.16, p=1.96xl0"5 as was
(ATG4D; FC -1.14, p=0.0007) and (ATG3; FC -1.06, p=0.0052). (ATG12; FC +1.1,
p=0.041), (ATG16L2; FC +1.1, p=0.045) and (LC3B; FC +1.18, p=0.0003) were
marginally upregulated in the CD biopsies compared to the controls.
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Figure 4.2 The autophagy pathway is illustrated (Alex Abbas, Genentech, personal
communication). Gene expression is shown as box- whisker plots. PE -
Phosphatidylethanolamine, a lipid which covalently attaches to ATG8/LC3 and mediates its
attachment to autophagic membranes.
4.3.8 Unsupervised Hierarchical Clustering Analysis
When all of the Crohn's disease (n= 99) and control biopsies (n= 73) were clustered together
using unsupervised hierarchical clustering analysis, no separation of the biopsies by either
disease status or by the degree of inflammation was observed. When the anatomical location
that the biopsies were taken from was considered, 18 terminal ileal biopsies clustered together
(6 control and 12 Crohn's disease) (X2 = 10.2, p < 0.001).
Unsupervised clustering analysis of the terminal ileal biopsies initially was confounded by the
sex ofpatients, however when a degree of supervision was introduced and only terminal ileal
biopsies from female patients and controls were clustered, clustering by disease status was
observed (Figure 4.3).
Gene ontology of the 593 downregulated sequences grouped by biological process revealed a
preponderance of genes associated with carboxylitic acid metabolic processes- (39 of a total of
464 genes classified by the ontology software to this biological group; OR 3.4, p =7xl0"13),
organic acid metabolic processes (38/464; OR 3.1 p =lxl0~12) and lipid metabolic processes
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(46/620; OR 3.0, p =6.6x10" ). When the downregulated sequences were grouped by
biological function genes grouped under solute/ cation transporter activity (11/50; OR 10.3, p
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=6.9xl0~15), electrochemical potential- driven transporter activity (23/188; OR 5.16, p
=2.7xl0"14) and solute/ sodium transporter activity (10/46; OR 10.1, p =2.4xl0"13) were
disproportionately downregulated. When these groups of genes were combined to encompass
all genes involved in transporter activity, there was a significant over representation of this
group in the downregulated genes (64/1138; OR 2.3, p =3.6xl0"9).
367 sequences were upregulated in a subset of the Crohn's disease samples compared to the
controls. Ontology of these genes grouping by biological processes showed that genes that
grouped into structural molecule activity (22/603; OR 2.62, p =4.5xl0~5) and extracellular
matrix structural constituents (6/87; OR 5.5, p =0.0003) were overrepresented. When the
genes were grouped by biological function upregulated genes grouped into sequence specific
DNA binding (11/430; OR 2.28, p =0.007) and transcription factor activity (20/810; OR 1.7, p
=0.043).
132
Figure 4.3: Hierarchical clustering of terminal ileal biopsies from females with
















Terminal ileal biopsies from 8 patients with Crohn's disease, three healthy controls with
normal terminal ileal pathology and one patient with ulcerative colitis who had normal
terminal ileal pathology were clustered. The Crohn's disease, ulcerative colitis and control
patients are annotated with the inflammation status of the biopsy. The degree of upregulation
measured in red and downregulation measured in blue can be quantified using the logarithmic
key. Two areas appeared to be driving this separation and these have been highlighted in
orange-downregulated and green-upregulated.
133
4.3.9 Hierarchical Clustering by Specific Probe Subsets: Immune Response in Silico
(IRIS) Probes
Using the previously defined IRIS probes to detect differential expression, Crohn's disease and
control biopsies from the ascending and descending colon were compared.(217) Using the B
cell, monocyte and T cell probes we were able to observe separation of the biopsies into
Crohn's disease and control biopsies by unsupervised clustering- B cell probes (p =0.0006,
OR 2.74), the monocyte probes (p <0.0001 OR 5.22) and the T cell probes (p =0.0047 OR 2.4)
using Chi squared analysis. In the monocyte cluster 2 genes CXCL1 and MMP1 were
markedly differentially regulated in the Crohn's disease biopsies and controls. No terminal
ileal clustering was observed for any of the examined probes.
4.3.10 Hierarchical Clustering by Epithelial Cell Markers
Unsupervised clustering analysis using a panel of 14 epithelial cell cytokines showed clear
separation between colonic biopsies from Crohn's disease patients and controls p <0.00001
(Figure 4.4). When terminal ileal biopsies were considered this separation was not observed (p
=0.052).
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Figure 4.4 The colonic biopsies are annotated along the top of the figure (green-controls,
blue-non-inflamed Crohn's disease, orange-inflamed Crohn's disease, red-untreated inflamed
Crohn's disease). On the right of the figure the epithelial cell cytokines are annotated. The
degree ofupregulation measured in red and downregulation measured in blue can be
quantified using the logarithmic key.
4.3.11 Real Time PCR Confirmation ofMicroarray Results
In line with the histological classification of the biopsies, and the microarray results
significantly higher IL-8 levels were observed in the Crohn's disease terminal ileal biopsies
compared to the control terminal ileal biopsies (p= 0.0045) and in the inflamed Crohn's
disease terminal ileal biopsies compared to the non-inflamed Crohn's disease terminal ileal
biopsies (p= 0.0046)(Table 4.9). Trends were also observed towards SAA1 being more highly
expressed in the Crohn's disease biopsies compared to the controls and in the inflamed
compared to the non-inflamed ileal Crohn's disease biopsies. No difference in DEFA5 & 6
expression was observed in the Crohn's disease terminal ileal biopsies compared to the control
terminal ileal biopsies (p= 0.73 and p= 0.97 respectively), nor when the inflamed Crohn's
disease terminal ileal biopsies were compared to non-inflamed Crohn's disease terminal ileal
biopsies (p= 0.39 and p= 0.69 respectively).
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IL-8 8.5 65.7 (0.0045) 20.1 (0.054) 307 (0.0037) 307 v 20.1 (0.0046)
DefA5 1.26 0.70 (0.73) 0.51 (0.43) 0.96 (0.95) 0.98 v 0.51 (0.39)
DefA6 0.87 1.07 (0.97) 1.1 (0.74) 1.04 (0.85) 1.04 v 1.1 (0.69)
SAA1 1.7 3.52 (0.20) 2.0 (0.52) 20.7(0.14) 20.7v 2.0 (0.18)
The relative expression of each gene is shown in disease groups along with the p value in
brackets. The p values are calculated compared to the control group for each gene analyzed.
The number of biopsy samples used in each analysis is also shown in brackets.
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4.4 DISCUSSION
In this accurately phenotyped data set, strict separation of the biopsies by anatomical location
and inflammatory status has allowed us to minimize background noise and real time PCR
confirmation has increased the confidence associated with the interpretation of the data. For
the large number of novel Crohn's disease susceptibility genes from GWAS where little data
are presently available, we have been able to investigate expression profiles in the human
colon and terminal ileum.
When all the Crohn's biopsies were compared to controls serum amyloid A1 (SAA1) was the
most upregulated gene, followed by regenerating C-type lectin family member (REGL) and
the S100A8 and A9 genes. SAA1 is a HLA- associated apolipoprotein acute phase reactant
and levels can be elevated in inflammation, trauma and neoplasia. Its transcription is induced
by the pro- inflammatory cytokines IL-2, IL-6, TNFa and bacterial LPS, and it is the major
factor responsible for the development of secondary AA amyloidosis in chronic immune
mediated diseases such as Rheumatoid arthritis or Crohn's disease.(221) Ray et al have
speculated that persistently elevated levels of SAA1 contribute to reactive AA
amyloidosis.(222) In Crohn's disease reactive AA amyloidosis is rare and a much more
attractive role for SAA1 would be as a marker of disease activity, severity, and potentially
because of its induction by TNFa a predictor of response to anti- TNF therapy.
Given current concerns with respect to the reproducibility ofmicroarray expression data it is
firstly reassuring that our results are consistent with the findings from a previous microarray
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study in Crohn's disease patients where increased expression of the SI 00 and the REG gene
families was also observed.(167) Furthermore, in parallel with the results of Costello et al we
observed a number of sequences representing novel proteins that were differentially expressed
and using ontology analysis we were able characterize genes into functions related to Crohn's
disease pathogenesis^ 196)
This is the first study where genome wide expression has been investigated in unpooled
terminal ileal endoscopic biopsies from Crohn's disease patients and controls. The most
upregulated gene in the Crohn's disease compared to the control terminal ileal biopsies was
diubiquitin or ubiquitin-like protein FAT10. The family of ubiquitin-like proteins function as
part of the ubiquitin proteasome system which is a crucial pathway for protein degradation in
eukaryotic cells.(223) The gene is located at the major histocompatibility complex locus in on
chromosome 6 (224), an established Crohn's disease susceptibility loci and its expression has
been observed to be increased in 90% ofhepatocellular carcinomas and in 80% of colon
cancers.(225)
Diubiquitin is a downstream target of p53 and in p53-defective cells its expression is increased
resulting in chromosomal instability.(226;227) Overall in this data set diubiquitin was
upregulated when all Crohn's disease biopsies were compared controls by a fold change of 1.5
and interestingly diubiquitin expression in hepatocellular cancer and colon cancer correlates
with increased expression of IFN-gamma and TNFa suggesting a mechanism for
carcinogenesis in this pro-inflammatory environment.(228)
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In the terminal ileal biopsies there was no difference in expression of the alpha defensins 5 and
6 (DEFA5&6) in the Crohn's disease patients and controls regardless of the degree of
inflammation in the biopsies. These results were confirmed by real time PCR and are contrary
to previous data where reduced DEFA5&6 expression was observed in the terminal ileum of
Crohn's disease patients regardless of the degree of inflammation.(66)
More recently, Simms et al also showed that expression ofDEFA5&6 was downregulated in
terminal ileal Crohn's disease biopsies.(229) However, this downregulation was inflammation
specific, probably reflecting a loss of the epithelial layer and a reduction of epithelial and
Paneth cells as a consequence of persistent inflammation. Previously we have shown that the
increase in colonic expression ofDEFA5&6 in ulcerative colitis patients is largely mediated
by Paneth cell metaplasia and that in the colon unregulated Paneth cell differentiation, and the
consequent increase in DEFA5&6 expression, may perpetuate mucosal inflammation.(230)
An interesting change in expression in the colonic Crohn's disease biopsies reflecting the
traditional Thl and novel Thl7 paradigm in Crohn's disease was the downregulation of
thymic stromal lymphopoietin (TSLP) in non-inflamed colonic Crohn's disease samples
compared to non-inflamed controls. TSLP is a cytokine that mediates its effect through
dendritic cells to promote the Th2 differentiation ofCD4+ T cells.(231) Moreover, mice with
an intestinal epithelial cell (IEC) deletion of intrinsic IkB kinase, have reduced TSLP
expression and as a consequence have a poor Th2 immune response resulting in an inability to
eradicate infection.(232) These mice also develop severe intestinal inflammation as a result of
dendritic cell derived Thl and Thl7 pathway activation and it is intriguing to speculate that in
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the non-inflamed human Crohn's disease colon decreased levels ofTSLP may perpetuate the
subsequent persistent and excessive inflammation.
When the colonic analysis was compared to our previous expression studies in ulcerative
colitis there was a 23% homology between the differentially regulated genes in the respective
Crohn's disease and ulcerative colitis analysis compared to controls.(230) The colonic
inflammatory expression signature observed in the Crohn's disease biopsies was also similar
to that observed in the ulcerative colitis biopsies and one of the most differentially regulated
genes in both of the data sets was serum amyloid A1 (SAA1).
The identification of IL-23R as a Crohn's disease susceptibility gene has focused investigation
towards the distinct Thl7 lineage.(54) We observed that expression of a number of
components of this pro-inflammatory pathway- IL-23A, STAT3, JAK2 and IFNy were
increased in Crohn's disease compared to controls and that this change was driven by active as
opposed to quiescent disease. These convincing genetic and expression data emphasize the
importance of this pro-inflammatory pathway in the pathogenesis of Crohn's disease. Multiple
therapeutic targets have been identified in this pathway and clinical trials of a monoclonal
antibody against the p40 subunit of IL-12/23 have produced promising early clinical data.(59)
The discovery of ATG16L1 as a Crohn's disease specific susceptibility gene has strongly
implicated the autophagy pathway in the pathogenesis of Crohn's disease. Autophagy is a
highly conserved cellular process where the cell digests part of its own cytoplasm and it
functions as a normal physiological response to remove toxic material or intracellular bacteria
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from the cell. The pathway has also been implicated in the pathogenesis of neurodegenerative
diseases such as Alzheimer's and Parkinson's disease.(52)
Recent data have linked the innate immune response and autophagy via Toll-like-receptor
(TLR) engagement. (233) TLR induced phagosomes within macrophages triggered ATG5 and
ATG7 mediated acidification and enhanced killing of the ingested organisms. These
interactions between the innate immune system and the autophagy pathway have provoked
investigators to speculate about specific interaction between NOD2/CARD15 and autophagy
and this is an area of active investigation.
NKX2.3, a novel IBD candidate gene was upregulated in Crohn's disease and it has been
observed that NKX2.3 deficient mice have smaller spleens and Peyers patches, and that in
these animals the T and B cells are disorganized.(234) Furthermore, NKX2.3 homozygote
mice lack mucosal adhesion cell molecule-1 (MAdCAM-1), probably as a result of a lack of
NKX2.3 mediated MAdCAM-1 transcription. MAdCAM-1 mediates lymphocyte homing and
extravasation during the inflammatory response and this pathway has clinical implications
with regards therapeutic intervention and monitoring response to treatment.(235)
Clustering analysis has allowed us to differentiate between biopsies from Crohn's disease
patients and controls and the observed separation was driven by a cluster of downregulated
genes involved in the normal homeostasis of the terminal ileum-organic acid and lipid
metabolic processes, and solute/cation transporter activity. The cluster of upregulated genes
had a preponderance of genes that grouped into structural molecule activity function. The
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differing expression signature observed in the terminal ileal biopsies appeared to be primarily
inflammation driven, rather than disease specific as the changes were less obvious in the non-
inflamed analysis than when the inflamed and non-inflamed Crohn's disease biopsies were
compared. These dysregulated probes could form the basis of a diagnostic expression chip to
help diagnose ileal Crohn's disease and grade its severity.
An alternative method of clustering analysis was to cluster samples using a subset of genes
related to cell lineage.(217) We have undertaken this analysis in our samples by separating by
genes from key immune cell types and observing clustering of the colonic biopsies. From this
we can clearly identify immune cell infiltration in the biopsies and characterize the most
differentially expressed genes. These expression signatures can also be used to gain insight
into genes of unknown function and provide a resource to investigate immune cell
differentiation in health and in different immune mediated diseases.
A final area of interest was in the role of the intestinal epithelial cell in the inflammatory
process. The fourteen intestinal epithelial cell markers we investigated showed good ability to
segregate Crohn's disease patients and controls by clustering analysis with the majority of the
chemokines being upregulated in the colonic Crohn's disease biopsies in an inflammation
dependant manner. These results are consistent with previous data from Puleston and
colleagues who observed a subset of chemokines- CXCLs 1-3 and CCL20 were upregulated in
colonic inflammatory bowel disease along with their receptors in a coordinated intestinal
epithelial cell inflammatory response.(236) The upregulation of these chemokines was
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significantly more than known leukocyte chemokines emphasizing the central role of the
intestinal epithelial cell in colonic inflammation.
Further studies carried out in human colonic inflammatory bowel disease biopsies, in human
colonic cell lines and in human fetal intestinal xenografts have all confirmed the central role of
the intestinal epithelial cell in mediating, coordinating and perpetuating the pathogenic
inflammatory response observed in the colon in both Crohn's disease and ulcerative
colitis.(218;237;238)
In conclusion this valuable data set has allowed us to gain novel insight into the pathogenesis
ofCrohn's disease at the mucosal level. A number of key regulators of intestinal inflammation
were observed to be differentially expressed. Furthermore, the data add considerably to the
recent genome wide association studies in providing complimentary human colonic and ileal
expression data along with detailed analysis of the IL-23 and autophagy pathways. In depth
analysis of these exciting new candidate genes along with intestinal epithelial cell specific




REGIONAL VARIATION IN GENE EXPRESSION IN THE HEALTHY COLON IS
DYSREGULATED IN ULCERATIVE COLITIS
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SUMMARY
Background and Aims: Microarray analysis allows a comprehensive picture of gene
expression at the cellular level. The aim of this study was to investigate differential intestinal
gene expression in patients with ulcerative colitis (UC) and controls.
Methods: 67 UC and 31 control subjects- 23 normal and 8 inflamed non-inflammatory bowel
disease patients were studied. Paired endoscopic biopsies were taken from 5 specific
anatomical locations for RNA extraction and histology. 41058 expression sequence tags were
analyzed in 215 biopsies using the Agilent platform. Confirmation of results was undertaken
by real time PCR and immunohistochemistry.
Results: In healthy control biopsies, cluster analysis showed differences in gene expression
between the right and left colon. (x2=25.1, p<0.0001). Developmental genes HOXA13,
(p=2.3xl0~16), HOXB13 (p <lxl0"45), GLI1 (p=4.0xl0"24), and GLI3 (p=2.1xl0~28) primarily
drove this separation. When all UC biopsies and control biopsies were compared, 143
sequences had a fold change of >1.5 in the UC biopsies (0.01>p>10~45) and 54 sequences had
a fold change of<-1.5 (0.01>p> 10"20). Differentially upregulated in UC genes included SAA1
(p<10~45) the alpha defensins, DEFA5&6 (p=0.00003 and p=6.95xl0"7 respectively), MMP3
(p=5.6xlO"10) and MMP7 (p=2.3xl0~7). Increased DEFA5&6 expression was further
characterized to Paneth cell metaplasia by immunohistochemistry and in-situ hybridization.
Sub-analysis of the IBD2 loci, and the ABC transporter genes revealed a number of
differentially regulated genes in the UC biopsies.
Conclusions: These data implicate a number ofnovel gene families, as well as established




In recent years, the application of non-parametric linkage analyses and well-designed case-
control association studies have led to the identification of a number of susceptibility genes or
loci strongly associated with Crohn's disease and ulcerative colitis. Candidate genes and loci
implicated in ulcerative colitis include the IBD2, and IBD5 loci, HLA complex and the MDR1
gene.(34) A recent genome wide association study identified a novel susceptibility locus
ECM1 that was associated with ulcerative colitis (152) and further genome wide association
studies carried out in patients ofEuropean ancestry have identified ulcerative colitis risk loci
on chromosomes lp36 and 12ql5(l53), and a SNP flanking IL-10, a strong candidate gene in
ulcerative colitis pathogenesis.(239) These studies all highlight important pathways involved
in disease pathogenesis and the emerging challenge now is to move from gene identification to
functional understanding.
The aims of the current study were to use microarray gene expression analysis to investigate
genome wide expression in endoscopic mucosal biopsies taken at colonoscopy from 67
patients with ulcerative colitis and 31 controls. This represents the largest cohort described to
date and particular care has been taken to characterize disease phenotype as well as the
anatomical location sampled. The data extend current understanding of gene expression in




5.2.1 Patients and Controls
67 patients with ulcerative colitis and 31 control patients undergoing colonoscopy were
recruited (Table 5.1) (Methods 3.2.1).
Table 5.1: Demographics of the ulcerative colitis patients
Ulcerative colitis
Number of patients 67
Male/ Female 33/34
Median age at diagnosis (years) 37





Disease extent at time of Endoscopy
Proctitis 15
L sided colitis 27
Extensive colitis 25
Current Smoker 6
Family history of IBD 5
5 ASA Therapy 40
Corticosteroid therapy 10
Immunosuppressant therapy (AZA, 6MP, MTX) 11
Eleven of the controls were male, 20 were female with a median age of 43 at the time of
endoscopy. Six of the controls had normal colonoscopies for colon cancer screening, 9
controls had symptoms consistent with irritable bowel syndrome and had a normal
colonoscopic investigation and 7 patients had a colonoscopy for another indication and
histologically normal biopsies were obtained. Eight control patients had abnormal inflamed
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colonic biopsies (1 pseudomembranous colitis, 1 diverticulitis, 1 amoebiasis, 2 microscopic
colitis, 1 eosoinophilic infiltrate, 2 scattered lymphoid aggregates and a history of
gastroenteritis). Written informed consent was obtained from all patients.
5.2.2 Biopsy Collection
Paired biopsies were taken from each anatomical location (Table 5.2).





Total number of paired biopsies 139 76
Removed from analysis 10 3
Inflamed Non- Inflamed Inflamed Non-Inflamed
Terminal Ileum 0 4 1 5
Ascending colon 12 21 3 14
Descending colon 15 20 6 17
Sigmoid colon biopsies. 35 22 8 19
5.2.3 Microarray Analysis
Detailed methods are provided in the methods section (Methods 3.2.5-8). Total RNA was
extracted from each biopsy using the micro total RNA isolation from animal tissues protocol,
according to the manufacturer's instmctions. One lpg of total RNA was amplified using the
low RNA input fluorescent linear amplification protocol. The samples were hybridized for 18
hours at 60°C with constant rotation. Microarray slides were scanned using the Agilent
G2505B model. Expression signals were calculated using the Agilent feature extraction
software (version 7.5).
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5.2.4 Real Time PCR, In Situ Hybridization for Defensin Alpha 5 and
Immunohistochemistry for Rabbit Anti-Human Lysozyme and Rabbit Anti-Human
Defensin Alpha 6
Methods are provided in the methods section 3.3.1-3.
5.2.5 Data Analysis
Microarray data were analyzed using the Rosetta Resolver software. Statistical significance of
the microarray data was determined by Student's unpaired t test, p < 0.01 and a fold change of
greater or less than 1.5 were considered statistically significant. To correct for multiple
hypothesis testing a q-value was calculated for each tested feature to estimate significance in
terms of the false discovery rate (FDR) rather than the false positive rate. From the q-values a
FDR was calculated using the method proposed by Storey and colleagues.(185) A FDR of less
than 5% was calculated for each of the presented analysis. Gene ontology was analyzed using
Ingenuity software. The Mann-Whitney U test was used to analyze the real time PCR data, p <
0.05 was considered significant.
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5.3 RESULTS
5.3.1 Influence of anatomical location on gene expression in the healthy colon and
terminal ileum
Unsupervised hierarchical clustering analysis using probes that had a fold change of greater or
less than 1.3 were used to interrogate 56 histologically normal biopsies from control patients.
Clear separation by anatomical location was observed- on one side of the dendrogram 25/25
biopsies were from the left colon (descending colon or sigmoid colon) where as on the other
side of the dendrogram 20/31 biopsies were from the ascending colon (^2 =25.1, p<0.0001)
(Figure 5.1). Biopsies from individual patients did not cluster together. The genes driving the
differential expression between the right and left colon that were causing the observed
clustering were predominantly involved in the embryological development of the GI tract-
Homeobox proteins HOXA13, Fold Change (FC) +4.93, p= 2.3xl0"16), HOXB13 (FC+16.96,
p <lxl0"45), Glioma-associated oncogenes GLI1 (FC+2.2, p= 4.0xl0~24), and GLI3 (FC+2.3,
p= 2.1x1(F28) were all upregulated in the left colon. 61 sequences had a fold change of greater
than 1.5 and 44 sequences had a fold change of less than 1.5 in the left colon in the control
biopsies. In the ulcerative colitis biopsies when non- inflamed left and right colonic biopsies
were compared 26 sequences had greater than a 1.5 fold increase in expression and 21
sequences had less than a -1.5 fold decrease in the left colon.
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All 25 Biopsies from the
left colon.
Terminal Ileal Biopsies
22/31 Biopsies from the
right colon.
X2 =25.1, p<0.0001
Histologically normal biopsies from control patients were analyzed by unsupervised
hierarchical clustering. Separation of the biopsies by anatomical location was observed and
this separation was predominantly driven by genes involved in the embryological development
of the GI tract.
When gene ontology was compared between these two analyses alternative splicing genes
were the most differentially regulated genes in both of the analysis (p= 1.7xl0~41 and p=
7.9x10"19 for controls and ulcerative colitis respectively). In the control analysis the next 3
most differentially regulated gene groups were nuclear protein function (p= 4.3x10"29), metal
binding (p= 4.7xl0~25) and membrane function (p= 4.2xlO~20). In ulcerative colitis
oxidoreductase function (p= 1.4xl0"13) was the 2nd most differentially expressed group
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followed by mitochondrial function (p= 4.7xl0"25) and catalytic activity (p= 2.7x10""). There
was a 34.5% overlap between the differentially expressed ontology groups in the control and
ulcerative colitis analysis.
5.3.2 Analysis of expression in ulcerative colitis and control biopsies
Using unsupervised hierarchical clustering we were unable to differentiate between biopsies
from ulcerative colitis patients and controls patients. In addition no clustering based on the
inflammation status of the biopsies was observed. When all of the ulcerative colitis biopsies
(129) and control biopsies (73) were compared, 143 sequence probes had a fold change of
greater than 1.5 in the UC biopsies (0.01 > p >10"45) and 54 sequences had a fold change of
less than 1.5 (0.01> p > 10"20). The 20 most upregulated and downregulated sequences are
shown in (Table 5.3) and the complete table is Supplementary Table 6 on the Appendix 1 CD.
Serum amyloid A1 (SAA1) was the most upregulated gene FC+8.18, p < 10"45. Other notably
upregulated genes were the S100 calcium-binding proteins A8 (FC+3.50, p = 2.3xl0~17),
S100A9 (FC+3.06, p = 4.1xl0"13), the alpha defensins, alpha 5 (DEFA5) (FC+3.25, p =
0.00003), alpha 6 (DEFA6) (FC+2.18, p = 6.95xl0"7) and the matrix metalloproteinases
MMP3 (FC+2.17, p = 5.6xlO"10) and MMP7 (FC+2.29, p = 2.3xl0"7). The differential gene
expression of a number of candidate genes of interest is shown in Table 5.4.
Gene ontology analysis involving the genes differentially expressed between the ulcerative
colitis and control biopsies showed a preponderance of differentially expressed genes were
involved in immune response (48 genes out of a total of 679 genes classified under immune
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response, p= 2.1xl0~9, OR 2.61, CI 1.85-3.56) and response to wounding (30 genes out of a
total of 359 genes classified under response to wounding, p= 6.42 xlO"9, OR 3.14, CI 2.09-
4.53) when biological systems were considered.
5.3.3 Analysis of expression in sigmoid colon biopsies in patients with quiescent
ulcerative colitis and non-inflamed control biopsies
To compare expression in biopsies without an acute inflammatory signal and to remove the
effect of anatomical variation, 22 biopsies from the sigmoid colon with no histological
evidence of inflammation from patients with ulcerative colitis were compared to 18
histologically normal control sigmoid colon biopsies. 102 sequences had a fold change greater
than 1.5 (0.01 > p > 4.77x10"13) and 84 sequences had a fold change of less than 1.5 (0.01 > p
> 1.8xl0"21). The 20 most upregulated and downregulated sequences are shown in (Table 5.5)
and the complete table is Supplementary Table 7. Upregulated genes in the ulcerative colitis
biopsies included defensin beta 14 (FC+2.11, p = 0.00002) and SAA1 (FC+2.01, p =
0.00024). Interesting genes that were down regulated included HLA-DRB1 (FC-3.0, p =
0.0010) and TSLP (FC-2.73, p = 2.7X10"10) (Table 5.4).
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Table 5.3: Expression changes in the 40 most dysregulated sequences comparing
ulcerative colitis biopsies to controls.
Gene Name(s) Sequence Code Fold
Change
P-value
SAA1 A 24 P335092 8.17928 <10E-45
TNIP3 A 23 P386478 8.02411 1.13E-17
S100A8 A 23 P434809 3.49944 2.31 E-17
DEFA5 A 23 PI 12086 3.24658 0.00003
S100A9 A 23 P23048 3.0603 4.17E-13
TZFP A 23 P131024 2.68388 3.03E-10
UNG2 A 23 P92860 2.60581 2.50E-32
KCND3 A 32 PI40268 2.56611 2.39E-09
MMP7 A 23 P52761 2.29453 2.24E-07
chromosome 10 open reading frame 81 A 23 P23980 2.25666 3.36E-07
C10orf81 A 24 P286951 2.24629 8.06E-12
regenerating islet-derived 3 gamma A 32 P65628 2.22868 0.00041
DEFA6 A 24 P363711 2.1836 6.95E-07
MMP3 A 23 P161698 2.17171 5.62E-10
MGC27165 A 23 P259763 2.15704 5.92E-06
SI OOP A 23 P58266 2.10221 3.53E-15
EP400 A 24 P298939 2.08571 4.10E-12
GW112 A 23 P2789 2.04692 5.47E-09
IL8 A 32 P87013 2.04605 4.24E-11
C14orf81 A 24 P608268 2.04054 0.00006
LOC92935 A 23 PI08492 -1.66981 3.27E-06
GBA2 A 24 P341187 -1.67013 4.57E-15
RNF150 A 24 P350589 -1.67698 0.00004
LOC346329 A 24 P127159 -1.68116 2.51E-14
CST A 23 P120863 -1.68211 3.82E-18
CLDN8 A 23 P427014 -1.70615 0.00532
H6PD A 24 P626850 -1.70685 6.14E-10
MSTP9 A 23 P340376 -1.71901 1.34E-08
A 24 P792748 A 24 P792748 -1.73936 5.83E-11
SESTD1 A 23 P367610 -1.75701 7.07E-07
membrane-bound transcription protein 1 A 24 P378368 -1.75966 4.43E-12
NKD1 A 24 P304881 -1.76319 2.06E-11
LOC92552 A 23 P361744 -1.76501 0.00398
LOC339881 A 24 P846810 -1.80788 1.76E-07
ECT2 A 24 P366033 -1.83638 1.54E-08
PRAC A 23 P15619 -1.84271 8.02E-06
LGALS2 A 23 PI20902 -1.89554 6.36E-12
POLK A 24 P919863 -2.14028 5.75E-11
LOC389023 A 32 P86578 -2.60671 7.74E-27
XIST A 24 P500584 -3.28307 0.0064
155





biopsies)v controls(73 biopsies) Foldchange (FC)
pvalue
UCsigmoid (22)vnon- inflamed controlsigmoid (18)FC
Pvalue
sigmoid(35)v inflamed control sigmoid(8) (FC)
pvalue


































































































































Foldchangesapvaluers owninnumb rfdifferentgefo ri experim t .T berb opsianalys d eachxperimentishownbrackets.G nofnt rw rcludedthblfsignificantonsistangesexp e sionr observedacrossmorthannexperim nt.G nnotation-TLR4-lllikrec ptor4,NIP3FAIP3(A20)in eractingpr tein 3,CCL20-chemokine( -Cm tif)ligand2 ,ABCB1transporter,HLA-DRB1-LAlassIIhistoco pa ibilityntig n, DRB1,TSLP-thymicstromallymphopoietinisof rm1.
156
Table 5.5: Expression changes in the 40 most dysregulated sequences comparing
quiescent sigmoid colon ulcerative colitis biopsies to non-inflamed control sigmoid colon
biopsies.
Gene Name(s) Sequence Code Fold
Change
P-value
D2S448 A 32 P41327 6.8545 1.12E-06
LOC285189 A 32 P197825 5.07286 3.27E-06
AL359654 A 32 P865343 4.79967 0.00017
BG221366 A 32 PI 18811 4.68596 0.00005
BC034913 A 32 P217128 4.55265 0.00174
ATPase, H+ transporting, lysosomal V0 subunit A 24 P923415 3.59124 5.26E-06
BX108833 A 24 P460405 3.41807 0.00424
TIMD4 A 32 P69616 3.30842 0.00008
RP11-653A5.1 A 32 P84237 3.06817 0.00859
LOC92552 A 23 P361744 3.02489 0.00044
FLJ31842 A 32 P19539 2.92736 7.86E-08
FLJ25393 A 24 P305993 2.78732 0.00654
TTTY15 A 24 P348861 2.58047 0.00006
QKI A 23 P81760 2.50397 0.00311
GSCL A 23 PI09382 2.27819 0.00001
DEFB14 A 24 P931533 2.10838 0.00002
LOC286207 A 24 P229638 2.07887 0.0023
AQP8 A 23 P26522 2.02749 0.00003
SAA1 A 24 P335092 2.01116 0.00024
THC1975338 A 24 P681218 1.95708 1.67E-10
EDG1 A 23 P404481 -1.73072 0.00107
CD86 A 24 P131589 -1.73515 0.00075
PLAA A 24 P78161 -1.76733 0.00116
THC1923453 A 32 P35668 -1.80382 0.00301
LOC284058 A 32 P210106 -1.81585 0.00456
TRA1 A 24 P150361 -1.86218 1.80E-21
BX119852 A 24 P640617 -1.88796 0.00818
chromosome 8 open reading frame 4 A 23 P253350 -1.89434 5.38E-06
LOC63929 A 24 P915710 -1.94095 0.00044
FGF12 A 24 P334300 -1.9687 0.00392
LOC339903 A 23 P80551 -2.08124 2.41E-11
CLIC6 A 23 P385067 -2.14902 1.32E-08
LOC285331 A 23 P396981 -2.18323 0.00106
LOC92935 A 23 PI08492 -2.26078 0.0035
CTSZ A 23 P40240 -2.27699 0.00056
MGC10814 A 23 P79032 -2.30755 5.22E-13
TTID A 23 PI 10764 -2.38686 0.00002
TSLP A 23 P121987 -2.73367 2.73E-10
HLA-DRB1 A 24 P169013 -3.0072 0.00101
XIST A 24 P500584 -10.3502 0.00012
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5.3.4 Inflamed versus non-inflamed ulcerative colitis sigmoid colon biopsies
When expression signals were compared between 35 histologically inflamed and 22 non-
inflamed sigmoid colon ulcerative colitis biopsies, 700 sequences had a fold change of greater
than 1.5 (0.01 > p > lxlO"45) and 518 sequences (0.01 > p > lxlO"45) had a fold change of less
than 1.5 in the inflamed biopsies. The 20 most upregulated and downregulated sequences are
shown in (Table 5.6) and the complete table is Supplementary Table 8. Notably upregulated
genes included SAA1 (FC+16.5, p = <10 45), TNFAIP3 interacting protein 3 (TNIP3)
(FC+10.5, p = lxlO"38), DEFA5 (FC+8.44, p = <10"45), DEFA6 (FC+6.72, p = 4.16xl0'19) and
regenerating islet-derived 3 gamma (REG3y) (FC+6.99, p = <10~45).
5.3.5 Analysis of Specific Gene Families- Alpha Defensins 5 and 6.
When DEFA5 and DEFA6 were analyzed expression in the normal controls and the non-
inflamed ulcerative colitis biopsies was similar across the different anatomical locations with
there being high expression in the terminal ileum, and expression decreasing as the biopsy
location became more distal in the colon (Figure 5.2). In the acute and chronically inflamed
UC biopsies there was marked upregulation of DEFA5 and DEFA6 expression in the
descending and sigmoid colon (Table 5.4).
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Table 5.6: Expression changes in the 40 most dysregulated sequences comparing
inflamed ulcerative and non-inflamed ulcerative colitis sigmoid colon biopsies.
Gene Name(s) Sequence Code Fold Change P-value
SAA1 A 24 P335092 16.50126 <10E-45
TNIP3 A_23_P386478 10.52272 1.03E-38
DEFA5 A_23_P112086 8.43598 <10E-45
MMP3 A 23 P161698 8.14743 2.33E-35
IL8 A 32 P87013 7.24295 8.42E-19
S100A9 A 23 P23048 7.11456 1.96E-32
regenerating islet-derived 3 gamma A_32_P65628 6.98725 <10E-45
S100A8 A 23 P434809 6.83944 1.16E-19
KCND3 A 32 P140268 6.74598 6.27E-30
DEFA6 A 24 P363711 6.72245 4.16E-19
GW112 A 23 P2789 6.14232 1.95E-27
MMP7 A 23 P52761 5.5287 1.01E-23
LCN2 A 23 PI69437 5.17756 1.30E-22
CXCL3 A 24 P183150 5.08356 2.26E-25
C14orf81 A 24 P608268 4.3061 2.78E-10
CHRDL2 A 23 P13548 4.08137 1.47E-16
CXCL1 A 23 P7144 4.05835 9.93E-13
REG4 A 24 P58673 3.99842 8.18E-21
DAF A 23 P103951 3.81241 5.06E-37
CXCL10 A 24 P303091 3.74657 1.37E-14
TTTY15 A 24 P348861 -2.49501 7.06E-06
SLC26A2 A 23 P250951 -2.57291 1.25E-10
similar to MGC9515 protein A 32 P215143 -2.62964 5.44E-09
A_32_P216970 A_32_P216970 -2.65464 6.22E-09
POSTN A 24 P347411 -2.69014 6.46E-09
LOC63928 A 23 P349463 -2.71812 2.28E-12
PNLIPRP2 A 23 P24083 -2.7412 2.27E-27
ANKRD17 A 24 P220771 -2.76491 3.22E-11
MT1K A 23 P66241 -2.77076 1.31E-13
CKB A 23 P25674 -2.79887 3.67E-16
ATF3 A 24 P33895 -2.95597 0.00067
AQP8 A 23 P26522 -3.18702 3.5 IE-15
OSTalpha A_24_P385732 -3.23873 6.36E-12
PCK1 A_23_P408249 -3.35965 3.86E-12
EIF1AY A_24_P237511 -3.71062 2.30E-07
CLDN8 A 23 P427014 -3.712 9.70E-10
FLJ21934 A 24 P334378 -4.79656 0.00002
LOC285189 A 32 P197825 -5.02416 0.00355
LOC389023 A_32_P86578 -5.04036 <10E-45
SLC38A4 A_24_P321581 -5.73668 5.40E-14
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5.3.6 ATP- binding cassette (ABC) transporter family and the Xenobiotic-transcription
regulators
Expression patterns from probes representing 48 ABC transcriptional genes and their key
mediators Pregnane X receptor (PXR), Farnesoid X-activated receptor, and Oxysterols
receptor LXR-beta were analysed. When these genes were compared in all the ulcerative
colitis and control biopsies, 7 genes were found to be significantly down regulated in the
ulcerative colitis samples when compared to the control samples- ABCA1 (p= 0.01), ABCA8
(p= 0.0064), ABCB1 (p= 0.00091), ABCC6 (p=0.0050), ABCB7 (p= 0.0068), ABCF1
(p=0.0005) and ABCF2 (p<0.00001). Only one probe representing ABCB2 was significantly
upregulated in ulcerative colitis (p= 0.0048).
ABCB1 expression was also significantly downregulated when inflamed ulcerative colitis
sigmoid colon biopsies were compared to non- inflamed ulcerative colitis sigmoid biopsies.
(FC-1.82, p= 5.6xl0~6) (Table 5.3). No difference in the expression ofPXR between ulcerative
colitis and controls was observed in any of the analysis.
5.3.7 RTPCR Analysis
In 8 genes implicated by microarray expression results, confirmatory real time PCR analysis
was undertaken in biopsies of patients form the original cohort following stratifying to
represent a range of SAA1 and IL-8 expression. Increased SAA1 expression in the inflamed
ulcerative colitis sigmoid colon biopsies compared to the normal control sigmoid colon
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biopsies and the non-inflamed ulcerative colitis sigmoid colon biopsies (p=0.041 and p=0.044
respectively) was observed. Elevated IL-8 expression was also confirmed in the inflamed
ulcerative colitis sigmoid biopsies when compared to the control sigmoid biopsies (p=0.031)
(Figure 5.3).
Increased expression ofDEFA5 and DEFA6 in the inflamed ulcerative colitis sigmoid colon
biopsies when compared to the non- inflamed ulcerative colitis sigmoid colon biopsies
(p=0.0008 and p=0.0005 respectively) and the control sigmoid colon biopsies (p=0.0002 and
p=0.0001 respectively) was observed (Figure 5.3). Increased expression in the inflamed
ulcerative colitis sigmoid colon biopsies when compared to the non-inflamed ulcerative colitis
sigmoid colon biopsies was also observed when MMP7, (p=0.0005), S100A8, (p=0.0029) and
TLR4, (p=0.019) were examined (Figure 5.4).
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Figure 5.3: Real time PCR expression of SAA1, IL-8 defensin alpha 5 and defensin alpha 6 in
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Control UC Non Inf
Disease Group
UC Inf
Real time PCR expression data comparing expression in 10 healthy control sigmoid biopsies
with normal histology, 9 quiescent UC sigmoid biopsies and 11 UC sigmoid biopsies with an
acute or chronic inflammatory cell infiltrate. Expression of SAA1, IL-8, DEFA5 and DEFA6
were compared between the control and the inflamed and non-inflamed UC biopsies.
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Figure 5.4: Real time PCR expression ofMMP3, MMP7, S100A8 andTLR4 in control
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Expression ofMMP3, MMP7, S100A8 and TLR4 were compared between the different
patient groups.
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5.3.8 ln-Situ Hybridization and Immunohistochemistry
In- Situ hybridization of the terminal ileal biopsies for DEFA5 showed strong hybridization in
the basal crypts consistent with Paneth cell location (Figure 5.5). In the ulcerative colitis
biopsies taken from the sigmoid colon strong, multifocal hybridization in the basal crypt
region of these biopsies was observed and this would be consistent with Paneth cell
metaplasia. This was not observed in the non-inflamed control biopsies.
Immunohistochemistry for DEFA6 confirmed that in the sigmoid colon ulcerative colitis
biopsies, staining was observed in the basal crypt region of these biopsies consistent with
Paneth cell metaplasia Again, this was not observed in the control biopsies (Figure 5.6).
5.3.9 Expression of Genes within the IBD2 Locus
Using the markers defining the IBD2 locus we identified 526 Agilent probes representing
genes or expressed sequence tags within this locus on chromosome 12. 12 probes had a greater
or less than 1.5 fold change in expression with p < 0.01 when expression of acute and
chronically inflamed ulcerative colitis sigmoid colon biopsies were compared to non-inflamed
ulcerative colitis sigmoid colon biopsies (Table 5.7).
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Figure 5.5 Terminal ileum (TI) upper panel: antisense probe shows strong hybridization in the
basal crypts consistent with Paneth cell location. Arrows indicate positive staining in crypt
cells. Lower panel: no significant hybridization with sense control probe. (A) Sigmoid colon
biopsy of a non-inflamed control patient. (B,C& D) Strong, multifocal hybridization in the
basal crypt region of sigmoid colon biopsies from 3 ulcerative colitis patients consistent with
Paneth cell metaplasia.
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Figure 5.6 (A) Terminal ileal immunohistochemistry shows positive staining marked with
arrows in the basal crypts consistent with Paneth cell location. (B & C) No significant staining
was observed in two non-inflamed control patients. (D, E & F) Strong, multifocal staining in
the basal crypt region of sigmoid colon biopsies from 3 ulcerative colitis patients consistent
with Paneth cell metaplasia.
Table 5.7: Gene expression in probes from the IBD2 locus, comparing inflamed
ulcerative colitis sigmoid colon biopsies to non-inflamed ulcerative colitis sigmoid colon
biopsies.
Agilent Probe Gene Symbol ulcerative colitis
sigmoid inflamed
(35 biopsies) v non-
inflamed (25) (FC)
p value
A 23 P98876 SLC39A5 -1.52855 1.36xl0"7
A 24 P647146 HDAC7A 1.53876 3.15xl0"lb
A 24 P941773 DKFZP586A0522 -2.27306 2.31xl0"u
A 24 P945113 ACVRL1 1.57956 6.33xl0"y
A 23 P128230 NR4A1 1.81844 0.00005
A 23 P331098 K5B 2.3845 0.0004
A 24 P246636 A 24 P246636 -1.69754 7.06x10"8
A 23 P2233 SILV 1.51557 9.07xl0"y
A 23 P105251 GLI -1.54447 7.73xl0"y
A 32 P3783 HMGA2 -1.94107 2.37x10"y
A 23 P162300 IRAK3 1.7382 3.1 lxlO"15
A 32 P83256 IRAKM 1.70847 4.56xl0"lu
Analysis of the 526 expression probes located within the IBD2 locus identified 12 probes that
were significantly differentially regulated when the inflamed ulcerative colitis sigmoid colon
biopsies were compared to the non- inflamed ulcerative colitis sigmoid colon biopsies. Gene
annotation- SLC39A5- solute carrier family 39A5, HDAC7A- histone deacetylase 7A,
DKFZP586A0522- Methyltransferase-like protein 7A precursor, ACVRL1- activin A
receptor type II-like 1, NR4A1- nuclear receptor subfamily 4, group A, member 1, KB5-
keratin 5B, A_24_P246636- unknown, SILV- silver homolog (mouse), HMGA2- high
mobility group AT-hook 2, IRAK3- interleukin-1 receptor-associated kinase 3, IRAKM-
interleukin-1 receptor-associated kinase M.
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5.4 DISCUSSION
In the present study we have taken particular care to address concerns currently being
expressed about micoarray studies in disease. We initially documented the regional variation
of gene expression in the healthy colon before undertaking comprehensive studies in
ulcerative colitis. By documenting the anatomical location for each biopsy, using appropriate
inflammatory controls, as well as the avoidance of pooling of samples, we have been able to
remove a considerable amount of background variability that has hampered previous studies.
(157; 169; 174; 179) A further strength of our study has been the fact that real time PCR
analysis consistently confirmed the significant changes in expression, substantially increasing
the confidence associated with the interpretation of the data.
We have made a number of novel observations. In the healthy adult colon this is the first
microarray study to show a gradient of expression of a number of genes. Genes involved in
developmental pathways- the HOX family and the hedgehog signaling pathway appeared to be
the most differentially regulated along the anatomical length of the healthy colon. HOXA13
has been shown to play a crucial role in the development of tail gut and mutations in the gene
result in urogenital abnormalities,(240) and interestingly it has been shown that HOXB13
expression is down regulated in colorectal tumours from the distal left colon.(241)
GLI1 is one of the major effector molecules of the hedgehog signaling pathway and the GLI1
gene lies within the IBD2 locus, strongly implicated in ulcerative colitis.(79;242;243) Data
from the present study would also suggest that GLI1 is downregulated in inflamed ulcerative
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colitis biopsies compared to non-inflamed biopsies from patients with ulcerative colitis. These
data add further weight to data from Cambridge and our own unit showing an association
between mutations in the GLI1 gene and ulcerative colitis.(244)
With regards to the observed gradient of expression in the healthy adult colon, our data
contrast with data from Costello and Wu and colleagues where no significant differences in
expression patterns were observed when comparing biopsies from caecum, transverse colon,
descending colon and sigmoid colon.(196;245) The observed differences in these data sets
may be explained by the fact that we have considered only non- inflamed healthy controls in
these studies and have not pooled healthy and diseased data. When anatomical variation in the
colon was compared between ulcerative colitis and control patients there was only a 34.5%
homology between the differentially expressed gene ontology groups. This difference may be
explained by environmental factors in the ulcerative colitis colon such as microbial dysbiosis.
In ulcerative colitis we demonstrated dysregulation of genes involved in innate immunity,
notably the alpha defensins 5 and 6, together with other pathways recurrently implicated in
inflammatory bowel disease. In our data set high levels of alpha defensin 5 and 6 expression
were observed in the terminal ileal biopsies of non-inflamed controls and patients with
ulcerative colitis. Levels of expression in these patients fell as the location that the biopsies
were retrieved from became more distal in the colon- ascending colon, descending colon and
sigmoid colon. However, in the inflamed ulcerative colitis biopsies increased expression of
both alpha defensins 5 and 6 was observed in the descending and sigmoid colon. Lawrance
and colleagues also noted that the defensins alpha 5 and 6 were upregulated in patients with
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UC compared to controls,(167) although RNA was extracted from surgical resections and no
details about the anatomical location of these specimens were given.
Recent data published by Varnat and colleagues have suggested that PPARp negatively
regulates Paneth cell differentiation by downregulating the expression of Indian hedgehog,
another of the major effector molecules in the hedgehog signaling pathway.(246)
Immunohistochemistry and in-situ hybridization have shown that this is largely mediated by
Paneth cell metaplasia. Given our present data now implicating germline GLI1 variation in
disease susceptibility, and the regional variation in health, we speculate that in patients with
ulcerative colitis, further as yet undetermined defects in the Hedgehog signaling pathway may
result in unregulated Paneth cell differentiation, Paneth cell metaplasia, increased alpha
defensin 5 and 6 expression, and mucosal inflammation.
It is of interest that many but not all of our results are broadly in line with two of the landmark
microarray papers in inflammatory bowel disease. Consistent with data from Lawrance and
colleagues (167) we have shown upregulation of S100A8 & A9 and the alpha defensins 5 & 6
in ulcerative colitis. Dieckgraefe and colleagues (166) observed upregulation of a number of
the MMP genes, again seen in our dataset. Another consistent finding was the upregulated
expression ofmembers of the REG family in the colon of patients with ulcerative colitis,
probably as a result of Paneth cell metaplasia.(247)
The downregulation of ABCB1 in our dataset is of significant interest, and consistent with
earlier microarray data from Langmann, Dieckgraefe, Lawrance, Wu and colleagues. (166-
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168;245) It is pertinent that when the entire class of proteins sharing homology with ABCB1
were analyzed, a further 6 out of 48 ABC transporters were significantly dysregulated in UC,
including ABCA1, ABCA8, ABCC6, ABCB7, ABCF1 and ABCF2. An important role of the
ABC transporters in the aetiopathogenesis of UC seems likely, supported by these consistent
microarray data, association with germline MDR1 variability, and animal data to date.
However, and in contrast to data produced by Langmann we did not observe any changes in
expression of the transcriptional regulator Pregnane-X receptor. These negative data are
consistent with genetic studies carried out in the inflammatory bowel disease population in
Edinburgh- using a haplotype tagging approach, there was an association between the ABCB1
gene and ulcerative colitis,(248) but no association between the Pregnane- X receptor and
ulcerative colitis.(249) Aspects of study design and patient recruitment may explain the
differences observed between our data and those of Langmann and colleagues.
When novel genes were considered, of particular note was the differential expression of the
poorly characterized gene TNFAIP3-interacting protein 3 (TNIP3) which is a nuclear or
cytoplasmic protein with three coiled domains that was first pulled down from a Yeast-2
hybrid scan of TNFAIP3 (A20).(250) The protein has been found to be expressed in
macrophages and is upregulated by infection with Listeria. Further to this TNFAIP3 was
recently identified as the closest gene to rs7753394 a 'second tier' hit from the UK genome
wide scan in Crohn's disease, focusing further interest on this NFkB dependant signaling
pathway.(57)
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In conclusion these data provide a rigorously characterized expression profile of the whole
genome in the terminal ileum and colon of patients with ulcerative colitis and controls. The
studies provide new insights into regional variation of gene expression in the healthy colon,
and also considerably extend previous studies in ulcerative colitis. These data also identify a
number of key regulators of intestinal inflammation worthy of further study. As further data
from genome-wide scanning emerges in this and other complex diseases, access to these data




THE CONTRIBUTION OF OCTN1/2 VARIANTS WITHIN THE IBD5 LOCUS TO
DISEASE SUSCEPTIBILITY AND SEVERITY IN CROHN'S DISEASE
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SUMMARY
Background & aims: Peltekova and colleagues have suggested that polymorphisms in the
organic cation transport genes, OCTN1 (SLC22A4) and OCTN2 (SLC22A5) represent the
disease-causing mutations within the IBD5 locus (chromosome 5q31). We investigated
associations with disease susceptibility, phenotype, and evidence for epistasis with CARD 15
in 679 patients with Crohn's disease (CD) or ulcerative colitis (UC). Expression of probes
representing 11 genes within the IBD5 locus was also investigated in endoscopic colonic and
terminal ileal biopsies.
Methods: 374 CD, 305 UC and 294 controls (HC) were studied. Genotyping for SNPs
IGR2096, IGR2198, IGR2230, OCTN1 variant (SLC22A4 1672C-*T) and OCTN2 variant
(SLC22A5 -207G—>C) was performed using the Taqman system. Gene expression was
compared in 53 CD, 67 UC and 31 control subjects.
Results: The IBD5, OCTN1 and OCTN2 polymorphisms were in strong linkage
disequilibrium (D' >0.959). IGR2198 variant allele frequency (49.1% v 40.8%,P=0.0046) and
homozygosity (21% v 14.8%,P=0.044) were associated with CD v HC. Variant allelic
frequency ofOCTN1 (53.6% v 43%,P=0.0008), OCTN2 (56.1% v 48.4%,P=0.0092)
polymorphisms and homozygosity for the OCTN1/2 TC haplotype (28.4% v 16%,P=0.0042)
were associated with CD v HC. IGR2198 homozygosity and TC homozygosity were
associated with stricturing/penetrating disease at follow-up (P=0.011, P=0.011 respectively)
and disease progression (P=0.038, P=0.049) on univariate analysis, and with need for surgery
on multivariate analysis (P=0.006, P=0.004). In the absence of the IBD5 risk haplotype, no
association of OCTN1/2 variants with CD was detected. No associations were seen with UC.
OCTN2 expression was marginally downregulated in CD and UC biopsies compared to
controls.
Conclusions: The IBD5 locus influences susceptibility, progression and need for surgery in
CD. However, the contribution of OCTN1/2 variants is not independent of the IBD5
haplotype: a causative role for these genes remains plausible but is not yet proven.
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6.1 INTRODUCTION
The 5q31 -33 area was originally identified in 1999 as conferring susceptibility for Crohn's
disease.(75) This finding was replicated using linkage disequilibrium mapping in the
Canadian Crohn's disease population and further delineated to the IBD5 loci- 5q31.(76) Fine
mapping of this area has identified a single, highly conserved 250-kb haplotype of 11 SNPs
spanning a cytokine gene cluster that is associated with Crohn's disease.(77) Further high
resolution analysis of the 5q31 region using 103 SNPs revealed 11 discrete haplotype blocks
that measure tens of kilobases in length, have limited diversity, and are punctuated by sites of
recombination.(89)
Peltekova and colleagues have suggested that mutations of two genes within the IBD5 region,
the organic cation transporters OCTN1 (SLC22A4) and OCTN2 (SLC22A5), may be
independently associated with Crohn's disease.(95) The construction of a two allele risk
haplotype OCTN1/2 TC (SLC22A4 exon 9 1672C^T and SLC22A5 promoter -207G-»C)
was reported to be associated with Crohn's disease in patients who lacked the extended IBD5
risk haplotype.
Peltekova and colleagues also suggested that the OCTN1 variant (1672C—>T) alters its
function in fibroblasts in vitro, with variant forms having less affinity for carnitine and a
greater affinity for tetraethyl ammonium and some xenobiotics, and that the OCTN2 variant (-
207G—>C) disrupted a heat-shock transcription factor binding site in fibroblasts in vitro.(95)
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In the present study we have assessed the contribution of the OCTN1 and OCTN2
polymorphisms implicated by Peltekova and colleagues in determining genetic susceptibility
in Crohn's disease and ulcerative colitis, specifically addressing whether these OCTN1/2
variants have an association with susceptibility to inflammatory bowel disease that is
independent of other markers within the extended the IBD5 linkage interval. We have also
investigated whether these polymorphisms are associated with specific disease phenotype,
assessed gene-gene interactions with established NOD2/CARD15 mutations and examined




6.2.2 Patients and Controls
Six hundred and seventy nine patients with well characterized inflammatory bowel disease
(IBD) and 294 control patients were recruited (Table 6.1). The IBD group comprised 374
patients with Crohn's disease (CD) and 305 patients with ulcerative colitis (UC).
Classification and data collection of these patients are described in the methods section
(Methods 3.4.1-3). Disease extent was recorded at diagnosis. The controls comprised of 294
healthy subjects and involved blood donors (163) recruited from the south east of Scotland
and healthy control subjects (131). There were 143 males and 151 females with a median age
of 39 years (IQR 27-52).
6.2.2 Genotyping
To examine the relative contribution of the OCTN1/2 variants relative to the extended IBD5
haplotype, 3 SNPs were genotyped- IGR2096 (which lies within haplotype block 4, as defined
by Daly et al (89)) (Figure 6.1), IGR2198 (within haplotype block 5) and IGR2230 (within
haplotype block 7). The rs 1050152 polymorphism of the OCTN1 gene (SLC22A4 exon 9
1672C—>T, IGR3002) and the rs26313667 (SLC22A5 promoter, -207G^C, IGR2222)
polymorphism of the OCTN2 gene were genotyped (Table 6.2). CD patients and controls were
genotyped for polymorphisms of the NOD2/CARD15 gene (R702W, G908R, and 1007fsinsC)
using previously described methods.(85)
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Total Number 374 305 294
Sex (male / female) 181/193 171/134 143/151
Median Age at diagnosis (yrs) (IQ range) 27.8 (20.9-40.4) 34 (25-50) 39(27-52)
Median duration of follow up (yrs) (IQ) 11.8 (6.5-20.2) 7.5(3.35-13.4)
Caucasian (%) 98.7% 98.3%
Age at diagnosis Al(<40 years)/ A2(>40) 72%/28%
Location at Diagnosis
Ileal disease (LI) 125 (34%) Proctitis 105
(34.5%)
Colonic Disease (L2) 139 (38%) Left sided colitis
116(37%)
Ileal and colonic (L3) 58 (16%) Extensive colitis
84 (27.5%)
Upper GI disease (L4) 30 (8%)
Oral Crohn's disease 6 (2%)
Peri-anal disease 75 (21%)
Disease Behaviour at Diagnosis
Inflammatory (Vienna Bl) 258 (74%)
Stricturing (Vienna B2) 32 (9%)
Penetrating (Vienna B3) 61 (17%)
Disease Behaviour at Follow Up
Inflammatory (B1) 128 (34%)
Stricturing (B2) 70(19%)
Penetrating (B3) 168 (48%)
Disease Progression
No progression from inflammatory (% of
inflammatory at diagnosis)
126 (49%)
Inflammatory to stricturing or penetrating. 132 (51%)
Surgery for luminal complications of CD1 237 (63%)
Disease behaviour at follow up was defined using the Vienna classification when the patient
was last clinically evaluated. Full phenotypic data were available on 94% of the CD patients at
diagnosis and 98% at follow up. In assessing disease progression, patients were grouped as
those who remained as inflammatory (Bl), non progressive disease and those whose disease
had progressed to stricturing (B2) or penetrating (B3) disease.
1 Examination under anaesthesia or drainage procedures for peri-anal sepsis were excluded.
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IGR2096 rs 12521868 Forward: tctgagacaggagccactagag
Reverse: cacagcatccagagtgatcct






IGR2230 rsl 7622208 Forward: gcaggcagaacagccatact
Reverse: ggccacagaactttcattaaagtagga




6.2.3 Expression of Genes Within the IBD5 Locus
Gene expression was analyzed in the IBD5 locus using data generated from the microarray
gene expression study. Detailed methods are provided in the methods section 3.2.1-9, 3.3.4.
Eleven probes were identified that represented genes within the IBD5 locus. Statistical
significance of the microarray data was determined by Student's unpaired t test, p < 0.01 and a
fold change of greater or less than 1.5 were considered statistically significant.
6.2.4 Data Analysis
Each SNP was analyzed for association with inflammatory bowel disease overall, Crohn's
disease, ulcerative colitis and disease phenotype. Each of the variants studied was shown to be
in Hardy-Weinberg equilibrium in patients, and in controls. Evidence for epistasis between the
OCTN1/2 allelic variants, the OCTN1/2 TC haplotype and NOD2/CARD15 variants was
investigated by comparing allelic frequencies of the individual OCTN1/2 variants, together
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with homozygosity for the OCTN1/2 TC haplotype between the sub-groups of patients with
and without NOD2/CARD15 variants by Chi squared analysis.
To identify significant independent variables associated with genotype, multiple logistic
regression analysis was carried out using Minitab vlO. The population attributable risk
percentage (PAR%) was estimated by the method of Schlesselman.(215) To calculate this, the
prevalence ofCrohn's disease was estimated at 100/100,000 and the frequency of all alleles in
the control population was assumed to reflect that of the general population.
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6.3 RESULTS
6.3.1 Linkage Disequilibrium across the IBD5 Locus
In the Crohn's disease population, strong linkage disequilibrium was observed between the
SNPs within the extended IBD5 haplotype as defined by Daly and colleagues (89)-IGR2096
(block 4), IGR2198 (block 5), OCTN2 (SLC22A5 promoter, -207G^C) (block 7), IGR2230
(block 7) and OCTN1 (SLC22A4 exon 9 1672C—»T)(block 7)(Figure 6.1). Pairwise D' values
(a measure between 0 and 1 where 0 is equal to no correlation and 1 shows complete
correlation) of greater than 0.959 between each SNP confirmed the difficulty of showing an
independent effect of OCTN1/2 variants and IBD5. In the detailed analyses of the IBD5
contribution to disease phenotype presented in the manuscript, data are presented for the
IGR2198 marker, representative of the three-locus haplotype (IGR2096, IGR2198, IGR2230).
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Figure 6.1. Haplotype Structure and Linkage Disequilibrium across the IBD5 region.
Genes
IL4 IL13 RAD50 P4HA2
IL5 IRF1 OCTN2 OCTN1 PDLIM3 CSF2 IL3
marker SNPs
The IBD5 locus (5q31) with the high resolution haplotype structure as reported by Daly
and colleagues (27): a: Candidate genes above the relevant haplotype blocks. Genes
above the line are transcribed from left to right and those below the line are transcribed
from right to left, b: Eleven blocks numbered 1 to 11 (between 3kb and 92kb) each of
limited genetic diversity are punctuated by sites of recombination, c: D' scores are shown
to demonstrate the tight linkage disequilibrium between the SNPs that were analysed. The
lowest D' (D' =0.959) was observed between IGR2096 and the OCTN2 variant (-
207G—>C). d: Location of the SNPs that were analysed, IGR2222 representing the
OCTN2 variant (-207G—>C) and IGR3002 representing the OCTN1 variant (1672C—>T).
IGR2078 which was used by Peltekova and colleagues to represent the extended IBD5
haplotype is located in block 4.
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6.3 2 Analysis of SNPs representing the extended IBD5 haplotype (IGR2096, IGR2198
and IGR2230).
Variant allelic frequencies differed significantly between Crohn's disease (CD) and healthy
controls (HC) for each of the three IBD5 single nucleotide polymorphisms studied, IGR2096
(49.4% CD v 41.9% HC, p= 0.030), IGR2198 (49.1% CD v 40.8% HC, p= 0.0046) and
IGR2230 (54.9% CD v 47.4% HC, p= 0.011) (Table 6.3). Carriage rates for the IBD5 variants
were significantly higher in the CD patients when compared to the control population
IGR2096 (79.3% CD v 68.7% HC, p= 0.0034), IGR2198 (77% CD v 67% HC, p= 0.011) and
IGR2230 (80% CD v 73.7% HC, p= 0.047). Individuals who were homozygous for the IBD5
risk alleles at the three SNPs examined (IGR2096, IGR2198 and IGR2230) were more
common in the CD group than the control group (Table 6.3). The PAR for IBD5
homozygosity was estimated as 15% if IGR2096 data were considered in calculation, 14.0%
for IGR2198, and 14.3% for IGR2230.
No associations were observed between allelic frequency of IBD5 variants and inflammatory
bowel disease overall (IBD) (IGR2198, 45% IBD v 40.8% HC, p= 0.077) or ulcerative colitis
(UC) (IGR2198, 43.7% UC v 40.8% HC, p= 0.325) (Table 6.4).
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Table 6.3: IBD5 variant allele frequency, carriage rates and homozygote frequency in







P value RR (CI)
Variant Allelic
Frequency
IGR2096 211 (41.9%) 347 (49.4%) 0.015 1.42(1.1-1.8)
IGR2198 209 (40.8%) 328 (49.1%) 0.0046 1.40(1.1-1.6)
OCTN2 (-207 G—>C) 242 (48.4%) 386 (56.1%) 0.0092 1.43 (1.2-1.8)
IGR2230 232 (47.4%) 355 (54.9%) 0.011 1.35 (1.1-1.7)
OCTN1 (1672C—»T) 216 (42.9%) 356 (53.6%) 0.0008 1.48 (1.2-1.9)
Variant Carriage
Rates
IGR2096 173 (68.7%) 264 (79%) 0.0034 1.75 (1.2-2.6)
IGR2198 171 (67%) 258 (77%) 0.011 1.61 (1.2-2.3)
OCTN2 (-207 G—»C) 187 (74%) 280 (81%) 0.034 1.52(1.0-2.2)
IGR2230 185 (73.7%) 261 (80%) 0.047 1.5 (1.1-2.23)
OCTN1 (1672C—>T) 178 (68.7%) 267 (80%) 0.0024 1.77(1.2-2.6)
TC Haplotype 170 (69%) 264 (80%) 0.0016 1.8(1.3-2.7)
IBD5 Haplotype(1) 166 (63.6%) 246 (73%) 0.016 1.5 (1.1-2.2)
Variant Homozygote
Frequency
IGR2096 38(15.1%) 73 (21.4%) 0.036 1.58(1.0-2.4)
IGR2198 38 (14.8%) 70 (21%) 0.044 1.56(1.0-2.4)
OCTN2 (-207 G—*C) 55 (22%) 106 (31%) 0.0155 1.59(1.1-2.3)
IGR2230 47 (18.6%) 94 (29%) 0.0038 1.79(1.2-2.6)
OCTN1 (1672C—»T) 44 (17%) 89 (25.6%) 0.011 1.69(1.1-2.5)
TC Haplotype 40 (16%) 86 (28.4%) 0.0042 1.83 (1.2-2.8)
IBD5 Haplotype(1) 38 (14.6%) 68 (20.5%) 0.071 1.48(1.0-2.3)
Three single nucleotide polymorphisms (SNPs) were used to define the extended IBD5 locus
(IGR2096, IGR2198 and IGR2230) (Figure 1). Each was independently associated with
susceptibility to Crohn's disease when allelic frequencies, carriage rates and homozygosity
were analysed. OCTN2 variant (-207G—>C) and OCTN1 variant (1672C—►T) were also
independently associated with susceptibility to Crohn's disease when allelic frequencies,
carriage rates and homozygosity were analysed. The two allele risk haplotype OCTN1/2 TC
haplotype was associated with susceptibility to Crohn's disease when carriage rates, and
homozygosity rates were analysed.
1 A two allele risk haplotype using the IBD5 marker SNPs IGR2198 and IGR2230 is also
illustrated for comparison to the OCTN1/2 TC haplotype.
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IGR2198 209 (40.8%) 266 (44.2%) 0.26(1.1)
OCTN2 (-207 G->C) 242 (48.4%) 295 (51%) 0.38(1.1)
OCTN1 (1672C—>T) 216(42.9%) 270 (44.7%) 0.53 (1.1)
Carriage Rates
IGR2198 171 (67%) 204 (68%) 0.86(1.0)
OCTN2 (-207 G—>C) 187 (74%) 217(72%) 0.56 (0.9)
OCTN1 (1672C^T) 178 (68.7%) 205 (68%) 0.98 (0.97)
TC Haplotype 170 (69%) 196 (65%) 0.4 (0.86)
Homozygote
Frequency
IGR2198 38 (14.8%) 62 (20.6%) 0.11 (1.43)
OCTN2 (-207 G^C) 55 (22%) 78 (26%) 0.31 (1.23)
OCTN1 (1672C—>T) 44(17%) 65 (22%) 0.26(1.28)
TC Haplotype 40(16%) 63 (21%) 0.1 (1.38)
No significant associations were observed in ulcerative colitis patients between disease
susceptibility and any variant studied.
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6.3.3 Analysis of OCTN1/2 variants and OCTN1/2 TC haplotype
Allelic frequencies differed between Crohn's disease patients and controls for the OCTN1
variant (SLC22A4 exon 9 1672C^T) (CD 53.6% v HC 42.9%, p= 0.0008) and the OCTN2
variant (SLC22A5 promoter, -207G-*C) (CD 56.1% v HC 48.4% p= 0.0092) (Table 6.3).
Carriage of the OCTN1/2 TC risk haplotype was present more frequently in patients with CD
than controls (80% CD v 68.5% HC, p= 0.0016, RR=1.8). It was clear that this difference
related to homozygosity as OCTN1/2 TC homozygotes were more common in the Crohn's
disease group (28.4% CD v 16.1% HC, p= 0.0042, RR 1.83). No significant difference was
observed between OCTN1/2 TC heterozygote rates (p= 0.3).
An association was observed between the OCTN1 variant and inflammatory bowel disease
when allelic frequencies were analyzed (IBD 48.9% v HC 42.9%, p= 0.019). This finding was
not replicated in analysis of the OCTN2 variant (IBD 51.7% v HC 48.4%, p= 0.162) and no
associations were observed between variant allelic frequencies ofOCTN1 (UC 44.5% v HC
42.8%, p= 0.58) or OCTN2 (UC 48.1% v HC 47.8%, p= 0.92) and ulcerative colitis (Table
6.4). No association was observed between the OCTN1/2 TC haplotype and IBD overall, or
with UC. There was no evidence of epistasis between the OCTN1/2 variants, the OCTN1/2
TC haplotype and CARD 15 variants (Table 6.5).
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Table 6.5: Frequency of OCTN1/2 variant alleles and the OCTN1/2 TC haplotype in






















Analysis of evidence for epistasis between OCTN2 variant (-207G—»C) and OCTN1 variant
(1672C—>T) and the TC haplotype ofOCTN1/2 was investigated by stratifying OCTN1/2
variants by carriage of one or more of the three common CARD15 variants- R702W, G908R,
and 1007fsinsC. No evidence of epistasis was observed.
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6.3.4 The OCTN1/2 association with Crohn's Disease is not independent of the
association with the extended IBD5 haplotype.
Previous data have suggested carriage of the OCTN1/2 TC haplotype to be an independent
risk factor for Crohn's disease. However, in our data-set, individuals who lacked the IBD5 risk
haplotype (homozygous with respect to the non- Crohn's disease associated alleles of
IGR2096, IGR2198 and IGR2230) the OCTN1/2 TC haplotype was not associated with
Crohn's disease (Table 6.6). In the absence of variants in the marker SNP IGR2096, which is
located in block 4, 21.5% of the controls carried the OCTN1/2 TC haplotype compared to
30.4% in the Crohn's disease group (p= 0.22). When the OCTN1/2 TC haplotype was
analysed in the absence of IGR2198 variants (block 5) 27.1% of the controls possessed the
OCTN1/2 TC haplotype versus 17.1% of the Crohn's disease patients (p= 0.13). In the
absence of variants of the SNP IGR2230 which is in the same block as OCTN1/2 (block 7)
3.2% of the controls possessed the OCTN1/2 TC haplotype versus 0% of the Crohn's disease
patients (p= 0.25).
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GENE EXPRESSION ANALYSIS
6.3.5 Expression of Genes within the IBD5 Locus
Using the microarry expression data, in Crohn's disease small but consistent
downregulation ofOCTN2 was observed when Crohn's disease biopsies were
compared to control biopsies (FC -1.19, p =0.0028) and inflamed Crohn's disease
sigmoid colon biopsies were compared to non-inflamed biopsies (FC -1.46, p
=0.00086) (Table 6.7). When Crohn's disease biopsies from the terminal ileal were
compared to control terminal ileal biopsies OCTN2 was again downregulated (FC -
1.58, p =0.068). Expression of IRF1 was upregulated in the inflamed Crohn's disease
sigmoid colon biopsies when compared to the non-inflamed Crohn's disease sigmoid
colon biopsies (FC +1.57, p =0.00052).
OCTN2 was downregulated in ulcerative colitis biopsies compared to controls (FC-
1.26 p= 3.37xl0"6) and when inflamed ulcerative colitis sigmoid colon biopsies were
compared to non-inflamed ulcerative colitis sigmoid colon biopsies (FC-1.50, p=
2.2x10"6) (Table 6.8).
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PHENOTYPIC ANALYSIS
6.3.6 Age of diagnosis
When allelic frequency was compared in sub-groups defined by the Vienna
classification for age in the Crohn's disease patients (A1 <40), (A2 >40) there was no
significant difference between variant and wild type allelic frequency for all studied
SNPs.
6.3.7 Anatomical Distribution
There was no association between the IBD5 marker SNPs, OCTN1/2 variants and
Crohn's disease when disease location was assessed by the Vienna classification (LI
terminal ileum, L2 colon, L3 ileo-colonic and L4 upper GI tract). Of note no
association was found between the presence of peri-anal Crohn's disease and
homozygosity for the OCTN1/2 TC haplotype (p= 0.875). When patients with
Crohn's disease were further stratified for NOD2/CARD15 variant carriage, no
associations between homozygosity for the OCTN1/2 TC haplotype and the disease
location, categorized by the Vienna classification, were observed- 45% ofOCTN1/2
TC homozygous Crohn's disease patients with terminal ileal disease (LI) carried no
NOD2/CARD15 variants, whereas 52% carried one or more NOD2/CARD15 variant,
P=0.75. The IBD5, OCTN1/2 variants were not associated with disease extent and
severity in the ulcerative colitis cohort.
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6.3.8 Disease Behaviour
When disease behaviour at diagnosis was analyzed, no significant association between
variants representing the extended IBD5 locus, individual OCTN1/2 variants and
stricturing (B2, Vienna classification) or penetrating (B3) behaviour was observed,
when compared to inflammatory, nonstricturing, nonpenetrating disease behaviour
(Bl). A significant association was observed between IGR2198 homozygosity and
stricturing/penetrating disease when compared with inflammatory disease at most
recent follow up (24.9% B2, B3 v 14.4% Bl, p= 0.026, RR-1.97) (Table 6.9).
Significant associations were also observed between stricturing/penetrating disease
when compared to inflammatory disease for OCTN1 variant homozygosity (30% B2,
B3 v 17.4% Bl, p= 0.011, RR=2.0), OCTN2 variant homozygosity (34.8% B2, B3 v
23.0% Bl, p= 0.029, RR=1.78) and homozygosity for the OCTN1/2 TC haplotype
(29.7% B2, B3 v 17.1% Bl, p= 0.011, RR=2.05). In individuals who lacked the IBD5
risk haplotype (homozygous with respect to the non- Crohn's disease associated allele
of the IGR2198 variant), there was no association between stricturing/penetrating
disease behaviour at follow up and homozygosity for the OCTN1/2 TC haplotype
(11.1% inflammatory v 14.9% stricturing/penetrating, p= 0.65).
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Table 6.9: Phenotypic associations of IGR2198, OCTN1/2 variant homozygosity
and homozygosity for the OCTN1/2 TC haplotype.







Vienna classification of disease
behaviour at follow up
Inflammatory (n=121) 14.4% 23.0% 17.4% 17.1%
Stricturing/Penetrating (n=217) 24.9% 34.8% 30.0% 29.7%
P Value (RR) 0.026(1.97) 0.029(1.78) 0.011 (2.0) 0.011 (2.05)
Disease progression from
diagnosis to follow up
No progression (n=126) 14.7% 23.4% 18.2% 17.8%
Progression (n=132) 25.9% 31.3% 26.9% 29.1%




No surgery (n=137) 13.1% 21.9% 11.7% 12.3%
Surgery (n=237) 23.2% 33.1% 26.6% 26.7%
P value (RR) 0.037 (1.91) 0.031 (1.77) 0.0007 (2.7) 0.0023 (2.2)
An association was observed between IGR2198 variant homozygosity, OCTN2
variant homozygosity, OCTN1 variant homozygosity and homozygosity for the
OCTN1/2 TC haplotype and stricturing/penetrating disease when compared with
inflammatory disease at most recent follow up. Of the 258 CD patients who had
inflammatory Vienna disease classification at diagnosis, 126 patients disease did not
progress at follow up and 132 patients progressed to the stricturing/penetrating group.
The average duration of follow up of these patients was 11.8 years.
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6.3.9 Disease Progression
As the Vienna classification is a hierarchical system, a number of patients will move
from inflammatory disease (Bl) at diagnosis to either stricturing (B2) or penetrating
disease (B3) during their follow up. Of the 258 patients who had inflammatory
disease at diagnosis, 126 patients remained in the inflammatory group at follow up
and 132 patients progressed to the stricturing group or the penetrating group. The
median duration of follow up of these patients was 11.8 years. Homozygosity rates of
IGR2198 variants and the OCTN1/2 TC haplotype were associated with disease
progression to Vienna (B2) or Vienna (B3) compared with those whose disease
remained as Bl (Table 6.9). The association between the OCTN1/2 TC haplotype and
disease progression was not observed in Crohn's disease patients who lacked the
IBD5 risk haplotype (18% progression v 13% non-progression, p= 0.56).
6.3.10 Requirement for Surgery
As a marker of disease severity, patients who had required surgery (n= 237) for
complications of luminal Crohn's disease were compared to those who had had no
surgery for Crohn's disease (n= 137). A significant association was observed between
requirement for surgery and homozygosity for variants of IGR2198, OCTN1, OCTN2
and the OCTN1/2 TC haplotype (Table 6.9).
Multiple logistic regression analysis was applied, using a model that considered age at
diagnosis, disease behaviour, smoking status, family history, NOD2/CARD15 carrier
status and IGR2198 homozygosity or the OCTN1/2 TC haplotype, with the outcome
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being surgery for luminal complications of Crohn's disease. Co-linearity between
IGR2198 and OCTN1/2 TC homozygosity was evident, and allowed for in modelling.
IGR2198 homozygosity (p= 0.016, OR=2.86, CI=1.21-6.76) and the OCTN1/2 TC




The present study has provided novel data regarding the contribution of the IBD5
locus as a determinant of disease susceptibility and phenotype in the Scottish
population, which is known to be characterized by low rates of racial admixture,
compared with others in Europe, and North America.(251) We have shown the
OCTN1 and OCTN2 polymorphisms to be in tight linkage disequilibrium (D'
>0.959) with allelic variants of the 3 SNPs representing the extended IBD5 haplotype
(IGR2096, IGR2198 and IGR2230). Susceptibility to Crohn's disease was associated
with each of the three IBD5 polymorphisms defining the extended IBD5 region, as
well as the variant alleles of the OCTN1 and OCTN2 genes. Homozygosity for each
of the three SNPs used to define the extended IBD5 haplotype and for the OCTN1/2
TC haplotype were strongly associated with disease susceptibility. These data
provide the first independent confirmation of the association with the OCTN1/2
variants studied by Peltekova and colleagues in Canada.(95)
However, our data are not entirely consistent with the results reported from Peltekova
and colleagues, in a potentially critical aspect. In the absence of allelic variants
representing the extended risk haplotype for IBD5, our results show no significant
difference in the presence of the OCTN1/2 TC haplotype in Crohn's disease patients
compared to controls. These findings lead to the important suggestion that the
OCTN1/2 TC haplotype may not confer risk ofCrohn's disease independently of
other closely linked determinants within the extended IBD5 locus, and that it is at
present premature to conclude that the OCTN1/2 variants are causative in the
pathogenesis ofCrohn's disease.
200
In comparing the studies reported from Peltekova and colleagues with our own, the
choice ofmarkers used to define the IBD5 locus is especially worthy of discussion.
In Peltekova's data set the single marker IGR2078, located in block 4 of the
haplotype map (89) was used to define the IBD5 risk haplotype, and not a marker
closer to the OCTN1/2 loci (block 7), such as IGR2198 (block 5) or IGR2230 (block
7) which were used in the present study. In light of this, recombination between the
IGR2078 marker in block 4 and OCTN1/2 in block 7 needs to be considered as an
explanation for the apparent independence reported by Peltokova and colleagues. In
our data the only marker for which any trend towards an independence of the
OCTN1/2 TC haplotype was observed concerned the IGR2096 variants, which is also
located in block 4. In the absence of variants of the markers IGR2198 and IGR2230,
the OCTN1/2 TC haplotype was in fact more prevalent in the control group, further
supporting the hypothesis of recombination between haplotype blocks four and
seven.(89)
Data from four large cohorts of inflammatory bowel disease patients in
Cambridge,(99) Stockholm, Sweden,(252) UK/ Germany (100) and the USA (253)
have all shown an association between the IBD5 locus and Crohn's disease. In each of
these data sets, as in the present study, there was no independent association between
the OCTN1/2 TC haplotype and Crohn's disease in the absence of the extended IBD5
risk haplotype. The association between the IBD5 locus and Crohn's disease has also
been convincingly replicated in the recent meta-analysis of genome wide association
studies with a Bonferroni corrected p value of less than 0.05.(151)
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The arguments as to the contribution of the OCTN1/2 variants, implicated by
Peltekova and colleagues, have been developed further, and clearly require resolution.
Studies involving 276 samples from healthy, ethnically diverse human populations
have allowed the identification of several non-conservative SNPs of OCTN1/2 in
evolutionary conserved sites in African-American and Chinese populations.(254) The
authors suggest that if these variants were shown to confer susceptibility to Crohn's
disease in their respective populations this would provide strong evidence that
OCTN1/2 contain the critical mutations. As yet these studies have not been
undertaken. Moreover, genetic mutations in OCTN2 cause systemic carnitine
deficiency, characterised by disease of skeletal muscle, cardiac muscle and liver, but
not inflammatory or intestinal disease.(255)
Genetic studies to resolve the limits of the association using markers p and q
telomeric to OCTN1/2 may help to clarify this issue, however, power of resolution
will become a critical issue in attempting to resolve this controversy by genetic
studies alone. We have calculated that 3200 Crohn's disease individuals would need
to be genotyped to prove the independence of OCTN1/2 from IGR2230 which is
situated between the two genes in haplotype block 7.(89)
In the largest study of IBD5 to date, Silverberg and colleagues used stepwise
regression analysis to investigate 1879 patients with inflammatory bowel disease. The
effect of three SNPs IGR2096, IGR2198 and OCTN1 (1672C—>T) were individually
enough to explain the effect of the IBD5 locus in Crohn's disease susceptibility.(253)
OCTN2 (-207 G—>C) was ruled out as the causal variant, however, the study did not
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have sufficient power to differentiate between the 3 remaining SNPs and a meta¬
analysis of the published data may help define the critical variant.
When gene expression was compared within the IBD5 locus consistent
downregulation ofOCTN2 expression was observed in Crohn's disease and ulcerative
colitis biopsies compared to controls. In Crohn's disease it was the inflamed biopsies
that were driving these changes and OCTN1 was also downregulated in inflamed
ulcerative colitis biopsies. These provocative data add weight to the hypothesis that
decreased expression of the OCTN1/2 genes may be involved in the pathogenesis of
IBD, however, we also noted expression of ERF-1- a transcriptional factor that is
involved in the regulation of a number of genes related to the innate and adaptive
immune response (256;257) to be dysregulated, emphasizing the uncertainties
pertaining to this locus at present.
Increasingly in Crohn's disease it is recognised that clinical phenotype is genetically
determined.(258) In our cohort, when the Vienna classification for disease behaviour
was analyzed at the patients' most recent follow up assessment, there was a
significant association between the IBD5 marker SNP IGR2198, OCTN1/2 variants,
the OCTN1/2 TC haplotype and the presence of stricturing and penetrating disease.
Crohn's disease patients who were homozygous for IGR2198 variants or homozygous
for the OCTN1/2 TC haplotype had a disease phenotype that was more likely to
progress to stricturing or penetrating disease behaviour, and multivariate analysis
showed an association between IGR2198, the OCTN 1/2 TC haplotype and the
requirement for surgery.
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Further more recent data from a cohort of 325 German patients using the IGR2096
SNP to represent the IBD5 haplotpye showed variant alleles were associated with
stricturing/ fistulising disease behaviour compared to inflammatory disease behaviour
and the effect was dose related with homozygous patients having a higher risk (OR
6.5) than heterozygous patients (OR 4.8).(259) Variants within the IBD5 locus have
also been associated with a more severe disease phenotype and growth failure in an
independent cohort of 200 Scottish patients, diagnosed with Crohn's disease at the age
of sixteen or under.(98) Overall, our data show an exciting, novel genotype-
phenotype association with the IBD5 locus and it is intriguing to propose that a
genetic variant within the IBD5 locus causes Crohn's disease to become more severe
(stricturing or penetrating disease) and hence require increased surgical intervention.
Previous work involving the IBD5 locus has shown an association between the IBD5
risk haplotype and peri-anal Crohn's disease but this was not replicated in our cohort.
(93) Phenotypic data from Newman et al showed an association with ileal disease
(112), however, no significant association was observed in our population.
Differences in definitions of ileal Crohn's disease may be the reason for the
differences between these two cohorts: ileal disease in our cohort was classified
strictly according to the Vienna classification (LI). Using these criteria, 34% of
patients had purely terminal ileal disease: in contrast, 70.6% of patients in the Toronto
cohort were classified as having ileal disease.(l 12) Newman and colleagues did not
appear to include any patients with proximal small intestinal or upper gastrointestinal
disease. No data were available in this cohort regarding disease behaviour, or disease
progression over time.
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In conclusion we have determined that the IBD5 locus is associated with disease
susceptibility in our Crohn's disease cohort in Scotland. This is the first independent
replication of the association of the OCTN1/2 haplotype with Crohn's disease outwith
the index population in Canada. However, a significant effect ofOCTN1 and OCTN2
variants was not seen in the absence of the IBD5 risk haplotype, and on the strength of
the present data it is not possible to conclude whether or not the OCTN 1/2 genes
contain the disease-causing mutation, or whether the association serves to only narrow
the region of association within the IBD5 locus. Finally, novel and potentially
important phenotypic associations have been identified with the IBD5 locus, which




DLG5 VARIANTS DO NOT INFLUENCE SUSCEPTIBILITY TO
INFLAMMATORY BOWEL DISEASE IN THE SCOTTISH POPULATION
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SUMMARY
Introduction and Aims: Data from Germany have suggested that specific haplotypic
variants of the DLG5 gene on chromosome 10q23, may be associated with
susceptibility to inflammatory bowel disease (IBD). Association ofDLG5 haplotypic
variants with disease susceptibility, genotype-phenotype relationships and epistasis
with CARD 15 was investigated in the Scottish population. Expression ofDLG5 was
also investigated in human colonic and ileal endoscopic biopsies.
Patients and methods: 374 CD, 305 ulcerative colitis (UC) and 294 healthy controls
(HC) were studied. Genotyping for the variants rs 1248696 (113A, representing
haplotype D) and the SNP tag rs2289311 (representing haplotype A) were typed using
the Taqman system. Expression of the DLG5 probe A 23 P161209 on the Agilent
microarray chip was investigated in 53 CD, 67 UC and 31 control subjects.
Results: On analysis of the DLG5 variant 113A there were no associations with IBD
when allelic frequency (11.4%IBD v 13.2%HC, P=0.30) and carrier frequency
(19.2%IBD v 24.6%HC, p= 0.069) were analyzed. No associations were observed
between 113A variant allelic frequency (p= 0.37), carrier frequency (p= 0.057) and
CD. No associations between DLG5 and UC were observed. Haplotype A was not
protective and there was no evidence of epistasis between DLG5 and CARD15. No
significant changes in expression ofDLG5 were observed in any of the disease groups
that were examined.
Conclusions: The present data contrast strongly with previous data from Germany.




A locus on chromosome 10 was first implicated in genome wide scanning of a
European cohort (United Kingdom, Germany and the Netherlands) in 1999 as
conferring susceptibility to inflammatory bowel disease (LOD score 2.30).(78)
Results now suggest that the gene DLG5 (Drosophila Discs Large Homolog 5)
located on chromosome 10q23 may be responsible for the observed linkage and
contain critical mutations that confer susceptibility to inflammatory bowel
disease.(107)
Stoll et al (107) identified two extended DLG5 haplotypes that influenced disease
susceptibility in the German population. The first haplotype, (named haplotype D)
was especially notable for the presence of a G—>A substitution at nucleotide 113 that
resulted in an amino change at position 30 from Arginine to Glutamine (R30Q). On
analysis of carrier frequency, Stoll found the 113A variant to be associated with
Crohn's disease (25% Crohn's disease v 17% healthy controls, P=0.001) in a case
control study and trends between 113A transmission and inflammatory bowel disease
(p= 0.09) and Crohn's disease (p= 0.065) were observed on transmission
disequilibrium testing.(107) In silico analysis suggests that the 113A (R30Q) variant
may impair DLG5 scaffolding function, but as yet no expression or functional studies
in the inflammatory bowel diseases have been conducted. Evidence of epistasis
between the 113A variant ofDLG5 and CARD 15 variants was also observed in the
Crohn's disease cohort.(107)
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The second haplotype, (haplotype A) was tagged by eight marker SNPs and was
observed to be significantly under-transmitted in the inflammatory bowel disease
group (p= 0.006) suggesting the haplotype may be protective.(107)
In the present study we have assessed the contribution of the DLG5 polymorphisms
rsl248696 (113A) and rs2289311 (one of the marker SNPs for the protective
haplotype A)(107)) in determining genetic susceptibility to Crohn's disease and
ulcerative colitis in the Scottish population which has a high incidence of
inflammatory bowel disease. We have also investigated genotype-phenotype
associations in our rigorously defined inflammatory bowel disease population and
examined expression ofDLG5 in the colon and terminal ileum of patients with
inflammatory bowel disease and controls.
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7.2 PATIENTS AND METHODS
7.2.1 Demographics: Crohn's Disease and Ulcerative Colitis.
Six hundred and seventy nine patients with well characterized inflammatory bowel
disease and 269 controls were recruited. The group comprised of 374 patients with
Crohn's disease and 305 patients with ulcerative colitis (Table 7.1) (Methods 3.4.1-3).
The duration of follow-up was defined as the time from diagnosis to the time ofmost
recent clinic review (median duration of 11.8 years in the Crohn's disease group and
7.5 years in the ulcerative colitis group). The Crohn's disease group consisted of 181
males and 193 females and the ulcerative colitis group consisted of 171 males and 134
females with a median age at diagnosis of 34 years. Vienna disease classification was
available for 347 (93%) of Crohn's disease patients at diagnosis and 374 (100%) of
Crohn's disease patients at follow up. Full phenotypic data were available for the
ulcerative colitis cohort.
7.2.2 Control Subjects
Two hundred and ninety four controls- 163 blood donors from the south east of
Scotland and 131 healthy controls subjects were enrolled. Allelic frequencies of
DLG5 variant single nucleotide polymorphisms (SNPs) 113A, rs2289311, OCTN1
variant (SLC22A4 1672C^T) and OCTN2 variant (SLC22A5 -207G-^C) are shown
in Table 7.2.
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Table 7.1: Demographics and clinical features of the Crohn's disease,
ulcerative colitis and control group.
Crohn's Disease Ulcerative Colitis Controls
Total Number 374 305 269
Sex (male / female) 181/193 171/134 135/134
Median Age at diagnosis (yrs) 27.8 34 39
Interquartile range 20.9-40.4 25-50 27-52
Median duration of follow up 11.8 7.5
(yrs) Interquartile range 6.5-20.2 3.35-13.38
Caucasian (%) 98.7% 98.3%
CD Location at Diagnosis UC disease extent
Ileal disease 125 (36%) Proctitis 105 (34.5%)
Colonic Disease 137 (39%) Left sided colitis 116 (37%)
Ileal and colonic 58 (14%) Extensive colitis 84 (27.5%)
Upper GI disease 30 (8.5%)
Perianal disease 75 (21.4%)
CD Location at Follow Up
Ileal disease 92 (25%)
Colonic Disease 130 (35%)
Ileal and colonic 103 (28%)
Upper GI disease 49 (13%)
CD Behaviour at Diagnosis
Inflammatory (Vienna Bl) 258 (74.8%)
Stricturing (Vienna B2) 30 (8.4%)
Penetrating (Vienna B3) 59 (16.8%)
CD Behaviour at Follow Up
Inflammatory (Vienna Bl) 142 (38%)
Stricturing (Vienna B2) 68 (18%)
Penetrating (Vienna B3) 164 (44%)
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Table 7.2: Demographics and allelic frequencies in the blood transfusion samples
and healthy volunteer control samples.
Blood Transfusion Samples Healthy Control Samples
Age Median (IQ range) 35 (26-47) 36(29-51)
Male/ Female 83/ 79 52/55
113A (Allelic Frequency) 14.4% 12%
rs2289311 30.4% 33%
OCTN1 (SFC22A4) 43.5% 42.4%
OCTN2 (SLC22A5) 49% 46.1%
IGR2198 42% 40.4%
Allelic frequencies ofDLG5 variant SNPs 113A, rs2289311, OCTN1 variant (C—»T),
OCTN2 variant (-207G—>C) and IBD5 marker SNP IGR2198 are shown to illustrate
the consistency between the blood transfusion controls and the healthy volunteer
controls.
7.2.3 Genotyping
The SNPs rsl248696, (113G—>A representing haplotype D) and rs2289311 [(chosen
because of its reliability in genotyping to represent the protective haplotype A), M
Stoll, personal communication] were typed using the Taqman system (Methods 3.4.4-
6). Inflammatory bowel disease patients and controls were typed for polymorphisms
of the CARD 15 gene (R702W, G908R, and 1007fsinsC) using previously described
methods.(85) All genotyping except the R702W was carried out using the Taqman
system. R702W genotyping was performed by restriction fragment length
polymorphism polymerase chain reaction.
7.2.4 Data Analysis
The two SNPs rs 1248696 and rs2289311, were analyzed for association with
Inflammatory bowel disease (IBD) overall, Crohn's disease, ulcerative colitis and
disease phenotype. Each allele was shown to be in Hardy-Weinberg equilibrium in the
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control population. Genotype-phenotype associations were analyzed by Chi squared
test using Minitab vlO. To identify significant independent variables associated with
genotype, univariate and multivariate analysis was carried out. Evidence for DLG5
epistasis with CARD 15 was investigated by stratifying DLG5 variants by carriage of
one or more of the three common CARD 15 variants- R702W, G908R, and
1007fsinsC. Allelic frequencies of the DLG5 variants were compared between the
sub-groups of patients with and without CARD 15 variants by Chi squared analysis.
The null hypothesis was that the frequency ofDLG5 variants did not differ between
these sub-groups. Phenotypic associations ofDLG5 variants were also stratified for
the presence and absence ofCARD 15 variants.
7.2.5 Expression of the DLG5 probe A23P161209
Gene expression ofDLG5 was analyzed using data generated from the microarray
gene expression study. Detailed methods are provided in the methods section 3.2.1-9,
3.3.4. Statistical significance of the microarray data was determined by Student's




7.3.1 Disease Susceptibility: Haplotype D (113A)
On analysis of the DLG5 variant 113A there were no associations with inflammatory
bowel disease (IBD) when allelic frequency (11.4% IBD v 13.2% HC, p = 0.30),
carrier frequency (19.2% IBD v 24.6% HC, p = 0.069) and homozygosity rates (2.3%
IBD v 1.5% HC, p = 0.48) were analyzed (Table 7.3). A negative association was
observed between heterozygous rates of 113A and IBD (16.9% IBD v 23% HC, p =
0.033). Furthermore a negative correlation was observed between heterozygous 113A
variants and Crohn's disease (CD) (16% CD v 23% HC, p = 0.029). No association
was observed between 113A variant allelic frequency (11.4% CD v 13.2% HC, p =
0.37), carrier frequency (18.3% CD v 24.6% HC, p = 0.057), homozygous rates (p =
0.36) and CD. No associations between 113A and UC were observed-allelic
frequency (12.8% UC v 13.2% HC, p = 0.34), carrier frequency (20.3% UC v 24.6%
HC, P=0.23) heterozygous rates (18% UC v 23% HC, p = 0.45) and homozygous
rates (2.3% UC v 1.5% CD, p = 0.5).
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Table 7.3: DGL5 113A variant allele frequency, carrier frequency, heterozygote
frequency and homozygote frequency in the IBD, CD, UC and control
populations.
Controls IBD Crohn's Disease Ulcerative
p value p value Colitis, p value
Allelic 13.2% 11.4% 11.4% 11.4%
Frequency p=0.30 p=0.37 p=0.34
Carrier 63/256 125/652 65/356 60/296
Frequency (24.6%) (19.2%) p=0.069 (18.3%) p=0.057 (20.3%) p=0.228
Heterozygosity 59/256 110/650 57/356 53/294
Rates (23%) (16.7%) p=0.033 (16%) p=0.029 (18%) p=0.45
Homozygosity 4/256 15/650 8/356 7/294
Rates (1.5%) (2.3%) p=0.48 (2.2%) p=0.36 (2.4%) p=0.50
The p values shown are calculated between the control group and each respective
disease group.
7.3.2 DLG5 Haplotype A
Haplotype A allelic frequencies, represented by rs2289311 variants did not differ
between HC (31.5%) and IBD (35%, P=0.17), CD (36.9%, P=0.078) or UC patients
(33.4%, P=0.51). No significant differences were observed between carriage rates of
rs2289311 variants, HC (52%), IBD (57.2%, P=0.18), CD (60.9%, P=0.052) and UC
(54%, P=0.65). The frequency of patients who were heterozygote or homozygote for
rs2289311 polymorphisms did not differ between IBD and HC groups (heterozygote
HC 41.1% v IBD 44.8% P=0.43, CD 48% P=0.13 and UC 42.1%, P=0.83)




On univariate analysis of Crohn's disease patients no association was observed
between DLG5 113A variants and the Vienna classification for age of diagnosis,
location of disease and disease behaviour. The location of disease and disease
behaviour in Crohn's disease patients was analyzed at time of diagnosis and at most
recent follow up and there was no association between DLG5 113A variants and
disease progression. No association was observed between DLG5 113A variants and
age of diagnosis in the inflammatory bowel disease and ulcerative colitis groups and
there was no association between DLG5 113A variants, disease extent and severity in
the ulcerative colitis patients.
When the frequency of the DLG5 113A was compared in males and females, there
was no difference in both the control, inflammatory bowel disease group and Crohn's
disease group- control 12.4% male v 12.8% female, p = 0.79, IBD male 12.2% v
female 9.5%, p = 0.14, Crohn's disease, male 9.9% v female 10.5%, p = 0.68. In the
ulcerative colitis group the DLG5 113A allele was more common in males 14.3%
than females 7.9%, p = 0.022, OR 1.9, CI (1.1- 3.3).
DLG5 113A variants displayed a trend towards being less common in inflammatory
bowel disease patients with joint problems (large joint arthralgias related to disease
activity, small joint arthralgias unrelated to disease activity, ankylosing spondylitis
and sacro-ilitis) (N=127) when compared to those who had no joint problems when
allelic frequency was analyzed (7.5% v 11.8%, p = 0.053). When allelic frequency of
113A variants was analyzed in ulcerative colitis patients with primary sclerosing
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cholangitis a trend towards these patients having fewer 113A variants was observed
(0%, (N=7) v 11.4%, p = 0.17). On analysis of the haplotype A, no genotype
phenotype associations were observed in the Crohn's disease and ulcerative colitis
patient groups. Multiple logistic regression analysis did not identify any variables that
were independently associated with haplotype D (113A) or haplotype A.
There was no evidence of epistasis between DLG5 113A variants and carriage of the
three common CARD15 variants Gly908Arg, Arg702Trp and Leul007fsinsC-
CARD15 carriage positive DLG5 113A allelic frequency 9.7% (N=108) v CARD15
carriage negative DLG5 113A allelic frequency 11.6% (N=584) (p = 0.43). When
Crohn's disease patients were stratified for CARD 15 variant carriage, no significant
genotype-phenotype relationships were found with DLG5 113A.
7.3.4 Expression of DLG5
Using the Agilent probe A 23 P161209 to represent DLG5, expression of the gene
was compared across a number of experiments (Table 7.4). No significant changes in
expression were observed when inflammatory bowel disease, Crohn's disease and
ulcerative colitis biopsies were compared to control biopsies (p= 0.78, p= 0.12 and p=
0.063 respectively). When inflamed and non-inflamed Crohn's disease and ulcerative
colitis sigmoid colon biopsies were compared, again no change in expression was
observed between the inflamed and non-inflamed groups (p= 0.29 and p= 0.94
respectively).
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Table 7.4: Expression of DLG5 probe A 23 P161209 across a number of different
experiments
Groups Analyzed (Number of biopsies) Fold Change p value
All IBD (228) v controls (73) -1.0057 0.78
All CD (99) v controls (73) +1.082 0.12
All UC (129) v controls (73) -1.046 0.063
Non-inflamed CD sigmoid (17) v non inflamed
control sigmoid (18)
-1.044 0.55





The present study has demonstrated that in the Scottish population, traditionally characterised
by low rates of admixture, the DLG5 variant 113A representing haplotype D is not a critical
determinant of susceptibility in either Crohn's disease or ulcerative colitis. Haplotype A
represented by the SNP rs2289311 was not protective in our Crohn's disease or ulcerative
colitis population and no change in expression ofDLG5 was observed in any of the disease
groups that were examined.
These data differ markedly from those of Stoll et al who showed that in a German population,
DLG5 113A variants were overtransmitted to individuals with inflammatory bowel disease,
and in a case control study there was significantly higher rates of 113A carriage in the
inflammatory bowel disease group when compared to the control group (25% v 17%, p =
0.001).(107) Considerations including sample size and phenotypic differences between the
present study and that of Stoll and colleagues may be responsible for the observed discrepancy
in results, but a more plausible explanation would be genetic heterogeneity between the
populations of Germany and Scotland. This has been clearly illustrated by data now available
with respect to the three common polymorphisms of the NOD2/ CARD 15 gene (G908R,
R702W and lOOfsinsC) which are significantly more common in the Central European
Crohn's disease population (42;82) than in the Northern European Crohn's disease
population.(85;260;261) Furthermore CARD 15 polymorphisms are absent in the Japanese and
Chinese Crohn's disease populations.(83;84;262) The different incidences of the R702W
polymorphism has also been shown in healthy volunteers in Europe, Africa and Asia.(263) At
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present DLG5 has not been associated with inflammatory bowel disease in any genome wide
association study and this would suggest that if indeed DLG5 plays a role in the pathogenesis
of inflammatory bowel disease its contribution may be small and limited to specific
populations.(151; 152;264)
Further data illustrating genetic heterogeneity in European inflammatory bowel disease
patients have been observed on analysis of the Asp299Gly mutation of the Toll-like receptor 4
gene (TLR4).(265) TLR4 is a member of the Toll like receptor family which are involved in
recognition of pathogen associated molecular patterns by the immune system and TLR4
functions as an extracellular pattern recognition receptor for lipopolysaccaride which is
common to many intraluminal bacteria.(266) The Asp229Gly variant has been shown to
confer susceptibility to Crohn's disease and ulcerative colitis in the Belgian population, (267)
but no association was observed between Asp229Gly variants and inflammatory bowel disease
in German and Scottish cohorts.(85;268)
Analysis of the original German cohort of patients used by Stoll and colleagues,(107)
combined with the Italian and Canadian patients used by Daly and colleagues,(120; 135)
showed a significant association between the 113A allele and Crohn's disease males, p <
0.001, OR = 2.49, but not females, p = 0.979, OR = 1.01.(135) The observed association of the
113A variant and Crohn's disease in males appeared to be driven by the difference between
the allelic frequencies of the 113A DLG5 variant in the control male (5.2%) compared to the
female population (11.3%).
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A meta-analysis of 12 case-control studies including the present data containing 4707 Crohn's
disease patients and 4937 controls showed no male-female allelic frequency differences in the
control populations and a trend towards the 113A/R30Q variant being less common in the
female Crohn's disease patients.(136) When these data were added to further analysis of 5
previous case-control studies the 113A/R30Q variant was associated with a small reduction in
risk in female Crohn's disease patients- OR = 0.86 (CI 0.76- 0.97).
Interestingly, in a cohort of patients diagnosed with inflammatory bowel disease at the age of
16 or under from Scotland, Russell and colleagues observed an overtransmission of the 113A
/R30Q allele in male patients with Crohn's disease compared to females- 29.3% vs. 16.9%,
p=0.04 OR 2.04.(269) Taken together these data suggest that if there is a genetic contribution
of the DLG5 113A/R30Q variant to disease susceptibility it may be more prominent in the
male population.
Trends were observed towards a lower DLG5 113A variant frequency in Crohn's disease
patients with arthropathy and ulcerative colitis patients with primary sclerosing cholangitis
(PSC) on univariate analysis. Both of these extra-intestinal complications have been shown to
have a molecular genetic basis. Susceptibility to axial arthropathy has been strongly associated
with HLA-B*27 in patients with and without inflammatory bowel disease (270) and peripheral
arthropathies in patients with inflammatory bowel disease have been associated with HLA-
DRB1*0103, HLA-B*35, HLA-B*27 and HLA-B*44.(271) In PSC strong disease
associations with extended HLA haplotypes have been observed (272) and a functional variant
of stromolysin (matrix metalloproteinase 3) has also been associated with susceptibility to
221
PSC and with disease progression.(273) In the current investigation the relatively small
numbers of inflammatory bowel disease patients studied with these specific extra intestinal
manifestations mean that these results regarding any DLG5 effect in these sub-groups should
be regarded as exploratory observations. Replication studies in other cohorts may help shed
some light on this question.
No evidence of epistasis between DLG5 113A variants and carriage of the three common
NOD2/ CARD15 variants Gly908Arg, Arg702Trp and Leul007fsinsC was observed in
patients with Crohn's disease. Again these data contrast with Stoll and colleagues who found a
significantly greater transmission of DLG5 113A in patients with Crohn's disease carrying
one of the risk associated alleles ofCARD 15.(107) A possible explanation for the absence of
epistasis between DLG5 and CARD15 could be the low incidence ofCARD15 variants in the
Scottish Crohn's disease population, 1007fsinsC= 4.7%, G908R=1.8% and R702W= 7.1%
and the combined population attributable risk these variants confer 11%.(85)
In conclusion, in our North European study population we were unable to replicate Stoll's data
that the DLG5 variant 113A confers susceptibility to inflammatory bowel disease. Haplotype
A represented by the SNP rs2289311 does not confer protection in our population. There was
no change in expression ofDLG5 in the colon and terminal ileum of inflammatory bowel
disease patients and controls and this allied to the lack of association in the recent genome
wide association studies would strongly suggest that DLG5 does not play a significant role in
the pathogenesis of inflammatory bowel disease.
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CHAPTER 8
CONCLUSIONS AND FUTURE DIRECTIONS
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8.1 CONCLUSIONS
In the healthy adult colon cluster analysis showed differences in gene expression between the
right and left colon. (%2=25.1, p<0.0001). Developmental genes, HOXA13, (p=2.3xl016),
HOXB13 (p <lxl0"45), GLI1 (p=4.0xl0 24), and GLI3 (p=2.1xl0"28) were involved in driving
these changes. These novel findings have important implications for disease pathogenesis in
the colon.
When all the Crohn's disease biopsies were compared to the controls, 259 sequences were
upregulated and 87 sequences were downregulated. Upregulated genes in Crohn's disease
included SAA1 (FC +7.5, p =1.47xl0"41) and REGL (FC +7.3, p =2.3xl0"16). Downregulated
genes included genes involved in cellular detoxification-SLC14A2 (FC -2.49, p =0.00002),
carbonic anhydrase 2 (CA2) (FC -2.4, p =8.4x10"'°) and CA1 (FC -2.3, p =7.5xl0"6). In the
Crohn's disease terminal ileal biopsies diubiquitin (FC+11.3, p<lxl0"45), MMP3 (FC+7.4,
p=1.3xlO""), IRTA1 (FC-11.4, p=4.7xl0"12) and CCL23 (FC-7.1, p=1.6xl0"'°) were
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differentially expressed compared to controls. In the colon SAA1 (FC+6.3, p=5.3xl0" ) was
upregulated and TSLP (FC-2.3, p=2.7xl0"6) was downregulated comparing non-inflamed
Crohn's disease and control biopsies, and the colonic inflammatory Crohn's disease signature
was characterized by downregulated organic solute carriers-SLC38A4, SLC26A2 and OST
alpha.
Analysis of the IL-23 pathway revealed that IL-23A/pl9, (FC +2.32, p =0.000099), JAK2,
(FC +1.90, p =9.4x10"7), STAT3, (FC +2.23, p =0.0004) and INFy, (FC +2.31, p =0.0019)
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were significantly upregulated in the Crohn's disease biopsies compared to controls and when
inflamed Crohn's disease biopsies were compared to non-inflamed Crohn's disease biopsies-
IL-23A/pl9, (FC +2.11, p =0.000031), JAK2, (FC +1.90, p =0.00003), STAT3, (FC +1.66, p
=0.0002) and INFy, (FC +2.33, p <0.0001). Modest changes in expression were also observed
in a number of the autophagy genes.
When the anatomical location that the Crohn's disease and control biopsies were taken from
was considered, 18 terminal ileal biopsies clustered together, separately from the colonic
biopsies (6 control and 12 Crohn's disease, X2 = 10.2, p< 0.001). No separation of the biopsies
by either disease status or by the degree of inflammation was observed. When the terminal
ileal biopsies alone were considered, clustering by disease status was observed. Gene ontology
showed this clustering was driven by a downregulated group of transporter genes and an
upregulated group of structural genes. A panel of 14 epithelial cell cytokines showed good
ability to cluster biopsies from Crohn's disease patients and controls emphasising their key
role in inflammation.
When all ulcerative colitis biopsies and control biopsies were compared, 143 sequences had a
fold change of>1.5 in the ulcerative colitis biopsies (0.01>p>10"45) and 54 sequences had a
fold change of <-1.5 (0.01>p>10"2°). Differentially upregulated genes in ulcerative colitis
included SAA1 (p<10^5) the alpha defensins, DEFA5&6 (p=0.00003 and p=6.95xl0"7
respectively), MMP3 (p=5.6xlO~10) and MMP7 (p=2.3xl0~7). When non-inflamed sigmoid
colon biopsies were compared between ulcerative colitis patients and controls upregulated
genes included defensin beta 14 (FC+2.11, p = 0.00002) and SAA1 (FC+2.01, p = 0.00024).
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Interesting genes that were down regulated included HLA-DRB1 (FC-3.0, p = 0.0010) and
TSLP (FC-2.73, p = 2.7xlO~10).
In the inflamed ulcerative colitis biopsies there was marked upregulation ofDEFA5 and
DEFA6 expression in the colon compared to non-inflamed ulcerative colitis biopsies and
control biopsies. This was characterized to Paneth cell metaplasia by immunohistochemistry
and in-situ hybridization. Sub-analysis of the IBD2 loci and the ABC transporter genes
revealed a number of differentially regulated genes in ulcerative colitis.
One of the limitations of the expression data set was the lack of genotypic data in the patients
and controls. Having DNA in these patients would have allowed a direct comparison between
genotype and expression analysis.
In our inflammatory bowel disease population it was observed that the IBD5, OCTN1 and
OCTN2 polymorphisms were in strong linkage disequilibrium and variants in all the examined
SNPs- IGR2198, IGR2198, OCTN2 (-207 G->C), IGR2230 and OCTN1 (1672C^T) were
associated with Crohn's disease compared to healthy controls (p<0.03). IGR2198 variants and
the OCTN1/2 TC haplotype were associated with a more severe disease phenotype-
stricturing/ penetrating disease at follow-up (p=0.011, p=0.011), disease progression from
inflammatory disease phenotype to stricturing/penetrating disease phenotype (p=0.038,
p=0.049), and with need for surgery (p=0.006, p=0.004 respectively).
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In the absence of the IBD5 risk haplotype, no association of OCTNI/2 variants with Crohn's
disease was detected. No associations were seen with ulcerative colitis. When the expression
data was compared using 11 probes representing genes from the IBD5 locus, small but
consistent downregulation ofOCTN2 was observed in the Crohn's disease and ulcerative
colitis biopsies compared to control biopsies and in inflamed compared to non-inflamed
Crohn's disease and ulcerative colitis biopsies.
Analysis of the DLG5 variant 113A showed there were no associations with inflammatory
bowel disease, Crohn's disease or ulcerative colitis. DLG5 haplotype A was not protective in
our inflammatory bowel disease population. Using the probe A23P161209 to represent
DLG5, no significant changes in expression were observed when inflammatory bowel disease,
Crohn's disease and ulcerative colitis biopsies were compared to control biopsies.
Overall these data emphasise the key role of a number of inflammatory molecules and
pathways in the pathogenesis ofCrohn's disease and ulcerative colitis, and their potential for
translation to therapeutic targets. Furthermore, the results add considerably to the recent
genome wide association studies in providing complimentary human colonic and ileal
expression data along with detailed analysis of the IL-23 and autophagy pathways.
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8.2 FUTURE DIRECTIONS
The expression data presented in this thesis have allowed us to gain insight into how
recognized and novel molecules are expressed in the colon and in the terminal ileum in
patients with quiescent and active inflammatory bowel disease. One of the next analyses to be
undertaken using the existing data set will be to see if small numbers of probes can be
identified to correctly assess inflammatory bowel disease in order to make a correct diagnosis
and also to grade disease severity. A diagnostic and severity chip may help in the diagnosis of
inflammatory bowel disease especially in patients where it is difficult to tell whether they have
Crohn's disease or ulcerative colitis.
To further investigate the pathogenesis of inflammatory bowel disease and better define the
roles of the novel and established genes investigated in this thesis, the next set of experiments
to be undertaken would be functional studies. Mouse models, colonic cell lines and human
endoscopic biopsies could be used to examine how central these molecules are to the
inflammation observed in inflammatory bowel disease. It would also be interesting to examine
the key inflammatory molecules at the protein level and compare this to the RNA expression
results. This would help with the ultimate aim of dissecting the immune response in
inflammatory bowel disease in order to identify new therapeutic targets.
A further avenue for gene expression studies is to investigate whether they can predict
response to therapy and allow clinicians to personalize treatment, maximizing efficacy and
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minimizing the risks of therapy. Data has recently been accepted for publication looking at
predicting response to infliximab therapy in patients with ulcerative colitis.(274) Gene
expression analysis in Crohn's disease before and after therapy especially in terminal ileal
biopsies could investigate determinates of response to treatment. Furthermore, it is imperative
for new biological therapies to have a diagnostic test to go with the therapy and gene
expression could provide this valuable data.
We have also undertaken genome wide expression analysis on whole blood from a number of
patients in this study and we also plan to publish this data and compare gene expression in the
colon, ileum and peripheral blood. Preliminary results show interesting changes between
expression in the bowel and peripheral blood and these results may help in diagnosis and
grading severity.
The whole expression data set has also been made available to scientists in Edinburgh,
Genentech and to the wider scientific community through Gene Expression Omnibus,
allowing investigators to look at expression of genes of interest. This has allowed the
development of a number of successful collaborations.
With regards to IBD5 we have calculated that 3200 Crohn's disease patients would be
required for a study to have the power to identify the disease causing variant and a meta¬
analysis with sufficient power could be put together with collaborators. At present there are no
plans for large scale detailed genotyping of this area, but as genotyping costs continue to fall
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this will become increasingly feasible. Subsequent studies into DLG5 have not observed any
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Objective: To investigate differential intestinal gene
expression in patients with ulcerative colitis and in
controls.
Design: Genome-wide expression study (41 058
expression sequence tags, 215 biopsies).
Setting: Western General Hospital, Edinburgh, UK, and
Genentech, San Francisco, USA.
Patients: 67 patients with ulcerative colitis and 31
control subjects (23 normal subjects and 8 patients with
inflamed non-inflammatory bowel disease biopsies).
Interventions: Paired endoscopic biopsies were taken
from 5 specific anatomical locations for RNA extraction
and histology. The Agilent microarray platform was used
and confirmation of results was undertaken by real time
polymerase chain reaction and immunohistochemistry.
Results: In healthy control biopsies, cluster analysis
showed differences in gene expression between the right
and left colon. (x2 = 25.1, p<0.0001). Developmental
genes, homeobox protein A13 (H0XA13),
(p = 2.3x10-16), H0XB13 (p<1x10~45), glioma-asso-
ciated oncogene 1 (GLI1) (p = 4.0x10"24), and GLI3
(p = 2.1 x10~23) primarily drove this separation. When all
ulcerative colitis biopsies and control biopsies were
compared, 143 sequences had a fold change of >1.5 in
the ulcerative colitis biopsies (0.01>p>10~45) and 54
sequences had a fold change of <-1.5
(0.01>p>10-20). Differentially upregulated genes in
ulcerative colitis included serum amyloid A1 (SAA1)
(p<10 45) the alpha defensins 5 and 6 (DEFA5 and 6)
(p = 0.00003 and p = 6.95 x10~7, respectively), matrix
metalloproteinase 3 (MMP3) (p = 5.6 x 10^10) and MMP7
(p = 2.3 x10 7). Increased DEFA5 and 6 expression was
further characterised to Paneth cell metaplasia by
immunohistochemistry and in situ hybridisation. Sub-
analysis of the inflammatory bowel disease 2 (IBD2) and
IBD5 loci, and the ATP-binding cassette (ABC) transporter
genes revealed a number of differentially regulated genes
in the ulcerative colitis biopsies.
Conclusions: Key findings are the expression gradient in
the healthy adult colon and the involvement of novel gene
families, as well as established candidate genes in the
pathogenesis of ulcerative colitis.
The inflammatory bowel diseases (IBDs), ulcera¬
tive colitis and Crohn's disease, are chronic
relapsing inflammatory diseases of the gastroin¬
testinal tract. Both diseases are complex clinical
entities that occur in genetically susceptible indi¬
viduals who are exposed to as yet poorly defined
environmental stimuli.12
In recent years, the application of non-parametric
linkage analyses and well-designed case-control
association studies have led to the identification of
a number of susceptibility genes or loci strongly
associated with Crohn's disease and ulcerative
colitis. In Crohn's disease, success has been
especially evident since the application of gen¬
ome-wide association studies that have implicated
at least 10 novel loci, including the genes encoding
interleukin 23R (IL23R), autophagy-related 16-like
1 (ATG16L1) and immunity-related GTPase
family, M (IRGM).3-6 Determinants implicated to
date in ulcerative colitis include the IBD2 and
IBD5 loci, the human leukoryte antigen (HLA)
complex, and the multidrug-resistance 1 (MDR1)
gene.17 These studies all highlight important
pathways involved in disease pathogenesis and
the emerging challenge now is to move from gene
identification to functional understanding.
Microarray expression analysis allow a compre¬
hensive picture of gene expression at the tissue and
cellular level, thus helping to understand the
underlying patho-physiological processes.8 Earlier
studies using microarray platforms to interrogate
resection specimens from patients with IBD
identified a number of novel genes that were
differentially regulated when diseased samples
from patients with severe disease were compared
to controls.9-11
Subsequently, the ability to use endoscopic
pinch mucosal biopsies rather than resection
samples has allowed investigators to microarray
tissue from a larger range of patients encompassing
those with less severe disease.12-15 Whilst these
studies have shown consistent differential expres¬
sion of a number of genes of interest, the data
generated also highlight the heterogeneity of
different experimental microarray platforms and
biopsy collection techniques. As microarray tech¬
nology has improved still further, data sets have
become even more consistent, and the degree of
replication between individual arrays and across
platforms has increased significantly.1617
The aims of the current study were to use
microarray gene expression analysis to investigate
genome-wide expression in endoscopic mucosal
biopsies taken at colonoscopy from 67 patients
with ulcerative colitis and 31 controls. This
represents the largest cohort described to date
and particular care has been taken to characterise
disease phenotype as well as the anatomical
location sampled. Comparisons have been made
between gene expression profiles in health and
disease, as well as within ulcerative colitis.
Thereby, the present data set has allowed us to
gain valuable insight into gradients of gene
expression along the healthy adult colon, as well
as changes associated with disease. The data
Gut 2008:57:1398-1405. doi:10.1136/gut.2008.148395
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le 1 Demographics of the patients with ulcerative colitis
Ulcerative colitis
number of patients 67
/female 33/34
an age at diagnosis (years) 37











ly history of IBD 5
A therapy 40
tosteroid therapy 10
inosuppressant therapy (AZA, 6MP, MTX) 11
SA, 5-aminosalicylate; AZA, azathioprine; IBD, inflammatory bowel disease;
P, 6-mercaptopurine; MTX, methotrexate.
:nd current understanding of gene expression in health, and
complementary to current studies of germline and somatic
ation associated with ulcerative colitis.
rHODS
ents and controls
y-seven patients with ulcerative colitis and 31 control
ents undergoing colonoscopy were recruited (table 1). All
ents with ulcerative colitis attended the clinic at the
;tern General Hospital, Edinburgh, and the diagnosis of
rative colitis adhered to the criteria given by Lennard-
:s.18 Phenotypic data were collected by interview and case-
; review.
leven of the controls were men and 20 were women. The
lian age was 43 years at the time of endoscopy. Six of the
trols had normal colonoscopies for colon cancer screening,
: controls had symptoms consistent with irritable bowel
drome and had a normal colonoscopic investigation and
:n patients had a colonoscopy for another indication and
ologically normal biopsies were obtained. Eight control
ents had abnormal inflamed colonic biopsies (one pseudo-
nbranous colitis, one diverticulitis, one amoebiasis, two
roscopic colitis, one eosoinophilic infiltrate, two scattered
phoid aggregates and a history of gastroenteritis). Written
rmed consent was obtained from all patients.
e 2 The location, number and inflammation status of biopsies in
snts with ulcerative colitis and in controls
Patients with ulcerative
colitis Controls
number of paired 139 76
ies
ived from analysis 10 3
Inflamed Non-inflamed Inflamed Non-inflamed
inal ileum 0 4 1 5
nding colon 12 21 4 13
anding colon 15 20 6 17
oid colon biopsies 35 22 9 18
!008;57:1398-1405. doi:10.1136/gut.2008.148395
Biopsy collection
Paired biopsies were taken from each anatomical location
(table 2). One biopsy was sent for histological examination
and the other was snap frozen in liquid nitrogen for RNA
extraction.
Each biopsy was graded histologically by an experienced
gastrointestinal pathologist as having no evidence of inflamma¬
tion, biopsies with evidence of chronic inflammation and
predominately chronic inflammatory cell infiltrate or simply
those with acute inflammation and an acute inflammatory cell
infiltrate.
Microarray analysis
Total RNA was extracted from each biopsy using the micro
total RNA isolation from animal tissues protocol (Qiagen,
Valencia, California, USA). One microgram of total RNA was
amplified using the Low RNA Input Fluorescent Linear
Amplification protocol (Agilent Technologies, Palo Alto,
California, USA). A T7 RNA polymerase single round of linear
amplification was carried out to incorporate the cyanine-3 and
cyanine-5 labels into cRNA. The cRNA was purified using the
RNeasy Mini Kit (Qiagen). One mictrolitre of cRNA was
quantified using the NanoDrop ND-1000 spectrophotometer
(NanoDrop Technologies, Wilmington, Delaware, USA). Seven
hundred and fifty nanograms of Universal Human Reference
(Stratagene, La Jolla, California, USA) cRNA labelled with
cyanine-3 and 750 ng of the test sample cRNA labelled with
cyanine-5 were fragmented for 30 min at 60°C before loading
onto the Agilent Whole Human Genome microarrays which are
annotated to represent 33 296 genes.
Figure 1 Histologically normal biopsies from control patients were
analysed by unsupervised hierarchical clustering. Separation of the
biopsies by anatomical location was observed and this separation was
predominately driven by genes involved in the embryological
development of the gastrointestinal tract.
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'he samples were hybridised for 18 h at 60°C with constant
ition. Microarrays were washed, dried and scanned on the
lent scanner according to the manufacturer's protocol.
:roarray image files were analysed using Agilent's Feature
taction software version 7.5. The genes were normalised
lg the Stratagene Universal Human Reference. The distribu-
t of log intensities for each sample was plotted and outlier
iples (ie, greater than 2 standard deviations from the mean)
e excluded from analysis. The whole data set is available at
le Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/
:essed 18 July 2008)) accession: GSE11223.
I, in situ hybridisation and immunohistochemistry
Tods for real time polymerase chain reaction (PCR), in situ
ridisation for defensin alpha 5, and immunohistochemistry
rabbit anti-human lysozyme and rabbit anti-human defensin
la 6 are provided in the supplementary methods section.
a analysis
roarray data were analysed using the Rosetta Resolver
ware (Rosetta Inpharmatics, Seattle, WA, USA). Statistical
.ificance of the microarray data was determined by Student's
aired t test. A value of p<0.01 and a fold change of greater
ess than 1.5 were considered statistically significant. Fold
age data were calculated using the Rosetta Resolver
ware. To correct for multiple hypothesis testing a q-value
calculated for each tested feature to estimate significance in
as of the false discovery rate (FDR) rather than the false
.tive rate. From the q-values a FDR was calculated using the
hod proposed by Storey and Tibshirani.19 A FDR of less than
was calculated for each of the presented analysis. Gene
alogy was analysed using Ingenuity software (Ingenuity
:ems, Mountain View, CA, USA). The Mann-Whitney U
was used to analyse the real time PCR data. A value of
).05 was considered significant.
RESULTS
Influence of anatomical location on gene expression in the
healthy colon and terminal ileum
Unsupervised hierarchical clustering analysis using probes that
had a fold change of greater or less than 1.3 were used to
interrogate 56 histologically normal biopsies from control
patients. Clear separation by anatomical location was observed;
on one side of the dendrogram 25/25 biopsies were from the left
colon (descending colon or sigmoid colon) whereas on the other
side of the dendrogram 20/31 biopsies were from the ascending
colon (x2 = 25.1, p<0.0001) (fig 1). Biopsies from individual
patients did not cluster together. The genes driving the
differential expression between the right and left colon which
were causing the observed clustering were predominately
involved in the embryological development of the gastrointest¬
inal tract: homeobox proteins HOXA13, fold change (FC),
+4.93, p = 2.3xl0"16), HOXB13 (FC, +16.96, p<lxlO"45);
glioma-associated oncogenes GLI1 (FC, +2.2, p = 4.0xl0-24)
and GLI3 (FC, +2.3, p = 2.1xl0~28) were all upregulated in the
left colon. Sixty-one sequences had a fold change of greater than
1.5 and 44 sequences had a fold change of less than 1.5 in the left
colon in the control biopsies. In the ulcerative colitis biopsies
when non-inflamed left and right colonic biopsies were
compared 26 sequences had greater than a 1.5-fold increase in
expression and 21 sequences had less than a —1.5-fold decrease
in the left colon.
When gene ontology was compared between these two
analyses alternative splicing genes were the most differentially
regulated genes in both of the analyses (p=1.7xl0~41 and
p = 7.9 xlO-19 for controls and ulcerative colitis, respectively). In
the control analysis the next three most differentially regulated
gene groups were nuclear protein function (p = 4.3xlO"29),
metal binding (p = 4.7xlCD25) and membrane function
(p = 4.2xlO"20). In ulcerative colitis oxido-reductase function
(p = 1.4xl0-13) was the second most differentially expressed
group followed by mitochondrial function (p = 4.7xl0~25) and
e 3 Expression changes in the genes of interest
FC of non-
inflamed FC of inflamed FC of inflamed
ulcerative colitis ulcerative colitis ulcerative colitis
sigmoid vs non- sigmoid vs sigmoid vs non-
FC of all ulcerative inflamed control inflamed control inflamed sigmoid
analysed colitis vs controls* p Value sigmoidt p Value sigmoid! p Value ulcerative colitis! p value
+8.18 <10 45 +2.0 0.00024 +17.5 2.9x10" +16.5 <10 45
isin alpha 5 +3.25 0.00003 +1.02 0.89 +7.27 6.3x10-3° +8.44 <10 45
isin alpha 6 +2.18 6.95x10-' -1.09 0.34 +4.41 9.7x109 +6.72 4.16x10 "
A8 +3.50 2.3x10 17 +1.21 0.19 +9.75 2.4x10a +6.84 1.16x10 "
A9 +3.06 4.1 x10'3 +1.05 0.16 +7.53 6.4x10 12 +7.11 1.96x10 32
3 +2.17 5.6x10 10 -1.55 0.0088 +11.0 1.22x10-" +8.15 2.32x10 35
7 +2.29 2.3x10 7 +1.16 0.080 +7.31 4.9x10-24 +5.53 1.01x10 23
+2.05 4.2x10 " +1.10 0.26 +6.36 9.27x10" +7.24 8.42x10 "
+1.34 4.5x10-' +1.15 0.18 +1.50 0.0044 +1.54 0.00073
i +8.02 1.1x10-" -1.30 0.20 +7.53 2.93x10"" +10.5 1x10"
0 +1.30 0.00011 +1.25 0.020 +1.79 0.00002 +2.36 4.68x10 "
11 -1.32 0.00091 +1.10 0.40 -1.82 5.6x10 6 -1.92 9.0 x10 10
DRB1 +1.03 0.88 -3.0 0.0010 +3.30 0.033 +2.67 0.0011
-1.12 0.31 -2.73 2.7x10 10 -1.15 0.61 +1.23 0.092
changes (FCs) and p values are shown in a number of different genes in four different experiments. Genes of interest were included in this table if significant consistent changes
tpression were observed across more than one experiment.
1 ulcerative colitis biopsies and 73 control biopsies. +22 ulcerative colitis biopsies and 18 control biopsies. J35 ulcerative colitis biopsies and 8 control biopsies. §35 inflamed
rative colitis biopsies and 22 non-inflamed ulcerative colitis biopsies.
; annotation: ABCB1, ABC transporter; CCL20, chemokine (C-C motif) ligand 20; HLA-DRB1, HLA class II histocompatibility antigen, DRB1; IL, interleukin; MMP, matrix
illoproteinase; S100A8, calcium-binding protein A8; SAA1, serum amyloid A1; TLR4, toll like receptor 4; TNIP3, TNFAIP3 (A20), interacting protein 3; TSLP, thymic stromal
ihopoietin isoform 1.
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ilytic activity (p = 2.7x10-"). There was a 34.5% overlap
A/een the differentially expressed ontology groups in the
trol and ulcerative colitis analysis.
lysis of expression in ulcerative colitis and control biopsies
ig unsupervised hierarchical clustering we were unable to
srentiate between biopsies from patients with ulcerative
tis and from controls patients. In addition no clustering based
he inflammation status of the biopsies was observed. When all
ulcerative colitis biopsies (129) and control biopsies (73) were
lpared, 143 sequence probes had a fold change of greater than
in the ulcerative colitis biopsies (0.01>p>10~45) and 54
rences had a fold change of less than 1.5 (0.01>p>10~20)
jplementary table 1). Serum amyloid A1 (SAA1) was the most
jgulated gene (FC, +8.18, p<10~45). Other notably upregu-
d genes were the S100 calcium-binding proteins A8 (FC, +3.50,
2.3xlO^17), S100A9 (FC, +3.06, p = 4.1 xlO"13), the alpha
:nsins, alpha 5 (DEFA5) (FC, +3.25, p = 0.00003), alpha 6
FA6) (FC, +2.18, p = 6.95xl0-7) and the matrix metallopro-
ases MMP3 (FC, +2.17, p = 5.6x10-'°) and MMP7 (FC, +2.29,
2.3xl0-7). The differential gene expression of a number uf
lidate genes of interest is shown in table 3.
ene ontology analysis involving the genes differentially
ressed between the ulcerative colitis and control biopsies
A'ed a preponderance of differentially expressed genes were
lived in immune response (48 genes out of a total of 679
;s classified under immune response, p = 2.1xlQ-9, odds
rohii'I diseasi
ratio (OR) 2.61, confidence interval (CI) 1.85 to 3.56) and
response to wounding (30 genes out of a total of 359 genes
classified under response to wounding, p = 6.42 xlO""9, OR 3.14,
CI 2.09 to 4.53) when biological systems were considered.
Analysis of expression in sigmoid colon biopsies in patients with
quiescent ulcerative colitis and non-inflamed control biopsies
To compare expression in biopsies without an acute inflamma¬
tory signal and to remove the effect of anatomical variation, 22
biopsies from the sigmoid colon with no histological evidence of
inflammation from patients with ulcerative colitis were
compared to 18 histologically normal control sigmoid colon
biopsies. One hundred and two sequences had a fold change
greater than 1.5 (0.01>p>4.77xl0-'3) and 84 sequences had a
fold change of less than 1.5 (0.01>p>1.8xl0-21) (supplemen¬
tary table 2). Upregulated genes in the ulcerative colitis biopsies
included defensin beta 14 (FC, +2.11, p = 0.00002) and SAA1 (FC,
+2.01, p = 0.00024). Interesting genes that were downregulated
included HLA class II histocompatibility antigen DRB1 (HLA-
DRB1) (FC, —3.0, p = 0.0010) and thymic stromal lymphopoietin
isoform (TSLP) (FC, -2.73, p = 2.7xl0"10) (table 3).
Inflamed versus non-inflamed ulcerative colitis sigmoid colon
biopsies
When expression signals were compared between 35 histologi¬
cally inflamed and 22 non-inflamed sigmoid colon ulcerative
colitis biopsies, 700 sequences had a fold change of greater than
DEFA5
p = 0.26 p = 0.0076 p< 0.00001
DEFA6
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re 2 Gene expression is shown as box-and-whisker plots. Each endoscopic biopsy has been separated by patient status, inflammation status and
omical location. Significantly higher defensin alpha 5 (DEFA5) and DEFA6 expression was observed in the inflamed ulcerative colitis descending
sigmoid colon biopsies when compared to the non-inflamed ulcerative colitis biopsies and the control biopsies. Asc, ascending colon;
descending colon; Sig, sigmoid colon; Tl, terminal ileum.
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ohn's disease!
(0.01>p>l xlO"45) and 518 sequences (0.01>p>l xlO-45)
a fold change of less than 1.5 in the inflamed biopsies
tplementary table 3). Notably upregulated genes included
tl (FC, +16.5, p = <10~45), TNFAIP3 interacting protein 3
1IP3) (FC, +10.5, p = 1 xlO"38), DEFA5 (FC, +8.44,
<10"45), DEFA6 (FC, +6.72, p = 4.16xl0~19) and regenerat-
islet-derived 3 gamma (REG3y) (FC, +6.99, p= <10~45).
lysis of specific gene families: alpha defensins 5 and 6
;n DEFA5 and DEFA6 were analysed expression in the
"nal controls and the non-inflamed ulcerative colitis biopsies
similar across the different anatomical locations with there
tg high expression in the terminal ileum, and expression
easing as the biopsy location became more distal in the
n (fig 2). In the acute and chronically inflamed ulcerative
:is biopsies there was marked upregulation of DEFA5 and
A6 expression in the descending and sigmoid colon (table 3).
-binding cassette transporter family and the xenobiotic-
scription regulators
ression patterns from probes representing 48 ATP-binding
ette (ABC) transcriptional genes and their key mediators
;nane X receptor (PXR), farnesoid X-activated receptor, and
sterols receptor LXR-beta were analysed. When these genes
e compared in all the ulcerative colitis and control biopsies,
n genes were found to be significantly downregulated in the
rative colitis samples when compared to the control
pies: ABCA1 (p = 0.01), ABCA8 (p = 0.0064), ABCB1
0.00091), ABCC6 (p = 0.0050), ABCB7 (p = 0.0068),
IF 1 (p = 0.0005) and ABCF2 (p<0.00001). Only one probe
esenting ABCB2 was significantly upregulated in ulcerative
:is (p = 0.0048).
BCB1 expression was also significantly downregulated
:n inflamed ulcerative colitis sigmoid colon biopsies were
pared to non-inflamed ulcerative colitis sigmoid biopsies
— 1.82, p = 5.6xl0~6) (table 3). No difference in the
■ession of PXR between ulcerative colitis and controls was
:rved in any of the analyses.
I time polymerase chain reaction analysis
:ight genes implicated by microarray expression results,
:irmatory real time PCR analysis was undertaken in biopsies
re 3 Terminal ileum (Tl) upper
I: antisense probe shows strong
idisation in the basal crypts
istent with Paneth cell location.
ms indicate positive staining in crypt
. Lower panel: no significant
idisation with sense control probe,
sigmoid colon biopsy of a non-
ried control patient. (B,C,D) Strong,
ifocal hybridisation in the basal crypt
in of sigmoid colon biopsies from
! patients with ulcerative colitis
istent with Paneth cell metaplasia.
of patients form the original cohort following stratifying to
represent a range of SAA1 and IL8 expression. Increased SAA1
expression in the inflamed ulcerative colitis sigmoid colon
biopsies compared to the normal control sigmoid colon biopsies
and the non-inflamed ulcerative colitis sigmoid colon biopsies
(p = 0.041 and p = 0.044, respectively) was observed. Elevated
IL8 expression was also confirmed in the inflamed ulcerative
colitis sigmoid biopsies when compared to the control sigmoid
biopsies (p = 0.031) (supplementary fig 1).
Increased expression of DEFA5 and DEFA6 in the inflamed
ulcerative colitis sigmoid colon biopsies when compared to the
non-inflamed ulcerative colitis sigmoid colon biopsies
(p = 0.0008 and p = 0.0005, respectively) and the control
sigmoid colon biopsies (p = 0.0002 and p = 0.0001, respectively)
was observed (supplementary fig 1). Increased expression in the
inflamed ulcerative colitis sigmoid colon biopsies when com¬
pared to the non-inflamed ulcerative colitis sigmoid colon
biopsies was also observed when MMP7 (p = 0.0005), S100A8
(p = 0.0029) and toll-like receptor 4 (TLR4) (p = 0.019) were
examined (supplementary fig 2).
In situ hybridisation and immunohistochemistry
In situ hybridisation of the terminal ileal biopsies for DEFA5
showed strong hybridisation in the basal crypts consistent with
Paneth cell location (fig 3). In the ulcerative colitis biopsies
taken from the sigmoid colon strong, multifocal hybridisation in
the basal crypt region of these biopsies was observed and this
would be consistent with Paneth cell metaplasia. This was not
observed in the non-inflamed control biopsies.
Immunohistochemistry for DEFA6 confirmed that in the
sigmoid colon ulcerative colitis biopsies, staining was observed
in the basal crypt region of these biopsies consistent with
Paneth cell metaplasia. Again, this was not observed in the
control biopsies (fig 4).
Expression of genes within the IBD2 locus
Using the markers defining the IBD2 locus we identified 526
Agilent probes representing genes or expressed sequence tags
within this locus on chromosome 12. Twelve probes had a
greater or less than a 1.5-fold change in expression with p<0.01
when expression of acute and chronically inflamed ulcerative
colitis sigmoid colon biopsies were compared to non-inflamed
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ression of genes within the IBD5 locus
ent probes representing 11 genes within the IBD5 locus
e identified and compared in healthy control, non-inflamed
inflamed ulcerative colitis biopsies (table 5). Solute carrier
ily 22A5 (SLC22A5) (OCTN2) was downregulated in
rative colitis biopsies compared to controls (FC, —1.26
3.37xl0-6) and when inflamed ulcerative colitis sigmoid
■n biopsies were compared to non-inflamed ulcerative colitis
roid colon biopsies (FC, —1.50, p = 2.2xl0-6).
2USSI0N
he present study we have taken particular care to address
terns currently being expressed about micoarray studies in
ase. We initially documented the regional variation of gene
ression in the healthy colon before undertaking comprehen-
studies in ulcerative colitis. By documenting the anatomical
tion for each biopsy, using appropriate inflammatory
rrols, as well as avoiding the pooling of samples, we have
l able to remove a considerable amount of background
ability that has hampered previous studies.17 20-22 A further
strength of our study has been the fact that real time PCR
analysis consistently confirmed the significant changes in
expression, substantially increasing the confidence associated
with the interpretation of the data.
We have made a number of novel observations. In the healthy
adult colon this is the first microarray study to show a gradient
of expression of a number of genes. Genes involved in
developmental pathways, the HOX family and the hedgehog
signalling pathway, appeared to be the most differentially
regulated along the anatomical length of the healthy colon.
HOXA13 has been shown to play a crucial role in the
development of the tail gut, and mutations in the gene result
in urogenital abnormalities,23 and interestingly it has been
shown that HOXB13 expression is downregulated in colorectal
tumours from the distal left colon.24
GLI1 is one of the major effector molecules of the hedgehog
signalling pathway and the GUI gene lies within the IBD2
locus, strongly implicated in ulcerative colitis.25-27 Data from the
present study would also suggest that GLI1 is downregulated in
inflamed ulcerative colitis biopsies compared to non-inflamed
Table 4 Gene expression in probes from the inflammatory bowel disease 2 (IBD2) locus, comparing inflamed
ulcerative colitis sigmoid colon biopsies to non-inflamed ulcerative colitis sigmoid colon biopsies
FC of ulcerative colitis sigmoid
Agilent probe Gene symbol inflamed vs non-inflamed* p Value
A23P98876 SLC39A5 -1.52855 1.36x10-'
A24P647146 HDAC7A 1.53876 3.15x10 16
A24P941773 DKFZP586A0522 -2.27306 2.31 x10-"
A24P945113 ACVRL1 1.57956 6.33X10-9
A23P128230 NR4A1 1.81844 0.00005
A_23 P331098 K5B 2.3845 0.0004
A24P246636 A24P246636 -1.69754 7.06x10 6
A23P2233 SILV 1.51557 9.07x10 9
A23P105251 GLI -1.54447 7.73x10-'
A32P3783 HMGA2 -1.94107 2.37x10'
A23P162300 IRAK3 1.7382 3.11 x10 15
A32P83256 IRAKM 1.70847 4.56x10-'°
Analysis of the 526 expression probes located within the IBD2 locus identified 12 probes that were significantly differentially
regulated when the inflamed ulcerative colitis sigmoid colon biopsies were compared to the non-inflamed ulcerative colitis sigmoid
colon biopsies.
*35 inflamed biopsies and 25 non-inflamed.
Gene annotation: A_24 P246636, unknown; ACVRL1, activin A receptor type II, like 1; DKFZP586A0522, methyltransferase-like
protein 7A precursor; GLI, glioma-associated oncogene; HDAC7A, histone deacetylase 7A; HMGA2, high mobility group AT-hook 2;
IRAK3, interleukin 1 receptor-associated kinase 3; IRAKM, interleukin 1 receptor-associated kinase M; KB5, keratin 5B;
NR4A1, nuclear receptor subfamily 4, group A, member 1; SILV, silver homolog (mouse); SLC39A5, solute carrier family 39A5.
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le 5 Fold expression changes in genes within the inflammatory bowel disease 5 (IBD5) locus in patients with ulcerative colitis and in controls
FC of non-inflamed
FC of inflamed sigmoid vs ulcerative colitis sigmoid
FC of all ulcerative non-inflamed sigmoid vs non-inflamed control
: analysed colitis vs controls* p Value (ulcerative colitisjt p Value sigmoid; p Value
+1.00 0.96 +1.06 0.62 +1.14 0.40
+1.12 0.057 -1.02 0.82 1.00 0.98
50 +1.02 0.20 -1.20 3.5 x10" +1.08 0.062
+1.09 0.037 +1.10 0.17 +1.04 0.53
+1.10 0.35 +1.12 2.9x10 6 -1.01 0.62
2A5 -1.26 3.37x10" -1.50 2.2x10" +1.02 0.75
2A4 -1.18 0.11 -1.79 1.53x10 9 +1.22 0.63
VI4 +1.10 0.0056 +1.14 0.00039 +1.01 0.78
\2 -1.05 0.13 1.00 0.98 -1.05 0.28
+1.10 0.056 +1.19 0.052 -1.04 0.63
-1.01 0.39 +1.02 0.67 +1.01 0.75
changes (FCs) in expression of genes within the IB05 locus comparing controls and patients with ulcerative colitis, who have been stratified for the degree of inflammation
erved in their sigmoid colon biopsies. Significant downregulation of the organic cation transporters SLC22A4 and SLC22A5 was observed when inflamed ulcerative colitis
loid biopsies were compared to non-inflamed ulcerative colitis sigmoid biopsies.
9 ulcerative colitis and 73 controls. t35 inflamed sigmoid and 22 non-inflamed. %22 ulcerative colitis and 18 controls.
e annotation: CSF2, colony stimulating factor 2; IL, interleukin; IRF1, interferon regulatory factor 1; P4HA2, prolyl 4-hydroxylase subunit alpha-2 precursor; PDLIM4, PDZ and LIM
lain 4; RAD50, DNA repair protein RAD50; SLC22, solute carrier family 22.
osies from patients with ulcerative colitis. These data add
her weight to data from Cambridge and our own unit
wing an association between mutations in the GLI1 gene
ulcerative colitis.28 29
/ith regards to the observed gradient of expression in the
[thy adult colon, our data contrast with data from Costello
i/12 and Wu et al15 where no significant differences in
ression patterns were observed when comparing biopsies
n caecum, transverse colon, descending colon and sigmoid
in. The observed differences in these data sets may be
lained by the fact that we have considered only non-
amed healthy controls in these studies and have not pooled
thy and diseased data. When anatomical variation in the
in was compared between patients with ulcerative colitis
controls there was only a 34.5% homology between the
srentially expressed gene ontology groups. This difference
' be explained by environmental factors in the ulcerative
:is colon such as microbial dysbiosis.
i ulcerative colitis, we demonstrated dysregulation of genes
lived in innate immunity, notably the alpha defensins 5 and
ogether with other pathways currently implicated in
immatory bowel disease. In our data set high levels of
la defensin 5 and 6 expression were observed in the terminal
biopsies of non-inflamed controls and patients with
rative colitis. Levels of expression in these patients fell as
location that the biopsies were retrieved from became more
al in the colon: the ascending colon, descending colon and
toid colon. However, in the inflamed ulcerative colitis
>sies increased expression of both alpha defensins 5 and 6
observed at each anatomical location. Lawrance and
sagues" also noted that the defensins alpha 5 and 6 were
:gulated in patients with ulcerative colitis compared to
trols, although RNA was extracted from surgical resections
no details about the anatomical location of these specimens
e given.
ecent data published by Varnat and colleagues30 have
jested that peroxisome proliferator activated receptor (3
VR(3) negatively regulates Paneth cell differentiation by
mregulating the expression of Indian hedgehog, another of
major effector molecules in the hedgehog signalling path-
'. Immunohistochemistry and in situ hybridisation have
wn that this is largely mediated by Paneth cell metaplasia.
Given our present data now implicating germline GLI1 variation
in disease susceptibility, and the regional variation in health, we
speculate that in patients with ulcerative colitis, further, as yet
undetermined, defects in the hedgehog signalling pathway may
result in unregulated Paneth cell differentiation, Paneth cell
metaplasia, increased alpha defensin 5 and 6 expression, and
mucosal inflammation.
It is of interest that many but not all of our results are
broadly in line with two of the landmark microarray papers in
IBD. Consistent with data from Lawrance and colleagues" we
have shown upregulation of S100A8 and A9, and the alpha
defensins 5 and 6 in ulcerative colitis. Dieckgraefe and
colleagues9 observed upregulation of a number of the MMP
genes, again seen in our dataset. Another consistent finding was
the upregulated expression of members of the REG family in the
colon of patients with ulcerative colitis, probably as a result of
Paneth cell metaplasia.31
The downregulation of ABCB1 in our dataset is of significant
interest, and consistent with earlier microarray data from
Langmann et al,13 Dieckgraefe et al,9 Lawrance et al,n and Wu et
al.15 It is pertinent that when the entire class of proteins sharing
homology with ABCB1 were analysed, a further six out of 48
ABC transporters were significantly dysregulated in ulcerative
colitis, including ABCA1, ABCA8, ABCC6, ABCB7, ABCF1 and
ABCF2. An important role of the ABC transporters in the
aetiopathogenesis of ulcerative colitis seems likely, supported by
these consistent microarray data, association with germline
MDR1 variability, and animal data to date.
However, and in contrast to data produced by Langmann et
al,13 we did not observe any changes in expression of the
transcriptional regulator pregnane-X receptor. These negative
data are consistent with genetic studies carried out in the IBD
population in Edinburgh; using a haplotype tagging approach,
there was an association between the ABCB1 gene and
ulcerative colitis,32 but no association between the pregnane-X
receptor and ulcerative colitis.33 Aspects of study design and
patient recruitment may explain the differences observed
between our data and those of Langmann and colleagues.
When novel genes were considered, of particular note was the
differential expression of the poorly characterised gene
TNFAIP3-interacting protein 3 (TNIP3) which is a nuclear or
cytoplasmic protein with three coiled domains that was first
Gut 2008;57:1398-1405. doi:10.1136/gut.2008.148395
Downloaded from gut.bmj.com on 13 September 2008
■•'■"til $'disease
led down from a yeast-2 hybrid scan of TNFAIP3 (A20).34
: protein has been found to be expressed in macrophages and
upregulated by infection with Listeria. Further to this,
FAIP3 was recently identified as the closest gene to
753394, a "second tier" hit from the UK genome-wide scan
Crohn's disease, focusing further interest on this nuclear
.or kB dependent signalling pathway.3
"he tight linkage disequilibrium spanning the IBD5 linkage
trval has limited genetic studies of this region.35-39 Consistent
vnregulation of the organic cation transporter SLC22A5
ZTN2) was observed in ulcerative colitis biopsies compared
:ontrols and in inflamed ulcerative colitis biopsies compared
non-inflamed biopsies. SL22A4 (OCTN1) was also down-
rlated in inflamed ulcerative colitis biopsies and these
vocative data add weight to the hypothesis that decreased
ression of these genes may after all be involved in the
hogenesis of IBD.40 However, we also noted expression of
:rferon regulatory factor 1 (IRF-1) and PDZ and LIM domain
PDLIM4), both plausible candidates within IBD5 to be
regulated, emphasising the uncertainties pertaining to this
is at present.
a conclusion, these data provide a rigorously characterised
ression profile of the whole genome in the terminal ileum
colon of patients with ulcerative colitis and controls. The
dies provide new insights into regional variation of gene
ression in the healthy colon, and also considerably extend
/ious studies in ulcerative colitis. These data also identify a
nber of key regulators of intestinal inflammation worthy of
:her study. As further data from genome-wide scanning
:rge in this and other complex diseases, access to these data
the ability to study expression, function and germline
ation in parallel will become all the more necessary.
peting interests: None.
:s approval: Approval for this study was granted by the Lothian Research Ethics
mittee: REC 04/S1103/22.
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ackground & Aims: Recent data suggest that poly-
lorphisms in the organic cation transporter (OCTN)
jnes OCTN1 (SLC22A4) and OCTN2 (SLC22A5) rep-
sent disease-causing mutations within the IBD5 lo¬
ts (chromosome 5q31). We investigated associa-
ans with disease susceptibility, phenotype, and
ridence for epistasis with CARD15 in 679 patients
ith Crohn's disease (CD) or ulcerative colitis (UC).
ethods: A total of 374 patients with CD, 305 pa¬
ints with UC, and 294 healthy controls (HCs) were
udied. Genotyping for single nucleotide polymor-
lisms IGR2096, IGR2198, and IGR2230, OCTN1
iriant (SLC22A4 1672C^T), and OCTN2 variant
LC22A5 — 207G—»C) was performed using the Taq-
an system. Results: The IBD5 OCTN1 and OCTN2
jlymorphisms were in strong linkage disequilibrium
>0.959). IGR2198 variant allele frequency
9.1% vs 40.8%; P = .0046) and homozygosity (21%
; 14.8%; P = .044) were associated with CD versus
Ds. Variant allelic frequency of OCTN1 (53.6% vs
3%; P = .0008) and OCTN2 (56.1% vs 48.4%; P =
092) polymorphisms and homozygosity for the
2TN1/2-TC haplotype (28.4% vs 16%; P = .0042)
ere associated with CD versus HCs. IGR2198 ho-
ozygosity and TC homozygosity were associated
ith stricturing/penetrating disease at follow-up (P =
11 and P = .011, respectively) and disease progres-
on (P = .038 and P = .049, respectively) on univar-
te analysis and with need for surgery on multivariate
lalysis (P = .016 and P = .004, respectively). In the
jsence of the IBD5 risk haplotype, no association of
2TN1/2 variants with CD was detected. No associa-
jns were seen with UC. Conclusions: The IBD5 locus
fluences susceptibility, progression, and need for
irgery in CD. However, the contribution of 0CTN1/2
iriants is not independent of the IBD5 haplotype; a
msative role for these genes remains plausible but
not yet proven. Further genetic, functional, and
Lpression data are now required.
The inflammatory bowel diseases (IBDs), Crohn's dis¬ase (CD) and ulcerative colitis (UC), are common
causes of gastrointestinal morbidity in the Western
world. The incidence of early-onset disease continues to
increase in northern Europe, notably in Scotland and
Scandinavia.'~*4 Epidemiologic, molecular, and clinical
studies have proven that genetic susceptibility combined
with environmental interaction are central to the patho¬
genesis of IBD.5
Genome-wide scanning has identified susceptibility
loci for CD on chromosomes l,6 5 (IBD5),7~9 6 (IBD3;
HLA),8'10 12 (7BD2),11 14 (IBD4),7-12 16 (/BD7),11'15
and 19 (77JD6).8 The most consistently replicated CD
susceptibility locus is located on chromosome 16 (IBD1),
and the susceptibility gene has been identified as the
N0D2/CARD15 gene.1445 N0D2/CARD15 contains a
caspase recruitment domain (CARD) that is linked to a
nucleotide-binding domain and a leucine-rich repeat re¬
gion. N0D2/CARD15 functions as an intracellular sen¬
sor of muramyl dipeptide, a highly conserved pepti-
doglycan motif common to many intraluminal
bacteria.16'17 Watanabe et al suggested that N0D2/
CARD15~'~ mice lose negative control of Toll-like re¬
ceptor 2—mediated activation of nuclear factor kB, po¬
tentially offering an explanation for the Thl phenotype
characteristic of CD.18 However, recently published
studies do not provide support for N0D2/CARD15 in¬
teraction with the Toll-like receptor 2 pathway, and
these data emphasize the complexity ofN0D2/CARD15
activation.19-20
Two single nucleotide polymorphisms (SNPs)
(Gly908Arg and Arg702Trp) and a frameshift mutation
(Leul()07fsinsC) induce structural changes in the
leucine-rich region of N0D2/CARD15 and have been
associated with CD. Reported N0D2/CARD15 carriage
Abbreviations used in this paper: HC, healthy control; OCTN, organic
cation transporter; SNP, single nucleotide polymorphism.
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.tes in CD vary between 0 and 50.0%, with highest
.tes seen in central European populations,14'21 while
lutations are absent in Japanese and Chinese series.22,23
>wer frequencies have been reported from Finland and
:otland, suggesting heterogeneity within Europe.24,25
0D2/CARD15 polymorphisms have consistently been
.sociated with a younger age of onset of CD, ileal
isease, and fibrostenosing disease.26
The IBD5 locus on chromosome 5q31-33 was origi-
illy identified in 1999 as conferring susceptibility for
D.7 This finding was replicated using linkage disequi-
brium mapping in the Canadian CD population and
irther delineated to 5q31-8 Fine mapping of this area
is identified a single, highly conserved 250-kilobase
iplotype of 11 SNPs spanning a cytokine gene cluster
lat is associated with CD.9 Further high-resolution
lalysis of the 5q31 region using 103 SNPs revealed 11
screte haplotype blocks that measure tens of kilobases
i length, have limited diversity, and are punctuated by
tes of recombination.27 Genotype-phenotype analysis
is suggested an association between the IBD5 locus,
;rianal disease,28 and early onset of disease,29 but evi-
mce for epistasis between IBD5 and NOD2/CARD15
is been inconsistent.9,28-30
More recently, data have suggested that mutations of
genes within the IBD5 region, the organic cation
ansporters OCTN1 (also known as SLC22A4) and
CTN2 (SLC22A5), may be independently associated
ith CD.31 The construction of a 2-allele risk haplotype
CTN1/2-TC (SLC22A4 exon 9 1672C-^T and
X22A5 promoter — 207G^C) was reported to be
sociated with CD in patients who lacked the extended
?D5 risk haplotype. Individual allelic data were not
ven.
OCTN1 is a 551—amino acid protein that is
rongly expressed in the kidney, trachea, bone mar-
iw, and, to a lesser extent, small bowel and has been
laracterized as a carnitine transporter.32 An intronic
SIP (rs2268277) in a Runt-related transcription fac-
ir 1 (RUNX1) binding site of OCTN1 has been
sociated with susceptibility to rheumatoid arthritis
i the Japanese population.33 OCTN2 is a 557—amino
id protein that is 75.8% homologous to OCTN1,
id functional studies have shown it to be a high-
finity sodium carnitine transporter that is expressed
i the kidney, smooth muscle, and heart tissue.34
sltekova et al suggested that the OCTN1 variant
672C-^T) alters its function in fibroblasts in vitro,
ith variant forms having less affinity for carnitine
id a greater affinity for tetraethyl ammonium and
ime xenobiotics, and that the OCTN2 variant
-207G—>C) disrupted a heat-shock transcription fac¬
tor binding site in fibroblasts in vitro.31 No data
demonstrating the altered function or expression of
OCTN1/2 gene products in CD have yet been pro¬
vided.
The provocative association data from Peltekova et al
have yet to be replicated in an independent population,
and epistasis with N0D2/CARD15 has not thus far been
assessed without the Canadian population. Phenotypic
data from the same Canadian cohort of patients with CD
have suggested a correlation between OCTN1/2 variants
and ileal disease, and this correlation becomes substan¬
tially stronger when carriage of N0D/CARD15 variants
is taken into account.35 However, the phenotypic de¬
scription of this cohort does not allow for analysis of
disease behavior, progression, or indeed proximal small
bowel disease.
In the present study, we assessed the contribution of
the OCTN1 and OCTN2 polymorphisms implicated by
Peltekova et al in determining genetic susceptibility in
CD and UC, specifically addressing whether these
OCTN1/2 variants have an association with susceptibil¬
ity to IBD that is independent of other markers within
the extended IBD5 linkage interval. We also investi¬
gated whether these polymorphisms are associated with
specific disease phenotype characteristics or progression
in our rigorously defined IBD population and assessed
gene-gene interactions with established N0D2/CARD15
mutations.
Materials and Methods
A total of 679 patients with well-characterized IBD
and 294 healthy controls (HCs) were recruited. All patients
with IBD attended the clinic at Western General Hospital
(Edinburgh, Scotland). This is a tertiary referral center for
IBD in southeastern Scotland. The IBD group comprised
374 patients with CD and 305 patients with UC. The
diagnosis of IBD adhered to the criteria of Lennard-Jones.36
Age at diagnosis, location, and behavior were classified
according to the Vienna classification.37 Phenotypic data
were collected by patient questionnaire, interview, and case
note review and were composed of demographics, date of
onset and diagnosis, disease location, disease behavior, pro¬
gression, extraintestinal manifestations, surgical operations,
smoking history, joint symptoms, family history, and eth¬
nicity. Written informed consent was obtained from all
patients. The Medicine and Oncology Subcommittee of the
Lothian Local Research Ethics Committee approved the
study protocol (LREC 2000/4/192).
Demographics
CD group. The demographics of the patients re¬
cruited are shown in Table 1. The duration of follow-up was
defined as the time from diagnosis to the time of most
i56 NOBLE ET AL GASTROENTEROLOGY Vol. 129, No. 6
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Ileal disease (LI)
Colonic disease (L2)
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)TE. Disease behavior at follow-up was defined using the Vienna classification when the patient was last clinically evaluated. Full phenotypic
ita were available on 94% of the patients with CD at diagnosis and 98% at follow-up. In assessing disease progression, patients were grouped
those who remained as having inflammatory (Bl), nonprogressive disease and those whose disease had progressed to stricturing (B2) or
metrating (B3) disease.
xamination under anesthesia or drainage procedures for perianal sepsis were excluded.
cent clinic review. Disease behavior at follow-up was
■fined using the Vienna classification of behavior at the
me point when the disease was last clinically evaluated
idiologically, endoscopically, or at surgery).24-37 In assess-
g disease progression, patients who had Vienna Bl (in-
Lmmatory) CD at diagnosis were identified and disease
■havior was compared with behavior at most recent follow-
■>. Patients were grouped as those who remained classified
having inflammatory (Bl) disease at follow-up (nonpro-
essive disease), and those whose disease had progressed to
ricturing (B2) or penetrating (B3) disease. Ninety-seven
itients (26%) in the CD group were current smokers, and
) (21%) had a first-degree relative with a family history of
ID.
UC group. Clinical details were available regarding
e entire UC group. The group consisted of 171 men and 134
amen with a median age at diagnosis of 34 years (Table 1).
isease extent was recorded at diagnosis.
Control group. The control group comprised 294
althy subjects: blood donors (n = 163) recruited from
utheastern Scotland and healthy control subjects (n = 131).
tere were 143 men and 151 women with a median age of 39
ars (interquartile range, 27—52 years).
Genotyping
Genomic DNA was extracted from peripheral venous
blood by a modified salting-out technique38 and resuspended
in IX Tris-EDTA buffer (10 mmol/L Tris [pH 8.0] and 1
mmol/L EDTA [pH 8.0]) at a final concentration of 100
ng/|xL. To examine the relative contribution of the OCTN1/2
variants relative to the extended IBD5 haplotype, 3 SNPs were
genotyped: IGR2096 (which lies within haplotype block 4, as
defined by Daly et al27) (Figure 1), IGR2198 (within haplo¬
type block 5), and IGR2230 (within haplotype block 7). The
rsl050152 polymorphism of the OCTN1 gene (SLC22A4
exon 9 1672C-»T, IGR3002) and the rs26313667 (SLC22A5
promoter — 207G—*C, IGR2222) polymorphism of the
OCTN2 gene were typed. Details of these variants and of the
TaqMan primers are provided in Supplementary Table 1 (see
supplemental material online at www.mmc.med.ed.ac.uk/gi/
supdata.shtml) and Figure 1.
Patients with CD and HCs were typed for polymorphisms of
the N0D2/CARD15 gene (R702W, G908R, and 1007fsinsC)
using previously described methods.24 All genotyping except the
R702W polymorphism was performed using the TaqMan system
(7900HT sequence detection system; Applied Biosystems, Foster
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Genes
IL4 IL13 RADSO P4HA2
IL5 IRF1 OCTN2 OCTN1 PDLIM3 CSF2 IL3
jure 1. Haplotype structure and linkage disequilibrium across the IBD5 region. The IBD5 locus (5q31) with the high-resolution haplotype
xicture as reported by Daly et al.27 (A) Candidate genes above the relevant haplotype blocks. Genes above the line are transcribed from left
right, and those below the line are transcribed from right to left. (B) Eleven blocks numbered 1-11 (between 3 and 92 kilobases), each of
lited genetic diversity, are punctuated by sites of recombination. (C) D' scores are shown to demonstrate the tight linkage disequilibrium
tween the SNPs that were analyzed. The lowest D' (0.959) was observed between IGR2096 and the 0CTN2 variant (-207G-C). (D) Location
the SNPs that were analyzed, with IGR2222 representing the 0CTN2 variant (-207G^C) and IGR3002 representing the 0CTN1 variant
572C—»T). IGR2078, which was used by Peltekova et al to represent the extended IBD5 haplotype, is located in block 4.31
ty, CA). R702W genotyping was performed by restriction
igment length polymorphism polymerase chain reaction. Re¬
action digestion was performed using 1 U Msp E at 37°C
ernight and polymerase chain reaction fragments run on 4%
uSieve 3:1 agarose gels (Cambrex Bio Science, Nottingham,
d, Nottingham, UK). These were stained with ethidium bro-
ide and viewed under UV light. An image was recorded
gitally.
Data Analysis
Each SNP was analyzed for association with IBD
erall, CD, UC, and disease phenotype. Allele frequencies
d carrier frequencies were determined for all polymor-
lisms. Each of the variants studied was shown to be in
ardy-Weinberg equilibrium in patients and in controls,
snotype-phenotype associations were analyzed by X2 test
ing the Minitab statistical software package (Minitab Ltd,
>ventry, England). Linkage disequilibrium and haplotype
alysis were investigated using cocaphase (Rosland Frank-
l Centre for genomics research; http://www.hgmp.mrc.a-
ak). Evidence for epistasis among the OCTN1/2 allelic
riants, the OCTN1/2-TC haplotype, and N0D2/CARD15
riants was investigated by comparing allelic frequencies
the individual OCTN1/2 variants, together with ho-
ozygosity for the OCTN1/2-TC haplotype between the
bgroups of patients with and without N0D2/CARD15
riants by x2 analysis.
To identify significant independent variables associated
th genotype, multiple logistic regression analysis was
rformed using the Minitab statistical software package
linitab Ltd). The population-attributable risk percentage
is defined as the excess rate of disease in individuals with
mutation compared with those without. This was esti-
ated by the method of Schlesselman,39 which estimates
population-attributable risk percentage as equal to attrib¬
utable risk as a function of the prevalence in the exposed
population divided by incidence of IBD in the population.
To calculate this, the prevalence of CD was estimated at
100/100,000 and the frequency of all alleles in the control
population was assumed to reflect that of the general pop¬
ulation.
Results
Linkage Disequilibrium Across the IBD5
Locus
In the CD population, strong linkage disequilib¬
rium was observed between the SNPs within the ex¬
tended IBD5 haplotype as defined by Daly et al27:
IGR2096 (block 4), IGR2198 (block 5), OCTN2
(SLC22A5 promoter -207G-Xi) (block 7), IGR2230
(block 7), and OCTN1 (SLC22A4 exon 9 1672C^T)
(block 7) (Figure 1). Pairwise D' values >0.959 between
each SNP confirmed the difficulty of showing an inde¬
pendent effect of OCTN1/2 variants and IBD5. In the
detailed analyses of the IBD5 contribution to disease
phenotype presented in this report, data are presented for
the IGR2198 marker, representative of the 3-locus hap¬
lotype (IGR2096, IGR2198, and IGR2230). All data are
available for each marker SNP on request.
Disease Susceptibility
Analysis of SNPs representing the extended IBD5
haplotype (IGR2096, IGR2198, and IGR2230). Variant
allelic frequencies differed significantly between patients
with CD and HCs for each of the 3 IBD5 SNPs studied
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able 2. IBD5 Variant Allele Frequency, Carriage Rates, and Homozygote Frequency in Patients with CD and Controls
Odds ratio
Control frequency CD frequency (confidence
SNP/haplotype examined (%) (%) P interval)
iriant allelic frequency
IGR2096 41.9 49.4 .03 1.42 (1.1-1.8)
IGR2198 40.8 49.1 .0046 1.40 (1.1-1.6)
OCTN2 (-207 G—>C) 48.4 56.1 .0092 1.43(1.2-1.8)
IGR2230 47.4 54.9 .011 1.35 (1.1-1.7)
OCTN1 (1672C^T) 42.9 53.6 .0008 1.48 (1.2-1.9)
iriant carriage rates
IGR2096 173(68.7) 264 (79) .0034 1.75(1.2-2.6)
IGR2198 171 (67) 258(77) .011 1.61(1.2-2.3)
0CTN2 (-207 G^C) 187 (74) 280 (81) .034 1.52 (1.0-2.2)
IGR2230 185(73.7) 261 (80) .047 1.5(1.1-2.23)
OCTN1 (1672C^T) 178(68.7) 267 (80) .0024 1.77 (1.2-2.6)
TC haplotype 170 (69) 264 (80) .0016 1.8(1.3-2.7)
IBD5 haplotype8 166 (63.6) 246 (73) .016 1.5 (1.1-2.2)
iriant homozygote frequency
IGR2096 38(15.1) 73 (21.4) .036 1.58 (1.0-2.4)
IGR2198 38(14.8) 70(21) .044 1.56 (1.0-2.4)
OCTN2 (-207 G^C) 55 (22) 106 (31) .0155 1.59(1.1-2.3)
IGR2230 47 (18.6) 94 (29) .0038 1.79(1.2-2.6)
0CTN1 (1672C—>T) 44(17) 89 (25.6) .011 1.69(1.1-2.5)
TC haplotype 40 (16) 86 (28.4) .0042 1.83(1.2-2.8)
IBD5 haplotype3 38 (14.6) 68 (20.5) .071 1.48 (1.0-2.3)
)TE. Three SNPs were used to define the extended IBD5 locus (IGR2096, IGR2198, and IGR2230) (Figure 1). Each was independently
isociated with susceptibility to CD when allelic frequencies, carriage rates, and homozygosity were analyzed. 0CTN2 variant (-207G^C) and
3TN1 variant (1672C^>T) were also independently associated with susceptibility to CD when allelic frequencies, carriage rates, and
imozygosity were analyzed. The 2-allele risk haplotype OCTN1/2-TC haplotype was associated with susceptibility to CD when carriage rates and
imozygosity rates were analyzed.
2-allele risk haplotype using the IBD5 marker SNPs IGR2198 and IGR2230 is also illustrated for comparison with the OCTN1/2-TC haplotype.
GR2096, 49.4% CD vs 41.9% HC [P = .03];
1R2198, 49.1% CD vs 40.8% HC [P = .0046};
1R2230, 54.9% CD vs 47.4% HC {P = .011}) (Table
i. Carriage rates for the IBD5 variants were significantly
gher in the patients with CD when compared with the
introl population (IGR2096, 79.3% CD vs 68.7% HC
' = .0034]; IGR2198, 77% CD vs 67% HC [P =
11}; IGR2230, 80% CD vs 73.7% HC [P = .047]).
idividuals who were homozygous for the IBD5 risk
leles at the 3 SNPs examined (IGR2096, IGR2198,
id IGR2230) were more common in the CD group than
the control group (Table 2). The population-attribut-
>le risk for IBD5 homozygosity was estimated as 15%
IGR2096 data were considered in calculation, 14.0%
r IGR2198, and 14.3% for IGR2230.
No associations were observed between allelic fre-
tency of IBD5 variants and IBD overall (IGR2198,
5% IBD vs 40.8% HC [P = .077]) or UC (IGR2198,
5.7% UC vs 40.8% HC [P = .325}) (Supplementary
ible 2; see supplemental material online at www.mmc.
ed.ed.ac.uk/gi/supdata.shtml).
Analysis of OCTN1/2 variants and OCTN1/2-TC
jplotype. Allelic frequencies differed between pa-
ents with CD and controls for the OCTN1 variant
(,SLC22A4 exon 9 1672C^T) (53.6% CD vs 42.9%
HC, P = .0008) and the OCTN2 variant (SLC22A5
promoter ~207G^C) (56.1% CD vs 48.4% HC, P =
.0092) (Table 2). Carriage of the OCTN1/2-TC risk
haplotype was present more frequently in patients
with CD than in controls (80% CD vs 68.5% HC, P
= .0016, OR, 1.8) (Table 2). It was clear that this
difference related to homozygosity because OCTN1/
2-TC homozygotes were more common in the CD
group (28.4% CD vs 16.1% HC, P = .0042, OR,
1.83). No significant difference was observed between
OCTN1/2-TC heterozygote rates (P — .3).
An association was observed between the OCTN1
variant and IBD when allelic frequencies were analyzed
(48.9% IBD vs 42.9% HC, P = .019). This finding was
not replicated in analysis of the OCTN2 variant (51.7%
IBD vs 48.4% HC, P — .162), and no associations were
observed between variant allelic frequencies of OCTN1
(44.7% UC vs 42.9% HC, P = .53) or OCTN2 (5% UC
vs 48.4% HC, P = .38) and UC (Supplementary Table
2; see supplemental material online at www.mmc.
med.ed.ac.uk/gi/supdata.shtml). No association was ob¬
served between the OCTN1/2-TC haplotype and IBD
overall or with UC. There was no evidence of epistasis
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able 3. Frequency of 0CTN1/2 Variant Alleles and the 0CTN1/2-TC Haplotype in Patients with CD Stratified by Carriage of
N0D2/CARD15 Variants
% NOD2/CARD15-posl\.\\ie % N0D2/CARD15-nega\.\ve
patients patients
SNP/haplotype examined (n = 84) (n = 188) P
TTN2 (-207 G^C) allelic frequency 55.2 56.3 .78
^TNl (1672C—>T) allelic frequency 51.9 53.4 .69
^TNl/2 TC haplotype carriage 72.3 71.1 .79
TTN1/2 TC haplotype homozygosity 22.0 24.5 .574
DTE. Analysis of evidence for epistasis between 0CTN2 variant (-207G-X)) and 0CTN1 variant (1672C^>T) and the TC haplotype of OCTN1/2
3s investigated by stratifying 0CTN1/2 variants by carriage of one or more of the 3 common CARD15 variants: R702W, G908R, and
)07fsinsC. No evidence of epistasis was observed.
ttween the OCTN1/2 variants, the OCTN1/2-TC hap-
type, and CARD 15 variants (Table 3).
The 0CTN1/2 association with CD is not indepen-
jnt of the association with the extended IBD5 haplo-
pe. Previous data have suggested carriage of the OCTN1/
■TC haplotype to be an independent risk factor for CD.
owever, in our data set, for individuals who lacked the
iD5 risk haplotype (homozygous with respect to the non—
D-associated alleles of IGR2096, IGR2198, and
tR2230), the OCTN1/2-TC haplotype was not associated
ith CD (Table 4). In the absence of variants in the marker
9P IGR2096, which is located in block 427 (Figure 1),
1.5% of the controls carried the OCTN1/2-TC haplotype
impared with 30.4% in the CD group (P = .22). When
e OCTN1/2-TC haplotype was analyzed in the absence of
tR2198 variants (block 5), 27.1% of the controls pos-
ssed the OCTN1/2-TC haplotype versus 17.1% of the
itients with CD (P = . 13). In the absence ofvariants in the
arker SNP IGR2230, which is in the same block as
CTN1/2 (block 7), 3% of the controls possessed the
OCTN1/2-TC haplotype versus 1.6% of the patients with
CD (P = .59).
Phenotypic Analysis
Age at diagnosis. No association was observed
between the age at diagnosis in patients with IBD
overall, or UC and the IBD5 OCTN1/2 variant alleles.
When allelic frequency was compared in subgroups
defined by the Vienna classification for age in the pa¬
tients with CD (Al, younger than 40 years; A2, older
than 40 years), there was no significant difference be¬
tween variant and wild-type allelic frequency for all
studied SNPs.
Anatomic distribution. There was no association
between the IBD5 marker SNPs, OCTN1/2 variants, and
CD when disease location was assessed by the Vienna
classification (LI, terminal ileum; L2, colon; L3, ileoco-
lonic; L4, upper gastrointestinal tract). Of note, no as¬
sociation was found between the presence of perianal CD
ible 4. Frequency of the 0CTN1/2 TC Haplotype in Individuals Not Possessing Disease Susceptibility Risk Alleles at the
Markers IGR2096, IGR2198, and IGR2230
No. of subjects
not possessing
No. of subjects 0CTN1/2-TC No. of subjects OCTN1/2-TC No. of subjects 0CTN1/2-TC IGR2096, OCTN1/2-TC
not possessing haplotype not possessing haplotype not possessing haplotype IGR2198, and haplotype
IGR2096 frequency IGR2198 frequency IGR2230 frequency IGR2230 frequency
variants (%) variants (%) variants (%) variants (%)
introls 79 17(21.5) 85 23(27.1) 66 2(3) 63 2(3.2)
tients 69 21(30.4) 76 13(17.1) 62 1(1.6) 41 0
with CD
.22 .13 .59 .25
)TE. The number of patients with CD and controls are shown in the absence of the IBD5 risk haplotype markers IGR2096, IGR2198, and
R2230 and all 3 SNPs combined. The location of these marker SNPs within the IBD5 locus is illustrated in Figure 1. The frequency of the
:TNl/2-TC haplotype within each of these respective groups is illustrated together with Rvalues. In these individuals not possessing allelic
riants associated with the extended IBD5 haplotype, the 0CTN1/2-TC haplotype was not significantly associated with CD for any of the 3
arkers, providing evidence against an independent effect of the 0CTN1/2 haplotype on disease susceptibility. In the data set from Peltekova
al, the single marker IGR2078 (block 4) was used to define the IBD5 risk haplotype. It is noteworthy that IGR2096, the only marker of the 3
adied in our population to show even a trend toward independent segregation from OCTN1/2, was the marker farthest from 0CTN1/2 and also
is closest to the single marker used by Peltekova et al.
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ible 5. Phenotypic Associations of IGR2198, 0CTN1/2 Variant Homozygosity, and Homozygosity for the 0CTN1/2-TC
Haplotype
Patients with CD homozygous for the variant allele/haplotype
0CTN2 0CTN1 OCTN1/2 TC
Phenotype IGR2198 (-207 G^C) (1672C—>T) haplotype
;nna classification of disease
behavior at follow-up
Inflammatory (n = 121) 14.4% 23.0% 17.4% 17.1%
Stricturing/penetrating (n = 217) 24.9% 34.8% 30.0% 29.7%
P (relative risk) .026(1.97) .029(1.78) .011(2.0) .011(2.05)
sease progression from diagnosis to
follow-up
No progression (n = 126) 14.7% 23.4% 18.2% 17.8%
Progression (n = 132) 25.9% 31.3% 26.9% 29.1%
P (relative risk) .038(1.72) .18(1.49) .12 (1.66) .049 (1.63)
rgery for luminal complications of CD
No surgery (n = 137) 13.1% 21.9% 11.7% 12.3%
Surgery (n = 237) 23.2% 33.1% 26.6% 26.7%
P (odds ratio) .037 (1.91) .031(1.77) .0007 (2.7) .0023 (2.2)
)TE. An association was observed between IGR2198 variant homozygosity, 0CTN2 variant homozygosity, 0CTN1 variant homozygosity, and
mozygosity for the 0CTN1/2-TC haplotype and structuring/penetrating disease when compared with inflammatory disease at most recent
low-up. Of the 258 patients with CD who had inflammatory Vienna disease classification at diagnosis, 126 patients did not progress at
low-up and 132 patients progressed to the stricturing/penetrating group. The average duration of follow-up of these patients was 11.8 years.
d homozygosity for the OCTN1/2-TC haplotype (P =
75). When patients with CD were further stratified for
0D2/CARD15 variant carriage, no associations be-
'een homozygosity for the OCTN1/2-TC haplotype
d the disease location, categorized by the Vienna clas-
ication, were observed; 45% ofOCTN1/2-TC homozy-
ius patients with CD with terminal ileal disease (LI)
rried no N0D2/CARD15 variants, whereas 52% car-
:d 1 or more N0D2/CARD15 variants (P = .75). The
D5 OCTN1/2 variants were not associated with dis-
se extent and severity in the UC cohort.
Disease behavior. When disease behavior at di-
nosis was analyzed, no significant association between
riants representing the extended IBD5 locus, individ-
1 OCTN1/2 variants, and stricturing (B2, Vienna clas-
ication) or penetrating (B3) behavior was observed
ten compared with inflammatory, nonstricturing, non-
netrating disease behavior (Bl). A significant associa-
)n was observed between IGR2198 homozygosity and
'icturing/penetrating disease when compared with in-
mmatory disease at most recent follow-up (24.9% B2
d B3 vs 14.4% Bl; P = .026; OR, 1.97) (Table 5).
gnificant associations were also observed between stric-
ring/penetrating disease when compared with inflam-
atory disease for OCTN1 variant homozygosity (30%
1 and B3 vs 17.4% Bl; P = .011; OR, 2.0), OCTN2
riant homozygosity (34.8% B2 and B3 vs 23.0% Bl;
= .029; OR, 1.78), and homozygosity for the OCTN1/
TC haplotype (29-7% B2 and B3 vs 17.1% Bl; P =
11; OR, 2.05). In individuals who lacked the IBD5
risk haplotype (homozygous with respect to the non—
CD-associated allele of the IGR2198 variant), there was
no association between stricturing/penetrating disease
behavior at follow-up and homozygosity for the OCTN1/
2-TC haplotype (11.1% inflammatory vs 14.9% strictur¬
ing/penetrating; P = .65).
Disease progression. Because the Vienna classi¬
fication is a hierarchical system, a number ofpatients will
move from inflammatory disease (Bl) at diagnosis to
either stricturing (B2) or penetrating (B3) disease during
their follow-up. Of the 258 patients who had inflamma¬
tory disease at diagnosis, 126 patients remained in the
inflammatory group at follow-up and 132 patients pro¬
gressed to the stricturing group or the penetrating
group. The median duration of follow-up of these pa¬
tients was 11.8 years. Homozygosity rates of IGR2198
variants and the OCTN1/2-TC haplotype were associated
with disease progression to B2 or B3 compared with
those whose disease remained as Bl (Table 5). The
association between the OCTN1/2-TC haplotype and
disease progression was not observed in patients with CD
who lacked the IBD5 risk haplotype (18% progression vs
13% nonprogression; P = .56).
Requirement for surgery. As a marker of disease
severity, patients who had required surgery (n = 237) for
complications of luminal CD were compared with those
who had had no surgery for CD (n = 137). A significant
association was observed between requirement for sur¬
gery and homozygosity for variants of IGR2198,
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'CTNl, OCTN2, and the OCTN1/2-TC haplotype (Ta¬
le 5).
Multiple logistic regression analysis was applied, us-
ig a model that considered age at diagnosis, disease
ihavior, smoking status, family history, N0D2/
ARD15 carrier status, and IGR2198 homozygosity or
le OCTN1/2-TC haplotype, with the outcome being
irgery for luminal complications of CD. Colinearity
.'tween IGR2198 and OCTN1/2-TC homozygosity was
ddent and allowed for in modeling. IGR2198 homozy-
3sity (P = .016; odds ratio, 2.86; confidence interval,
21-6.76) and the OCTN1/2-TC haplotype (P = .004;
ids ratio, 3.52; confidence interval, 1.49— 8.31) were
gnificantly associated with the need for surgery.
Discussion
The present study has provided novel data regard-
g the contribution of the IBD5 locus as a determinant
disease susceptibility and phenotype in the Scottish
jpulation, which is known to be characterized by low
tes of racial admixture compared with others in Europe
id North America.40 We have shown the OCTN1 and
CTN2 polymorphisms to be in tight linkage disequi-
Drium (D', >0.959), with allelic variants of the 3 SNPs
presenting the extended IBD5 haplotype (IGR2096,
1R2198, and IGR2230). Susceptibility to CD was as-
ciated with each of the 3 IBD5 polymorphisms defin-
g the extended IBD5 region and the variant alleles of
ie OCTN1 and OCTN2 genes. Homozygosity for each
the 3 SNPs used to define the extended IBD5 haplo-
pe and for the OCTN1/2-TC haplotype was strongly
sociated with disease susceptibility. These data provide
ie first independent confirmation of the association with
ie OCTN1/2 variants studied by Peltekova et al in
mada.31
However, our data are not entirely consistent with the
suits reported by Peltekova et al in a potentially critical
pect. In the absence of allelic variants representing the
tended risk haplotype for IBD5, our results showed no
gnificant difference in the presence of the OCTN1/
TC haplotype in patients with CD compared with
mtrols. These findings lead to the important suggestion
at the OCTN1/2-TC haplotype may not confer risk of
D independently of other closely linked determinants
ithin the extended IBD5 locus and that it is at present
emature to conclude that the OCTN1/2 variants are
usative in the pathogenesis of CD.
In comparing the studies reported by Peltekova et al
ith our own, the choice of markers used to define the
iD5 locus is especially worthy of discussion. In the data
t from Peltekova et al, the single marker IGR2078,
located in block 4 of the haplotype map-'7 (Figure 1), was
used to define the 1BD5 risk haplotype and not a marker
closer to the OCTN1/2 loci (block 7), such as IGR2198
(block 5) or IGR2230 (block 7), which were used in the
present study. In light of this, recombination between
the IGR2078 marker in block 4 and OCTN1/2 in block
7 needs to be considered as an explanation for the ap¬
parent independence reported by Peltekova et al. In our
data, the only marker for which any trend toward an
independence of the OCTN1/2-TC haplotype was ob¬
served concerned the IGR2096 variants, which are also
located in block 4. In the absence of variants of the
markers IGR2198 and IGR2230, the OCTN1/2-TC
haplotype was in fact more prevalent in the control
group, further supporting the hypothesis of recombina¬
tion between haplotype blocks 4 and 7.27
Recent data presented in abstract form involving 3
large cohorts of patients with IBD (more than 1200
patients with CD in total) in Cambridge,41 Stockholm,
Sweden (Torkvist et al, personal communication, May
2005), and the United Kingdom/Germany42 have all
shown an association between the IBD5 locus and CD. In
each of these data sets, as in the present study, there was
no independent association between the OCTN1/2-TC
haplotype and CD in the absence of the extended 1BD5
risk haplotype.
The arguments as to the contribution of the OCTN1/2
variants implicated by Peltekova et al have been devel¬
oped further recently and clearly require resolution.
Studies involving 276 samples from healthy, ethnically
diverse human populations have allowed the identifica¬
tion of several nonconservative SNPs of OCTN1/2 in
evolutionary conserved sites in black and Chinese popu¬
lations.43 The investigators suggest that if these variants
were shown to confer susceptibility to CD in their re¬
spective populations, this would provide strong evidence
that OCTN1/2 contain the critical mutations. As yet,
these studies have not been undertaken. Moreover, ge¬
netic mutations in OCTN2 cause systemic carnitine
deficiency, characterized by disease of skeletal muscle,
cardiac muscle, and liver but not inflammatory or intes¬
tinal disease.44
Genetic studies to resolve the limits of the association
using markers p and q telomeric to OCTN1/2 may help
to clarify this issue; however, power of resolution will
become a critical issue in attempting to resolve this
controversy by genetic studies alone. We have calculated
that 3200 individuals with CD would need to be geno-
typed to prove the independence of OCTN1/2 from
IGR2230, which is situated between the 2 genes in
haplotype block 7.27 Complementary approaches such as
functional and expression studies in CD are clearly re-
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uired. Whereas OCTN1/2 remain strong and plausible
indidates within the haplotype structure on 5q31, the
ise is yet to be proven beyond doubt.
Other immunoregulatory genes that have the poten-
al to play a role in the pathogenesis of CD and are
>cated on the IBD5 haplotype are interleukin-3, inter-
:ukin-4, interleukin-5, and CSF2.9 The interleukins
ave a well-defined role in immune regulation, and CSF2
icodes for granulocyte-macrophage colony—stimulating
ictor.9'45
Increasingly, in CD, it is recognized that clinical
henotype is genetically determined.46 In our cohort,
hen the Vienna classification for disease behavior was
lalyzed at the patients' most recent follow-up assess-
lent, there was a significant association between the
3D5 marker SNP IGR2198, OCTN1/2 variants, the
•CTN1/2-TC haplotype, and the presence of stricturing
id penetrating disease. Patients with CD who were
omozygous for IGR2198 variants or homozygous for
te OCTN1/2-TC haplotype had a disease phenotype
tat was more likely to progress to stricturing or pene-
ating disease behavior, and multivariate analysis
lowed an association among IGR2198, the OCTN1/
-TC haplotype, and the requirement for surgery, a
irrogate marker for severity in CD.47
It is important to point out that all the genotype-
henotype data contained within our study are internally
insistent, with the significant association of the IBD5
•CTN1/2 variants, stricturing and penetrating disease
: latest follow-up, and disease progression from inflam-
latory to stricturing and penetrating disease, because
lese patients with progressive complicated disease are
lore likely to require surgical intervention. Although no
assification system has gained universal approval, the
ienna classification is increasingly widely used and is
jrrently subject to reevaluation.48 Variants within the
3D5 locus have also been associated with a more severe
isease phenotype and growth failure in an independent
ihort of 200 Scottish patients diagnosed with CD at 16
jars of age or younger.49 Overall, our data show an
cciting, novel genotype-phenotype association with the
3D5 locus, and it is intriguing to propose that a genetic
iriant within the IBD5 locus causes CD to become more
were (stricturing or penetrating disease) and hence re-
uire increased surgical intervention.
Previous work involving the IBD5 locus has shown an
isociation between the 1BD5 risk haplotype and peri-
lal CD, but this was not replicated in our cohort.28
henotypic data from Newman et al showed an associa-
on with ileal disease,35 but no significant association
as observed in our population; 32.2% of patients with
eal CD were OCTN1/2-TC homozygous and 78% car¬
ried the OCTN1/2-TC haplotype compared with 22.6%
of patients with nonileal CD who were OCTN1/2 ho-
mozygotes and 75.5% of whom carried the OCTN1/
2-TC haplotype (P = .075 and P = .63, respectively).
Differences in definitions of ileal CD may be the reason
for the differences between these 2 cohorts; ileal disease
in our cohort was classified strictly according to the
Vienna classification (LI). Using these criteria, 34% of
patients had purely terminal ileal disease; in contrast,
70.6% of patients in the Toronto cohort were classified as
having ileal disease.35 Newman et al did not appear to
include any patients with proximal small intestinal or
upper gastrointestinal disease. No data were available in
this cohort regarding disease behavior or disease progres¬
sion over time.
NOD2/CARD15 variants have consistently been asso¬
ciated with a younger age of onset of disease, ileal disease,
and stricturing disease.26 In the present study, no evi¬
dence of epistasis was observed between the OCTN1/2
variants and N0D2/CARD15 variants. Genetic hetero¬
geneity between the Scottish population and that of
Canada may be responsible for observed differences in
this context, and it is pertinent to note the low frequency
of CARD15 variants in the Scottish CD population
(1007fsinsC, 4.7%; G908R, 1.8%; R702W, 7.1%) and
the low combined population-attributable risk these
variants confer, which is estimated at 11%.24
In conclusion, we have determined that the IBD5
locus is associated with disease susceptibility in our CD
cohort in Scotland. This is the first independent replica¬
tion of the association of the OCTN1/2 haplotype with
CD outside the index population in Canada. However, a
significant effect of OCTN1 and OCTN2 variants was
not seen in the absence of the IBD5 risk haplotype, and
on the strength of the present data it is not possible to
conclude whether or not the OCTN1/2 genes contain the
disease-causing mutation or whether the association
serves to only narrow the region of association within the
IBD5 locus. Finally, novel and potentially important
phenotypic associations have been identified with the
IBD5 locus, which implicate this region as a determinant
of disease severity in CD as well as susceptibility.
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INFLAMMATORY BOWEL DISEASE
DLG5 variants do not influence susceptibility to
inflammatory bowel disease in the Scottish
population
ST
C L Noble, E R Nimmo, H Drummond, L Smith, I D R Arnott, J Satsangi \*j|LINE
Gut 2005;54:1416-1420. doi: 10.1136/gut.2005.066621
Introduction: Recent data have suggested that specific haplotypic variants of the DLG5 gene on
chromosome 10q23 may be associated with susceptibility to inflammatory bowel disease (IBD) in
Germany. Haplotype D, notably characterised by the presence of a G^»A substitution at nucleotide 1 13,
was associated with susceptibility to Crohn's disease (CD) whereas an extended haplotype A conferred
protection.
Aims: Association of DLG5 haplotypic variants with disease susceptibility, genotype-phenotype relation¬
ships, and epistasis with CARD15 was investigated in the Scottish population.
Patients and methods: A total of 374 CD, 305 ulcerative colitis (UC), and 294 healthy controls (HC) were
studied. Genotyping for the variants rsl 248696 (113A, representing haplotype D) and the single
nucleotide polymorphism tag rs2289311 (representing haplotype A) were typed using the Taqman
system.
Results: On analysis of the DLG5 variant 113A, there were no associations with IBD when allelic frequency
(11.4% IBD v 13.2% HC; p = 0.30) and carrier frequency (19.2% IBD v 24.6% HC; p = 0.069) were
analysed. No associations were observed between 113A variant allelic frequency (p = 0.37), carrier
frequency (p = 0.057), and CD. In fact, 11 3A heterozygosity rates were lower in CD (16%) and IBD
(16.9%) than in HC (23%) (p = 0.029 and p = 0.033, respectively). No associations between DLG5 and UC
were observed. Haplotype A was not protective and there was no evidence of epistasis between DLG5 and
CARD15.
Conclusions: The present data contrast strongly with previous data from Germany. DLG5 11 3A is not
associated with disease susceptibility and haplotype A does not confer resistance. Further work is required
to evaluate the significance of DLG5 in other populations from geographically diverse regions.














Crohn's disease (CD) and ulcerative colitis (UC) arecommon causes of gastrointestinal morbidity in thedeveloped world, and the incidence of early onset CD
has continued to rise in Northern Europe.1 3 Increasing
insight has been gained into the critical role of the
disregulated immune response to bacterial flora and it is
clear that genetic susceptibility to environmental agents are
central to the pathogenesis of chronic intestinal inflamma¬
tion.4 5
Genome wide scanning has identified six confirmed loci
that confer susceptibility to CD and the first discovered and
most consistently replicated critical mutations were found in
the CARD 15 (NOD2) gene on chromosome 16 (IBDl).67The
physiological role of the CARD15/NOD2 protein remains
under detailed examination. In vitro data suggest that
CARD 15 functions as an intracellular sensor of muramyl
dipeptide, a highly conserved peptidoglycan motif common to
many intraluminal bacteria.8 9 These observations have now
been complemented by studies of genetically engineered
mouse models. Watanabe et al have suggested that
CARD15-/- mice lose negative control of Toll-like receptor
2 (TLR2) mediated activation of nuclear factor kB, potentially
offering an explanation for the Thl phenotype characteristic
of CD."' However, recently compiled studies do not provide
support for NOD2/CARD15 interaction with the TLR2 path¬
way and emphasise the complexity of NOD2/CARD15
activation." 12
Carriage rates of the three common NOD2/CARD15
mutations single nucleotide polymorphisms (SNPs)
Gly908Arg, Arg702Trp, and the frame shift mutation
Leul007fsinsC vary between 0% and 50% in different CD
cohorts, with high rates reported in Central European
populations'' and low rates in Northern Europe (Finland
and Scotland)." 14 Genetic heterogeneity between the popu¬
lations of North and Central Europe is an obvious reason for
the difference in CARD 15 carriage rates and as more
susceptibility genes are being discovered this explanation
has become increasingly pertinent."
A locus on chromosome 10 was first implicated in genome
wide scanning of a European cohort (UK, Germany, and the
Netherlands) in 1999 as conferring susceptibility to inflam¬
matory bowel disease (IBD) (LOD score 2.30).15 Recent data
now suggest that the gene DLG5 (Drosophila discs large
homologue 5) located on chromosome 10q23 may be
responsible for the observed linkage and contains critical
mutations that confer susceptibility to IBD.16
DLG5 is a member of the MAGUK (membrane associated
gyanylate kinase) gene family which encode cell scaffolding
proteins and are also involved in intracellular signal
transduction.17 MAGUKs interact with other proteins to
create an assembly of large multiprotein complexes that bind
transmembrane proteins at the cytoplasmic side to other
signal transduction proteins, thus creating a platform for
specific signal interactions.18 19 The DLG5 gene spans 79 kb,
Abbreviations: IBD, inflammatory bowel disease; CD, Crohn's disease;
UC, ulcerative colitis; HC, healthy controls; SNP, single nucleotide
polymorphism; TLR, Toll-like receptor; D1G5, Drosopnila discs large
homologue 5; MAGUK, membrane associated gyanylate kinase; PSC,
primary sclerosing cholangitis
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contains 32 exons, and is expressed most strongly in
placental tissue and less so in heart, skeletal muscle, liver,
small bowel, and colon.20
Stoll and colleagues'6 identified two extended DLG5
haplotypes that influenced disease susceptibility in the
German population. The first haplotype (named haplotype
D16) was especially notable for the presence of a G—>A
substitution at nucleotide 113 that resulted in an amino
change at position 30 from arginine to glutamine (R30Q). On
analysis of carrier frequency, Stoll et al found the 113A
variant to be associated with CD (25% CD v 17% healthy
controls; p = 0.001) in a case control study and trends
between 113A transmission and IBD (p = 0.09) and CD
(p = 0.065) were observed on transmission disequilibrium
testing.16 In silico analysis suggests that the 113A (R30Q)
variant may impair DLG5 scaffolding function, but as yet no
expression or functional studies in IBDs have been con¬
ducted. Evidence of epistasis between the 113A variant of
DLG5 and CARD 15 variants was also observed in the CD
cohort.16
The second haplotype (haplotype A16) was tagged by eight
marker SNPs and was observed to be significantly under
transmitted in the IBD group (p = 0.006), suggesting the
haplotype may be protective.16 No phenotypic associations
were investigated and as yet no replication data have been
published.
In the present study, we have assessed the contribution of
the DLG5 polymorphisms rs 1248696 (113A) and rs2289311
(one of the marker SNPs for the protective haplotype A)16) in
determining genetic susceptibility to CD and UC in the
Scottish population which has a high incidence of IBD. We
have also investigated genotype-phenotype associations in
our rigorously defined IBD population and assessed epistasis
with established CARD 15 mutations.
PATIENTS AND METHODS
A total of 679 patients with well characterised IBD (IBD) and
294 controls were recruited. All IBD patients attended the
clinic at the Western General Hospital, Edinburgh, a tertiary
referral centre for IBD in the South East of Scotland. The
group comprised of 374 patients with CD and 305 with UC.
The diagnosis of IBD adhered to the criteria of Lennard-
Jones.21 CD patients were classified according to the Vienna
classification which involves age at diagnosis (Al, <40 years;
A2, >40 years), location (LI, terminal ileum; L2 colon; L3,
ileocolon; L4, upper gastrointestinal), and behaviour (Bl,
non-stricturing, non-penetrating; B2, stricturing; B3, pene¬
trating).22 UC disease severity was judged by the criteria
proposed by Truelove and Witts.23 Phenotypic data were
collected by patient questionnaire, interview, and case note
review, and comprised of demographics, date of onset of
symptoms and diagnosis, disease location, disease behaviour,
progression, extraintestinal manifestations, surgical opera¬
tions, smoking history, joint symptoms, family history, and
ethnicity. The study protocol was approved by Lothian
Research Ethics Committee (LREC 2000/4/192).
Demographics: CD and UC
The demographics of the CD and UC patients are shown in
table 1. Duration of follow up was defined as the time from
diagnosis to the time of the most recent clinic review (median
duration 11.8 years in the CD group and 7.5 years in the UC
group). The CD group consisted of 181 males and 193 females
and the UC group 171 males and 134 females, with a median
age at diagnosis of 34 years.
Vienna disease classification was available for 347 (93%)
CD patients at diagnosis and 374 (100%) CD patients at
follow up. Full phenotypic data were available for the UC
cohort.
Control subjects
A total of 294 controls (163 blood donors from the south east
of Scotland and 131 healthy controls subjects) were enrolled.
Allelic frequencies of DLG5 variant SNPs 113A, rs2289311,
OCTN1 variant rsl050152, OCTN2 variant rs26313667, and
IBD5 marker SNP IGR2198 are shown in table 2.
Genotyping
Genomic DNA was extracted from peripheral venous blood by
a modified salting out technique and resuspended in 1 xTE
(10 mM Tris (pH 8.0), 1 M EDTA (pH 8.0)) at a final
concentration of 100 ng/pl. SNPs rsl248696 (113G—>A
representing haplotype D) and rs2289311 (chosen because
of its reliability in genotyping to represent the protective
haplotype A; M Stoll, personal communication) were typed
using the Taqman system. IBD patients and controls were
Table 1 Demographics and clinical features of the Crohn's disease (CD), ulcerative colitis (UC), and control groups
Crohn's disease Ulcerative colitis Controls
(n = 374) |n = 305) (n = 294)
Sex (M/F) 181/193 171/134 143/151
Age at diagnosis (y) (median (IQR)) 27.8 (20.9-40.4) 34 (25-50) 39 (27-52)
Duration of follow up (y) (median (IQR)) 11.8 (6.5-20.2) 7.5 (3.35-13.38)
Caucasian (%) 98.7% 98.3%
CD location at diagnosis UC disease extent
Ileal disease 125 (36%) Proctitis 105 (34.5%)
Colonic disease 137 (39%) Left sided colitis 116 (37%)
Ileal and colonic 58 (14%) Extensive colitis 84 (27.5%)
Upper Gl disease 30 (8.5%)
Perianal disease 75 (21.4%)
CD location at follow up
Ileal disease 92 (25%)
Colonic disease 130 (35%)
Ileal and colonic 103 (28%)
Upper Gl disease 49(13%)
CD behaviour at diagnosis
Inflammatory (Vienna Bl) 258 (74.8%)
Stricturing (Vienna B2) 30 (8.4%)
Penetrating (Vienna B3) 59(16.8%)
CD behaviour at follow up
Inflammatory (Vienna Bl) 142 (38%)
Stricturing (Vienna B2) 68 (18%)
Penetrating (Vienna B3) 164 (44%)
IQR, interquartile range.
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Table 2 Demographics and allelic frequencies in the
blood transfusion samples and healthy volunteer control
samples
Blood transfusion Healthy control
samples samples
Age (y) (median (IQR) 35 (26-47) 36(29-51)








Allelic frequencies of DLG5 variant single nucleotide polymorphisms
(SNPs) 113A, rs2289311, OCTN1 variant rsl050152, OCTN2 variant
rs26313667, and IBD5 marker SNP IGR2198 are shown to illustrate the
consistency between the blood transfusion controls and the healthy
volunteer controls.
typed for polymorphisms of the CARD 15 gene (R702W,
G908R, and 1007fsinsC) using previously described meth¬
ods." All genotyping except R702W was carried out using the
Taqman system. R702YV genotyping was performed by
restriction fragment length polymorphism polymerase chain
reaction. Restriction digestion was preformed using 1 u Msp/
at 37°C overnight and polymerase chain reaction fragments
run on 4% NewSieve 3:1 agarose gels. These were stained
with ethidium bromide and viewed under ultraviolet light.
An image was recorded digitally.
Data analysis
The two SNPs rs 1248696 and rs2289311 were analysed for
association with IBD overall, CD, UC, and disease phenotype.
Allelic frequency, carrier frequency, heterozygosity, and
homozygosity rates were studied. Each allele was shown to
be in Hardy-Weinberg equilibrium. Genotype-phenotype
associations were analysed by y" analysis using the Minitab
statistical software package version 13/02 (Minitab Ltd,
Coventry, UK). To identify significant independent variables
associated with genotype, univariate and multivariate analy¬
sis was carried out. Evidence for DLG5 epistasis with CARD 15
was investigated by stratifying DLG5 variants by carriage of
one or more of the three common CARD 15 variants—R702W,
G908R, and 1007fsinsC. Allelic frequencies of the DLG5
variants were compared between the subgroups of patients
with and without CARD 15 variants by y2 analysis. The null
hypothesis was that the frequency of DLG5 variants did not
differ between these subgroups. Phenotypic associations of
DLG5 variants were also stratified for the presence and
absence of CARD 15 variants.
RESULTS
Disease susceptibility: haplotype D (1 13A)
On analysis of the DLG5 variant 113A there were no
associations with IBD when allelic frequency (11.4% IBD v
13.2% healthy controls (HC); p = 0.30), carrier frequency
(19.2% IBD v 24.6% HC; p = 0.069), and homozygosity rates
(2.3% IBD v 1.5% HC; p = 0.48) were analysed (table 3). A
negative association was observed between heterozygous
rates of 113A and IBD (16.9% IBD v 23% HC; p = 0.033).
Furthermore, a negative correlation was observed between
heterozygous 113A variants and CD (16% CD v 23% HC;
p = 0.029). No associations were observed between 113A
variant allelic frequency (11.4% CD v 13.2% HC; p = 0.37),
carrier frequency (18.3% CD v 24.6% HC; p = 0.057),
homozygous rates (p = 0.36), and CD. No associations
between 113A and UC were observed—allelic frequency
(12.8% UC v 13.2% HC; p = 0.34), carrier frequency (20.3%
UC v 24.6% HC; p = 0.23), heterozygous rates (18% UC v 23%
HC; p = 0.45), and homozygous rates (2.3% UC v 1.5% CD;
p = 0.5).
DLG5 haplotype A
Haplotype A allelic frequencies, represented by rs2289311
variants, did not differ between HC (31.5%) and IBD (35%;
p = 0.17), CD (36.9%; p = 0.078), or UC (33.4%; p = 0.51)
patients. No significant differences were observed between
carriage rates of rs2289311 variants—HC (52%), IBD (57.2%;
p = 0.18), CD (60.9%; p = 0.052), and UC (54%; p = 0.65).
The frequency of patients who were heterozygotes or
homozygotes for rs2289311 polymorphisms did not differ
between IBD and HC groups (heterozygote HC 41.1% v IBD
44.8% (p = 0.43), CD 48% (p = 0.13), and UC 42.1%
(p = 0.83); homozygote HC 10.9% v IBD 12.6% (p = 0.49),
CD 12.6% (p = 0.61), and UC 12.9% (p = 0.50)).
Phenotypic analysis
On univariate analysis of CD patients, no association was
observed between DLG5 113A variants and the Vienna
classification for age of diagnosis, location of disease, or
disease behaviour. Location of disease and disease behaviour
in CD patients was analysed at the time of diagnosis and at
the most recent follow up and there was no association
between DLG5 113A variants and disease progression. No
association was observed between DLG5 113A variants and
age at diagnosis in the IBD and UC groups and there was no
association between DLG5 113A variants, disease extent, and
severity in UC patients.
DLG5 113A variants displayed a trend towards being less
common in IBD patients with joint problems (large joint
arthralgias related to disease activity, small joint arthralgias
unrelated to disease activity, ankylosing spondylitis, and
sacroilitis) (n = 127) compared with those who had no joint
problems when allelic frequency was analysed (7.5% v 11.8%;
Table 3 DGL5 113A variant allele frequency, carrier frequency, heterozygote frequency,
and homozygote frequency in the inflammatory bowel disease, Crohn's disease,








































The p values shown are calculated between the control group and each respective disease group.
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p = 0.053). When allelic frequency of 113A variants was
analysed in UC patients with primary sclerosing cholangitis, a
trend towards these patients having fewer 113A variants was
observed (0% (n = 7) v 11.4%; p = 0.17). On analysis of the
haplotype A, no genotype-phenotype associations were
observed in the CD and UC patient groups. Multiple logistic
regression analysis did not identify any variables that were
independently associated with haplotype D (113A) or
haplotype A.
There was no evidence of epistasis between DLG5 113A
variants and carriage of the three common CARD 15 variants
Gly908Arg, Arg702Trp, and Leul007fsinsC—CARD 15 car¬
riage positive DLG5 113A allelic frequency 9.7% (n = 108)
versus CARD15 carriage negative DLG5 113A allelic fre¬
quency 11.6% (n = 584) (p = 0.43). When CD patients were
stratified for CARD15 variant carriage, no significant geno¬
type-phenotype relationships were found with DLG5 113A.
DISCUSSION
The present study has demonstrated that in the Scottish
population, traditionally characterised by low rates of
admixture, the DLG5 variant 113A, representing haplotype
D, is not a critical determinant of susceptibility in either CD
or UC. In fact, heterozygous rates of 113A were significantly
higher in the healthy control population when compared
with the IBD cohort and the CD cohort. Haplotype A
represented by the SNP rs2289311 was not protective in our
CD or UC population.
These data differ markedly from those of Stoll et al who
showed that in a German population, DLG5 113A variants
were overtransmitted to individuals with IBD, and in a case
control study there were significantly higher rates of 113A
carriage in the IBD group compared with the control group
(25% v 17%; p = 0.001).16 Considerations, including sample
size and phenotypic differences, between the present study
and that of Stoll et al, may be responsible for the observed
discrepancy in results but a more plausible explanation
would be genetic heterogeneity between the populations of
Germany and Scotland. This has been clearly illustrated by
data now available with respect to the three common
polymorphisms of the NOD2/CARD15 gene (G908R,
R702W, and lOOfsinsC) which are significantly more
common in the Central European CD population6 24 than in
the Northern European CD population." 14 25 Furthermore,
CARD 15 polymorphisms are absent in Japanese and Chinese
CD populations.26"28 The different incidences of the R702W
polymorphism has also been shown in healthy volunteers in
Europe, Africa, and Asia.2' In the eight independent groups
worldwide who have performed genome wide scans in IBD
patients, chromosome 10 has not met the stringent criteria
for significant linkage.30 31 This would suggest that if indeed
DLG5 plays a role in the pathogenesis of IBD, its contribution
may be limited to specific populations.
Further data illustrating genetic heterogeneity in European
IBD patients have been observed on analysis of the
Asp299Gly mutation of the TLR4 gene.32 TLR4 is a member
of the Toll-like receptor family which are involved in
recognition of pathogen associated molecular patterns by
the immune system and TLR4 functions as an extracellular
pattern recognition receptor for lipopolysaccharide which is
common to many intraluminal bacteria.33 The Asp229Gly
variant has been shown to confer susceptibility to CD and UC
in the Belgian population34 but no association was observed
between Asp229Gly variants and IBD in German and Scottish
cohorts." 35
Univariate and multivariate phenotypic analysis showed
no associations with DLG5 113A variants (haplotype D) and
the Vienna classification of CD or with age of onset of disease
or disease severity in UC. Trends were observed towards a
lower DLG5 113A variant frequency in CD patients with
arthropathy and UC patients with primary sclerosing
cholangitis (PSC) on univariate analysis. Both of these
extraintestinal complications have been shown to have a
molecular genetic basis. Susceptibility to axial arthropathy
has been strongly associated with HLA-B*27 in patients with
and without IBD,36 and peripheral arthropathies in patients
with IBD have been associated with HLA-DRB1*0103, HLA-
B*35, HLA-B*27, and HLA-B*44.37 In PSC, strong disease
associations with extended HLA haplotypes have been
observed,38 and a functional variant of stromolysin (matrix
metalloproteinase 3) has also been associated with suscept¬
ibility to PSC and with disease progression.39 In the current
investigation, the relatively small numbers of IBD patients
studied with these specific extraintestinal manifestations
mean that these results regarding any DLG5 effect in these
subgroups should be regarded as exploratory observations.
Replication studies in other cohorts may help shed some light
on this question.
No evidence of epistasis between DLG5 113A variants and
carriage of the three common CARD 15 variants Gly908Arg,
Arg702Trp, and Leul007fsinsC was observed in patients with
CD. Again, these data contrast with Stoll et al who found
significantly greater transmission of DLG5 113A in patients
with CD carrying one of the risk associated alleles of
CARD 15.16 CARD 15 variants have consistently been asso¬
ciated with a younger age of onset of disease, ileal disease,
and stricturing disease.40 A possible explanation for the
absence of epistasis between DLG5 and CARD15 could be the
low incidence of CARD 15 variants in the Scottish CD
population (1007fsinsC = 4.7%, G908R=1.8%, and
R702W = 7.1%) and the combined population attributable
risk these variants confer (11%)." Furthermore, Moore has
illustrated the problems in using statistical epistasis to
interpret genetic and biological phenomena.41
Although the present data suggest the these DLG5 variants
are not important determinants in the Scottish IBD popula¬
tion, our own recent studies suggest that NOD2/CARD15,
MDR1, and IBD5 variants are involved in disease suscept¬
ibility and behaviour."42 The identity of other genetic
determinants in the Northern European IBD population
remains under detailed investigation.
In conclusion, in our North European study population, we
were unable to replicate Stoll's data that the DLG5 variant
113A confers susceptibility to IBD. Haplotype A represented
by the SNP rs2289311 did not confer protection in our
population. Further genetic studies of DLG5 polymorphisms
in IBD populations are required to elucidate whether these
variants play a role in the pathogenesis of IBD. These studies
must be complemented by data regarding the expression and
function of DLG5 in the gastrointestinal tract.
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Hopkins Endoscopy Prize 2006
Applications are invited by the Endoscopy Committee of the British Society of
Gastroenterology who will recommend to Council the recipient of the 2006 Award.
Applications (10 copies) should include:
• A manuscript (two A4 pages only) describing work conducted
• A bibliography of relevant personal publications
• An outline of the proposed content of the lecture, including title
• A written statement confirming that all or a substantial part of the work has been
personally conducted in the UK or Eire.
An applicant need not be a member of the Society. The recipient will be required to deliver
a 20 minute lecture at the annual meeting of the Society in Birmingham in March 2006.
Applications (10 copies) should be made to the Endoscopy Section Secretary, British Society
of Gastroenterology, 3 St Andrews Place, London NW1 4LB by 1 December 2005.
www.gutjnl.com
